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Abstract 
EVALUATION OF ANALYTICAL, PHARMACOKINETIC 
AND PHARMACODYNAMIC METHODS 
FOR THE STUDY OF DIGOXIJ\ 
Santosh J. Vetticaden 
Medical College of Virginia-Virginia Commonwealth l:nh'ersity. 1985. 
Major Director: William H. Barr Pharm.D., Ph.D. 
The primary objective of the research was to investigate the pharmacodynam­
ics of digoxin in dogs. Initially an . assay specific for digoxin in the presence of 
its major metabolites. viz. , digoxigenin, digox.igenin mono-digitoxoside, digoxigenin 
bi:-:-d igitoxoside and dihydrodigoxin was developed using HPLC-RIA. Methodology 
for non-invasive measurement of left ventric1dar ejection time (LVET) and other 
· .• '-. t . .::,l i<- t ime int.ervals (STJ) in beagle dogs were developed. This involved surgery 
fr,r r:x t.eriorization of the carotid art-ery in t he dogs and subsequent measurement of 
LVET and STI after recovery. ST1, heart rate (HR) and digoxin levels were moni­
tored in normal beagle dogs administered 0.05 mg/kg or 0.025 mg/kg i.v ., infused 
uniformly over a 5 min. period. The STJ did not lend itself to pharrp.acodynamic. 
modelling. The LVET, QS2 and P-R interval were found to be inversely, but lin­
early, related to the he.art rate. Therefore, the bradycardic response to digoxin was 
extensive]y investigated in beag]e dogs. Pharmacodynamic mode]s evaluated for 
modelling the bradycardic respo�,s� to digoxin were: the pharmacokinetic model 
with a direct linear link, the linear mode] , the physiologic-pharma.cokinetic mode] 
with direct linear link and the effect. compartment model. The physiologic pharma­
cokinetic modell was simu]ated using SPJCE2 which uses network ·thermodynamics 
to simulate · biological systems. Criteria for the selection of appropriate models 
were established. Using the established criteria, the effect compartment model was 
demonstrated to be the best model. The implications and applications of pharma­
codynamic models in general and specifically of the pharmacodynamic model for 
the bradycardic response to digoxin are discussed . 
AIMS AND OBJECTIVES OF PROGRAM 
The primary aim of the research project was to investigate, develop and eval­
uate the methods and means fo1 pharmacokinetic and pharmacodynamic studies 
with digoxin . Specifically, the objectives of the project were: 
1 .  To develop an assay specific for digoxin in the presence of its major metabolites 
digoxigenin, digoxigenin mono- digitoxoside, digoxigenin bis- digitoxoside and 
dihydrodigoxin. 
2. To investigate and evaluate methods for the measurement of systolic time in-
vervals (STI) and other pharmacologic responses to digoxin in dogs. 
3. To characterize digoxin pharmacokinetics in dogs. 
4 .  To investigate digoxin pharmacodynamics in dogs. 
5. To develop and evaluate mathemat,ical models. cornpu t,er programs and simula­
tion programs for describing digoxin pharmarnk ine1 ic& and pharmacodynamics 
in dogs. 
6. To establish criteria for the selection of appropriate model(s) when more than 
one pharmacokinetic-pharmacodynamic. model may be representative of the 
obtained data. 
7. To evaluate applications and implications of investigated models. 
1 
CHAPTER 1 
LITERATURE SURVEY 
REVIEW OF DIGOXIN PHARMACOKINETICS 
History: 
Digoxin is one of the digitalis glycosides. The introduction of digitalis glyco­
sides has been at tribut.ed to Withering who published the first monograph on the 
action of digitalis in 1 785. Since then digitalis therapy has become well established 
and digoxin 1 t he most widely used of digitalis glycosides, is an indispensable drug 
in the treatment of cardiac insufficiency. Despite this Jong history of digoxin usage, 
implementation and maintenance of digoxin therapy in pat.ients is still complicated. 
This is due to various pharmacokinetic factors that have to be considered in design­
ing the optimal dosage for each individual. 
I) Review of Digoxin Pharmacokinetics 
In the absence of sensitive analytical met hodology, estimation of the quantity of 
glycoside in the body was possible only by observ ing t,he pharmacologic effect. More 
precise estimations became possible with the introduction of radiolabeled digoxin. 
The subsequent deYelopment of sensitive radioimmunoassays and HPLC a$Says have 
resulted in a greater understanding of pharmacokinetics in animals and humans. 
However, radioimmunoassay procedures are also non-specific and measure some of 
t he metabolites of digoxin , making them unsuitable for accurately characterizing 
t. he pharmacokinetics of digoxin. Hence, non-specificity of the assay procedure used 
2 
3 
is one of the factors that has to be considered when reviewing the existing body of 
literature on digoxin pbarmacokinetics. 
Following an intravenous dose, factors that contribute to the observed digoxin 
pharmacokinetics in animals or humans may be broadly classified as follows: 
a) Absorption 
b) Excretion 
c) Distribution 
d) Protein Binding 
e) Metabolism 
a)  Absorption: 
Digoxin is absorbed from the gastrointestina] tract b¥ a passive, nonsaturable 
transport process (Greenberger and Caldwell, 1972). The authors determined that 
40-60% of the dose of digoxin is absorbed in the duodenum and upper jejunum and 
only 1 0% is absorbed in the stomach. The first order rate constant for absorption is 
several times gr1ea.ter than the elimination rate constant ( Jelli:ffe, 1967) and1 there­
fore. variation in the rate of absorption bas little clinical relevance (Keys, 1980) . 
Studies indicate negligible metabolism of digoxin during "first pass" through the 
liver ( Beerman et al. 1972; Greenblatt et al. 1 976). Reviews on the bioavailability 
of digoxin have indicated tha.t the average bioavailability of digoxin tablets is 68% 
to 70% and that for the elixir is about 77% (Collaizzi, 1977; Greenblatt et al. 1976) . 
b) Excretion: 
Digoxin is eliminated primarily by renal excretion. Biliary elimination makes 
a smaller contribution to the total elimination of digoxin. 
4 
1) Renal excretion: 
60%-70% of the dose of digoxin administered as 3 H -digoxin is recovered in the 
urine over a period of 5-7 days (Huffman and Azarnoff, 1972; Greenblatt et al. 
1973, 1974; Sanchez et al. 1973; Marcus et al. 1976; Lindenbaum 1973; Bochner 
1977 ; Danon et al. 1977; Koup et al. 1975; Falch 1973; Falch et al. 1973; Gilfrich 
et al. 1973; Greenwood et al. 1975; Iisalo and Dahl, 1974; lisalo and Ruikka, 1974; 
Johnson et al. 1976; Ochs et al. 1975 and Wittrell et al. 1974). However changes 
in the amount of digoxin excreted in the urine may also represent differences in the 
bioavailability of the different dosage forms. In a group of six healthy subjects, dig­
oxin renal elimination varied from 50%-80% of the dose during maintenance dosage. 
This variation represented differences in bioavailability for the same preparation in 
different patients {Kongola et al. 1976, Mawer 1980) . 
2) Renal excretion of metabolites: 
Most of the dose of digoxin appears in the urine as unchanged drug. Major 
metabolites of digoxin that have been identified in the urine include digoxigenin, 
digoxigenin bis-digitixoside, digox.igenin mono-digitoxoside and reduced forms of 
digoxin and the corresponding metabolites (Clark and Kalman 1974; Peters et al. 
1978; Watson et al. 1973; Reitbrock and Abshagen, 1 973; Marcus et al. 1966 and 
Zilly et al. 197 5 ) .  
!J) Factors influencing renal elimination: 
S ince a major part of digoxin is excreted by the kidney, a good correlation 
exists between digoxin clearance and creatinine clearance. It has been generally 
well accepted that 60%-70% of the plasma digoxin passes into the ultrafiltrate, and 
creatinine clearance is used as a measure of digoxin clearance ( Jelliffe 1967 ,Iisalo 
1977) . . However, a few studies have shown that digoxin may also be eliminated by 
5 
active tubular secretion (Steiness 1974., Waldorf et al. 1978 ) .  These observtions 
do not detract from the usefulness of creatinine clearance as an index of digoxin 
clearance, since creatinine itself may be subject to active transport (Weiner 1973) . 
Gibson et al. 1984, however, found no evidence of concentration-dependent 
renal excretion of digoxin. This is in agreement with similar findings by Ochs et al. 
1 978 and Wagner et al. 1981.  However. Cldig ·'Clinulin (digoxin clearance/inulin 
clearance)' exceeded 2.00 in all subjects indicating that net tubular secretion is 
responsible for a large amount of the digoxin excreted in the urine. A strong cor­
relation between Cldig and renal plasma flow as measured by Clpah (para- amino 
hippurate clearance) was also observed and may be further evidence for the involve­
ment of a secretory mechanism in overall Cldig . Net tubular secretion of digoxin was 
also found in other studies (Cogan et al. 1981,  Jelliffee et al. 1967) and can account 
for up to 60% of the total digoxin secreted in the urine. 
Malcolm et al. (1977) , however, observed no significant effect for paired com­
parisons on the digoxin renal excretion in 8 healthy subjects receiving a single 
0. 75 mg oral dose of digoxin before and during the administration of oral furosemide 
40 mg daily. Their results seem to agree with those by Bissett et al. (1973) who 
showed that digoxin excretion is not dependent on urine flow rate. The above two 
studies are supported by those of Brown et al. (1976) . Tilstone et al. (1977) , and 
Tsutsumi et al. (1979) , where no significant effect of furosemide on digoxin renal 
elimination was found. All these studies involved an increase in urine flow rate as 
compared to patients with congestive heart failure ( CHF) . CHF patients usually 
have a low urine flow rate and hence might have a higher than normal digoxin 
tubular reabsorption. Moreover Tsutsumi et al. produced evidence that furosemide 
inhibits· the tubular secretion of digoxin, thus further confusing the issue. Halkin 
et al. (1975) in studies in 35 p13-tients foUI?-d that the variation in digoxin clearance 
6 
in these patients was more related to urine flow and urea clearance than to creati­
nine clearance. Urea clearance may therefore be a better way of estimating digoxin 
clearance in patients. 
Another drug affecting digoxin renal elimination is guinidine, which produces 
a reduction in renal clearance and a corresponding increase in serum digoxin con­
centration of about 2.5 times by an action which may involve inhibition of digoxin 
secretion (Doering 1979, Hayer et al. 1979) . 
4) Extrarenal excretion: 
Koup et al. (1975) found a mean value for total body clearance of digoxin 
(Cltbc) of 188 ± 44 ml/min/1.73 m 2 • which wa.5 significantly higher than that 
for digoxin renal clearance 144 ± 41 ml/min/1.73 m2 indicating that digoxin may 
also be eliminated through non-renal routes. These results together with similar 
results from Sumner and Russe] (1976) indicate that around 18%-28% of digoxin is 
eliminated by non-renal routes in patients with normal renal function. 
Based on the ratio of non-renal to total body clearance (Clnr/ Cltbc) ,  it is 
estimated that 25% of the elimination of digoxin occurs via non-renal routes (21.6% 
ba"3ed on the ratio of total amount of unchanged digoxin excreted in the urine and 
t .be dose administered i .e., Xuinf./dose) . These values are somewhat lower than 
t.he value rommon]y used by Je11iffe (1967). The data. is in agreement with that 
by Sheiner et al. (1972) , which suggest that. only 26% of the Cltbc of digoxin is 
accounted for b_r non-renal routes. 
· According to CaldwelJ and Cline (1976) , about 30% of an intravenous dose of 
3 H-digoxin reaches the _digestive tract in 24 hr. About 45%-50% of the radioactivity 
recovered in the stools after a dose of labeled digoxin consists of unchanged drug, 
10%-20% as digoxigenin bis-digitoxoside and 25% as digoxigenin mono-digitoxoside 
(Doherty and Kane, 1975). 
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In patients with renal failure. the reduced renal elimination rate results in 
a greater fraction of the dose b�in� .excreted through the non-renal mechanisms. 
Bloom and Nelp ( 1966) found a much larger qu-�1-ity of digoxin in the stools of pa­
tients with renal failure than in normal subjects without any indication of impaired 
GI abSQrption. Also. Doherty et al. 1967, observed an increase in fecal elimination 
of 3 H-digoxin in anephric subjects. 
c) Tissue Distribution: 
The estimation of the glycoside concentration in the ;nyocardium is the first 
and most obvious means of providing an answer to the question - does a constant 
relationship exist between the concentration of cardiac g]ycoside in the blood and 
that in the myocardium ? 
Studies on the distribution of digoxin haYe revealed large variations in the con­
c.t>n t ration of digoxin in cardiac tissue. This var iation in the estimation of digoxin 
ronc<'nt ration in cardiac tissue can be explained by rat io of muscle tissue to fat 
and conuectivt> t is5ue in the sample taken, patient groups studied, dosage and com­
pliance, time of sampling, different methods of sample preparation and analysis, 
...-ariations in electrolyte levels in the blood, or changes in myocardial concentra­
tio�s d ue to various pathologic states. However after steady state conditions have 
been established there exists a constant ratio between serum and myocardial levels 
of digoxin which permit plasma digoxin levels to be reliabl�1 used in the control of 
digoxin therapy. 
Doherty et al. (1967). in a study involving 11 patients found that highest 
tissue/serum ratio of digoxin in heart, kidney and liver and lowes1. for brain. Dry 
weights of tissues were also obtained in an attempt to determine if fluid-retention 
in tissues would affect the concentrations of 3 H-digoxin found in the tissue. There 
was no correlation between patients with varying degrees of CHF and the dry /Yvet 
8 
t.issue ratio showing that this factor is unimportant in relation to the distribution of 
digoxin. Anephric patients and those with renal failure showed highest tissue/serum 
ratio in heart muscle followed by liver and kidney and lowest in brain. The low 
concentration in brain tissue suggests the presence of a blood brain barrier for 
digoxin. 
Considerable differences in the distribution of digoxin have been found in the 
CNS. Andersson et al. ( 1975) found a mean digoxin concentration of 32 ng/ml 
wet weight in the telencephalon region of the brain in humans during steady-state. 
This was comparable to that in the skeletal muscle, but was 3 times higher than the 
concentration in fatt.y t issue. A concentrat.ion seven times that in the telencephelon 
was recorded for the choroid plexus where the con<'.entrat ion exceeded even that in 
the D:lyocardium by a factor of 1.7 (Kuhlmann et al. 1 9i9) .  Digoxin distribution 
studies on various brain tumors by Williams et al. (1976) indicate the i.n+porta.nce 
of blood-brain barrier and Na+ , K+ -ATPase in glycoside uptake. Corresponding 
to the si�nifi<:antly higher ATPase in meningiornas in comparison with malignant 
bias�omas . (Laws and O'Connor, 1970; Agren et al. 1971) the concentrations of 
digoiirl ��·�re 2 1.� -: 7.3 ng/gm. and 5.7 ± 5.2 ng1gm wet weight 11espective]y. 
In �<;>gs then is a dist inct concentration difference between the cerebrum, cere­
be1lum �d different sections of the brain stem ( Kuhlmann et al. 1979). On a daily 
rnaint�rian.ce dost'. digoxin accumulation in the dog brain is higher than in other 
iisi:;u.es: (Reitbrock and Alken, 1980) , a large part of it being bound non-specifically. 
r,he reported values for cerebrospinaJ fluid : serum ratio in patients on main­
te��c�. ��s�s of digoxin vary between 0.03 and 0.3 (Allonen et al. 1 977 , Gayes et 
al. ·\978� Schott et al. 1976) . Children have the samt> ra.tio as adults (Allonen et 
al. 1977) . 
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d)  Protein binding: 
Using equilibrium dialysis. St.qr�tein et  al. (1976) : determined protein binding 
of digoxin to be 22.4 ± 2.1  %; and that for digoxigenin mono-digitoxoside to be 
1 8.8 ± 1.9%. Protein binding of d igoxin may ht- ahered in serum of individuals 
with Kwashiorkor (Buchanan et al. 1 97fi) . and in uremic- patients on hemodialysis 
(Hawlina and Rahn 1974) .  
e) l\1etabolism: 
Studies have shown that digoxin metabolism involves reactions ranging from 
cleavage of sugar molecules to conjugation reactions. The major pathways are : 
1 )  c leavage of the d igitoxose residues 
2) conjugat ion reactions 
3) Hydrogenation 
S t.ructures of digoxin and some of its major metabolites is given in fig. 1 . 1  
1 )  Cleavage of digitoxose residues 
One of the earliest reports of the cleavage of cardiac glycosides into the genin 
and sugar moiety by enzymatic hydrolysis has been by Kelsey ( 1957) .  The first 
condusive analytical investigations however, came from the research activities of 
Okita ct al. ( 1975) , and Repke (1959, 1966, 1970} . 
The l iver is the principal site for the cleavage of the p-g]ycoside bond. The 
precise nature of the enzyme however is not yet clear!) e.xplained. A c leavage by 
8-g.J��u�onidase is unlikely since this enzyme has an absolute specificity for carbon 
a.t.9rr� � �\•hkh in digoxin has the -OH group linking the sugars in the epimer form 
(Repke 1 970) . The cleavage of a sugar chain is therefore probably not a simple 
hytirolysis titer,. Investigations on rat. liver microsomal preparations have shown 
that- the · digitoxose group of digitoxin is only released in the presence of NADPH 
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Fig. 1 . 1  Structure of d i goxi n and i ts metabo l i tes . 
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and that the reaction can be inhibited by the microsomal inhibitor SKF-525A and 
by carbon monoxide (Schmoldt et al. 1975) . The neonate liver is: unable to carry 
out the cleavage reaction, thus supporting the participation of these postnatally 
acquired enzymes (Hermann and Repke, 1963a) .. Schmoldt et al .  ( 1980), by in­
cuba�ing digoxigenin (dg..O), digoxigenin bis-digitoxoside (dg-2), and digo;x:igenin 
mono-digitoxoside (dg-1)  and digoxin (dg-3) ,  with rat microsomes found that mi­
crosomal monooxygenases can oxidize the axial hydroxy] group of the terminal 
digitoxosyl of digoxin, or bis- or mono-digitoxosides to an oxo group. Only after 
this oxidation c:an the terminal sugar be split off, presumably biy ,B-elimination. 
Therefore for the degradation of dg-3, three successive cytochrome P-450 catalyzed 
oxidations are neccessary before dg-0 can be obtained. 
2} Conjugation reactions 
Conjugation reactions with sulfate and glucuronide must be considered as fac­
tors in the biotransformation and rapid elimination of the mono-glycosides and 
aglycones (Hermann and Repke 1963 a,b; Kuhlmann et al. 1974) .  
T he possibility of direct conjugations with tri--digitoxosides and their sugar defi­
cient metabolites has also been considered. Almost all the relevant studies Jeft room 
for contradictory interpretations. Up to the present time, direct structural analysis 
of the ch Jorofor m-soluble metabolites of plasma, urine and feces has been frustrated 
owing to difficu]ties in isolation and the small quantities recovered. Despite t,he 
lack of definitive methodological alternatives, thin layer chromatographic analysis 
reveai·�. t-yi.-ii ·d:�tinct pathways : the direct conjugation of the mono-digitoxoside, ,and 
the conj�gation (possibly confined to the rat only) of the �-epimer of the aglycone 
(Herm�n and Repke, 1963a,b; Reitbrock and Vohringer, 1974) .. Both reaction 
steps lead ·to a considerable incr,ease in elimination rate (Repke 1970) . It is safe 
to assume that clue .to the higher polarity of the conjugates their elimination rates 
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are high and their accumulation comparatively low. This is in agreement with the 
half-lives of 1.2 hr. ,  11.5 hr., 8.5 hr., and 2 hr. for dihydrodigoxin, digoxin bis­
digitoxoside. digoxin mono-digitoxoside and digoxigenin respectively, reported by 
Gault et al. (1979) . That the metabolites of digoxin have a shorter half-life than 
that for digoxin was also brought out by Gierke et al. (1980) , who studied the dis­
position of digoxin bis-digitoxoside in dogs before and during chronic azotemia. The 
bis-digitoxoside was eliminated primarily by non-renal mechanisms. The t 112 for 
the bis-digitoxoside was 18.5 hours and was not significantly increased in azotemic 
dogs. 
9} Hydrogenation 
There have been several reports on the occurrence of dihydro compounds in 
plasma and urine of humans (Luchi and Gruber 1968; Watson et al. 1973, Clark 
and Kalman 1974: Peters et al. 1978) . The saturation of the double bond between 
C20 and C22 is effected by intestinal microorganisms (Hermann and Repke 1968). 
The microorganisms responsible are probably anaerobic since saturation of the 
)actone ring becomes completely suppressed when lanatoside C is incubated with 
cecum contents in the presence of oxygen (Hermann and Repke 1968). Since t.he 
hydrogenation occurs in the lower intestine, the appearance of the cardenolide in 
urine is observed with a clearly defined lag phase. Formation and absorption of 
hydrogenated compounds is subject to considerable individual variation depending 
on the nature of the bacterial flora of the gut and the bioavailability of the parent 
glycosi°dt>. The cardioactivity of dihydrodigoxin is only 1/20 th of that for digoxin 
(Hermann and Repke 1968). 
Wat.son et al. (1973), succeeded in the determination of dihydrodigoxin in 
plasma and urine using gas chromatography - mass spectroscopy (GC-MS) . A high 
dihydrodigoxin concentration in plasma was detected in 3 of 150 patients. In one 
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case it  amounted to 30% of the total glycoside and was suprising in view of the report 
from Luchi and Gruber (1968) , that none of the patients required an unusually high 
dose of digoxin. The highest daily dose administered was 1 mg. and the lowest 
0.25 mg. Clark and Kalman (1974) , examined the distribution and excretion of 
metabolites in 50 patients on maintenance therapy with 0.125 - 0.75 mg. daily. 
From 2% - 10% of the glycosides excreted in the urine were polar, water soluble 
metabolites. 50% of the patients excreted dibydrodigoxin, mean value 13%, with a 
range of 1 % ·- 4 7% of the total glycoside output. However, studies by Magnusson 
et al. (1982) in 8 healthy men administered oral tritiated digoxm revealed that 
dihydrodigoxin constituted only 0. 7 ± 0.4 % of the total radioactivity excreted in the 
urine. Gault et al. (1979) determined the elimination of digoxin and its metabolites 
in 6 subjects with normal renal function and 6 patients with minimal renal function. 
Dihydrodigoxin constituted 0.3% and 0.03% of ingested radioactivity in these two 
groups. 
The clinical importance of such dihydrodigoxin compounds must be evaluated 
from two aspects . The first is with regard to the radioimmunoassay of glycoside 
concentrations in plasma and urine since it is known that digoxin antibodies cross­
react with digoxin metabolites (Kramer et al. 1976; Stoll et al. 1972) . 
The second aspect remains to be investigated and is whether individual dif­
ferences in transformation of digitalis glycosides into their dihydrodigoxin ha.s an 
effect on the variation of glycoside plasma concentrations. Animal experiments have 
shown that dihydrodigoxin persists in the tissue of t.he dog for an extremely short 
period (Rietbrock et al. 1981) .  Furthermore the presenC'.e of a plasma-tissue con­
centration gradient of approximately 1.0 indicates the absence of an organ-specific 
distribution . 
Peters et al. ( 1978) , also indicated that the occurence of significant quanti­
ties of dihydrodigoxin in the urine could be dependent on diet or gut fl.or�. That 
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the gastrointestinal flora play an active role in the hydrogenation of digoxin and 
metabolites to give digoxin reduction products (DRP's) was proven by Linden­
baum et al. (1981) .  He found that in approximately 10% of the patients given 
digoxin, substantial conversion of the drug to cardioinactive DRP's occurs. Stool 
cultures from subjects known to make DRP's in vivo (excretors) , converted digoxin 
to DRP's: cultures from non-excretors did not. T hree excretors were given digoxin 
tablets for 22 - 29 days. In these excretors urinary excretion of DRPs was greatest 
after administration of the poorly absorbed tablet and least after i.v .  administra­
tion. A 5-day course of erythromycin or tetracycline after a baseline period of 10  -
1 7  days, markedy reduced or eliminated DRP excretion in urine and stool .  Serum 
digoxin concentration rose as much as two fold after antibiotics were given. It is 
thus evident that the enteric flora is responsible for the hydrogenatfon of digoxin to 
give DRP's and that changes in the enteric flora may alter digoxin levels. 
Effect of acidity: 
Magnusson et al. (1982), studied the 3-day urinary excretion of digoxin. its con­
jugated and unconjugated hydrolytic metabolites and dihydrodigoxin , in 8 healthy 
men after oral administration of tritiated digoxin. Analysis was performed by 
HPLC. 42.4 = 2.7% of the dose of 3H-digoxin was recovered before and 44.0 ± 
2.2o/c after deconjugation of the urine samples. Digoxin and dihydrodigoxin consti­
tuted 40.3 ::: 2.9% of the total radioactiv ity recovered in the urine of which 0. 7 ± 
0.4% was dihydrodigoxin. The sum of the hydro)ytic metabolites was 2.1  ± 0.3% 
before and 3.4 :t 0.15% after deconjugation. No correlation was found between 
fasting gastric pH measured just prior to the administration of the dose of digoxin 
and the production of hydrolytic metabolites. 
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Magnusson et al. (1984) , studied the metabolic profile of digoxin in patients 
with a low gastric hyperacidity (GH) , and a group of patients on digoxin treat­
ment in coronary care. The overall metabolic profile of the two groups was not 
significantly different. For the patients with low gastic pH the percentage of to­
tal radioactivity excreted in the urine in 24 hrs. constituted 21 .3 ± 0.6% of the 
dose. i5.2 ± 8.5% was excreted as digoxin and dihydrodigoxin. Dihydrodigoxin 
represented onl�, O.i ± 0.1 % of the digoxin-dihydrodigoxin fraction. Digoxigenin 
and its conjugated version constituted 7 ::i: 2.5% of total radioactivity, digoxigenin 
mono-digitoxoside and its conjugat.e constituted 1.5 ± 0.5% and digoxigenin bis­
digitoxoside and its conjugate constituted 4.3 ± «;).8% of the dose. The metabolic 
profile for the coronary care group was similar. The pH in the gastric hyperacidity 
(GH) group ranged from 1.15 to 2.04. It thus seems that the gastric acid degrada­
tion of digoxin is small and the clinical importance of the hydrolysis of the g)ycoside 
seems limited. 
Effect of renal function: 
Gault et al. (1984) , studied the effect of renal function on digoxin biotransfor­
mation. Group I patients consisted of 10 dialysis-dependent chronic renal failure 
patients with creatinine clearance ranging from 0 to 5 ml/min. and Group II con­
sisted of 5 pat.ients with creatinine clearance ranging from 38 to 100 ml/min. Pa­
tients were on maintenance doses of digoxin. They were then administered 150 µCi 
of 3 H-digoxin-1 2-a .  Blood and urine collected over 24 hours was assayed by HPLC. 
The variation in the degree of biotransformation among patients was great in both 
groups and no significant differences between the means for digoxin for the two 
groups or for the metabolites was found. The mean percentages for digoxigenin, 
3-keto-digoxigenin� 3-a:-(epi)-digoxigenin and for the mono- and bis-digitoxosides 
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were less than 3% of the total radioactivity in both groups. Polar metabolites con­
stituted a mean percentage of 28% of the total radioactivity in Group I and 22% of 
the total radioactivity in Group ll. 
Studies on CAPD patients have shown that means for percent digoxin and 
metabolites for CAPD patients did not differ significantly from those on hemodial­
ysis and that CAPD removes only relatively small amounts of digoxin from the 
body (Vitali et al. 1981 ) .  
In conclusion, it appears that the biotransformation of digoxin involves all the 
classic metabolic reactions. In one route there is initially hydrolysis with release of 
the sugars, either in the stomach (Gault et al. 1980), or in the liver, to produce 
3-,8-digoxigenin. This is then followed by oxidation to produce 3-keto-digoxigenin, 
epimerization to give the 3-a- ( epi)-digoxigenin, and finally conjugation, as with 
glucuronic acid, to give polar end-metabolites. It is possible that conjugation of 
t.he mono-digitoxoside takes place (Kuhlmann et al. 1974) , and that steriod ring 
hydroxylation may also take place. Reduction may occur in the lactone ring to give 
significant amounts of dihydrodigoxin in some patients. Clearly biotransformation 
of digoxin to polar metabolites occurs to a major extent in some patients and may 
result in an appreciable component of the serum digoxin concentration measured 
by RIA being metabolites some of which may be cardioinact,ive. 
Compartmental Analysis 
The digoxin concentration-time curve after intravenous injection or infusion can 
be described by a model containing at least two kinetically distinct compartments. 
(Doherty et al. 1 968: Greenblatt et al. 1974; Nyberg et al. 1974; Reuning et al. 
1973). A three compartment model has been proposed by Kramer et al. ( 1974) and 
by 8-µmner and Russel] (1976). 
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The initial decline in plasma concentration is the rapid d istribution i n  to the 
peripheral compartmen;t�from the central or plasma compartment. This d istributive 
phase has a half-life which varies from 20-60 mins. Extensive distribution into the 
peripheral compartment is indicated by an average volume of d istribution at steady 
state which grea.tly exceeds the volume of the central compartment and the volume 
of body water (Reuning et al. 1973; Nyberg et al. 1974 ; Koup et al. 1975) . 
The peripheral compartment is mainly the skeletal muscle. The deep compartment 
includes erythrocytes and brain where the equilibrium concentration is reached later 
than in most other tissues (Gorodischer et al. 1976: Kuhlmann et al. 1979) . The 
volume of distribution, calculated at steady state rv ds_, ) .  varies in hea1thy subjects 
between 5.1 and 8 . 1  I /kg.: in patients with cardiac failure it is approximately 5 .0 
1 /kg.: and in renal failure, 3.3 to 4 .4 1/kg. (Reuning et al. 1973; Nyberg et al. 1974 ; 
Koup et al. 19i5. 1976) . Infants and neonates seem to have a higher volume of 
distribution at steady state than found in adults. 
Investigators have used 2 or 3 compartment models (Sumner et al. 1976, Shen­
field et al. 1977, Koup et al. 1975) . The two compartment mode) consists of a 
central and peripheral (or tissue) compartment while the 3 compar1,ment mode] has 
2 peripheral compartments one being a deep compartment, (Sumner et al. 1976) . 
The central compartment is usually regarded as being the serum and highly perfused 
organs sueh as liver, kidneys and lungs . Skeletal and cardiac tissue are regarded as 
belonging to the peripheral compartment (Iisalo 1977) . 
Kramer et al. ( 1974) fit plasma concentration vs. time profiles for d igoxin in 
5 health� volunteers. to appropriate equations describing two and three compart­
ment open model!- using weighted non-linear lea5t, squares regression analysis . The 
comparison of two and three compartment model indicates that the three compart­
ment open mode] is the simplest model consistent with the observed data. The 
improved fit using the three compartment model, as evidenced by F-tests, weighted 
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residual plots: and semilogarithmic plots of predicted and experimental serum dig­
oxin concentrations yields more meaningful parameter estimates and an improved 
estimate of the half-life of the terminal exponential phase of the serum digoxin 
concentration-t ime data. 
Bal ant. et al. ( 1980) , in an excellent article, observed that the results of previous 
workers indicat.ed that a three compartment (mammillary) model more accurately 
describes digoxin disposition after an i .v .  dose than do simpler models and that the 
more accurate model. consistent with <la.ta is needed when blood and/or tissue con­
centrations are to be correlated with the acute effects of digoxin on left ventricular 
ejection time, heart rate or on the duration of electromechanical systole. 
However in the postdistributive phase after single or multiple dosing, digoxin 
disposition may be adeqately described by a mono-exponential or bi-exponential 
equation. Therefore, although a three compartment model is kinetically most ac­
curate in describing digoxin kinetics in man , the simpler t,wo and one compartment 
model are clinically useful as long as its limitations a.re appreciated. 
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Effect of Disease on Digoxin Pharmacokinetics 
a) Renal insufficiency 
Severa) authors h ave reported e.xcessjveJy hjgh se.rum. digoxin le-veJs jn patients 
with renal impairment receiving apparently normal maintenance doses (Beller et al. 
1 9i l ;  Doheny et al. 1975; Marcus et al. 1966) . Ochs et al. 1978a, noted that the 
a.ge rela.ted increase in serum levels probably reflects the decline in renal function 
in the elderly. 
A high proportion of patients with digitalis intoxication have impaired renal 
funct.ion (Beller et al. 1971 ;  Bodem et al. 1979). The incidence of adverse ef­
fects during clinical use of digoxin is reported to be as high as 18% in the general 
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population (Shapiro e t  al. 1969) and as high as 40% in  patients with severe renal 
impairment (Ogilvie and Ruedy 1972) . 
It is well accepted that renal clearance of the intact drug accounts for the total 
digoxin clearance (Bodem and Ochs 1979; Greenblatt et al. 1974 ) .  Both tubular 
reabsorption and secretion of digoxin have been demonstrated (Bloom et al. 1966; 
Doherty et al. 1 969: Marcus 1972; Steiness 1974; Roman and Kauker 1976; Wal­
dorg et. al. 19i8) . Steiness ( 1974) has shown that d igoxin serum levels may rise 
when tubular secretion is blocked by concurrent administration of spironolactone. 
In patients with hypokalemia, active tubular secretion of digoxin is reduced (St.ei­
ness 1978) . This also occurs with combined treatment of digoxin and furosemide. 
Tubular secretion is enhanced by potassium supplementation. 
Jusko and Weintraub (1974) ,  using radioimmunoassay studied the relationship 
of myocardial digoxin distribution at autopsy and the ante-mortem renal func­
tion. The myocardial serum concentration ratio became progressively smaller in 
patient$ with decreasing creatinine cJearance. These altered tissue-serum concen­
tration ratios probably explain the changes in volumes of distribution (Aronson and 
Grahame-Smith 1 976: Brass 1970) . 
Doherty et al. (1967) examined the distribution of tritiated digoxin in human 
tissues in patients who received the labeled drug prior to death . The highest tis­
sue/serum ratios were seen in heart, kidney: liver and the lowest for brain . Anepbric 
patients and those with renal failure showed the highest tissue/serum concentration 
ratios in heart, muscle and liver . In patients with normal renal function, the highest 
ratio v,as found in the kidney. 
Studies by Doherty et a�. ( 1964) , showed a 7-day stool excretion of 31% of the 
dose after oral administration of tritiated digoxin in anephric patients as compared 
to 12% in normals. After kidney transplantation in these patients 21 % of the 
radioactivity was detected in the stools over a 7-day period. The serum half-life of 
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digoxin is prolonged from 1.5-2 days in individuals with normal renal function to 
4-10 days in dialysis dependent patients (Doherty and Perkins 1962; Doherty et al. 
1967) .  Differences in volume of distribution (V d) , may also account for changes in 
half-life since changes in half-life depends on both clearance and V d. Koup et al. 
(1975) , found V d values ranged from a mean of 330 liters in patients with severe 
renal impairment to 530 liters in young healthy adults. Reuning et al. (1973) 
estimated an av,erage V d of 510 liters in normal subjects as compared to 230-380 
liters in patients with renal disease. 
Dengler et al. (1973) determined a mean V d of 375 liters in patients suffering 
from heart failure but with serum creatinine concentrations in the normal range. 
Data in young subjects show mean V d values of 4 .9-5.9 liters/kg. (Ochs et al. 
1978b) . Ohnhaus et al. ( 1979a) reported that abso[ute bioavailability of oral digoxin 
was not altered in patients with renal failure despite a decrease ill V d. A decreased 
V d in patients with severe renal impairment may be of c1inical importance since it 
implies a need for reduced loading doses. However the reduced ·v d in renal failure 
is a.ttributable to reduced uptake into tissues, including myocardium. In 9 patients 
with end stage renal disease, an intravenous dose of O.i mg. resulted in a mean 
serum digoxin level of 1.43 ng/ml (range 1 .0 - 2.1)  24 h. later. with none of the 
patients showing evidence of toxicity (Gault et al. 1976). Although a given loading 
dose will lead to a higher serum level in a renal failure patient. this does not imply 
a proportionately higher myocardial level . 
Koup et al. (1975b) found a. value of 47.7 ml!/min/ 1.73 m2 for the metabolic 
or non-r�nal clearance. This value agrees very well with the average reported by 
Koup et al. (1975a) in patients with severe renal failure. This suggests that the 
metabolic clearance of digoxin may be constant in reI_1al failure. 
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b) Thyroid Disease 
Hyperthyroid patients appear to require larger doses of digitalis (Watters and 
Tomkin 1975; Klassen et al. 1977) . Unusually high doses may be needed to control 
ventricular rate in atrial fibrillation due to thyrotoxicosis (Wenkebach and Winter­
berg 1927; Boas 1931; .Barker et al. 1932; Frye and Braunwald 1961; Morrow et al. 
1963) . However, hypothyroid patients need smaller doses of cardiac glycosides to 
treat congestive h<:>art. failure (CHF) (Morrow et al. 1963). 
The altered sensit ivity to digitalis in patients with thyroid disease has been 
attributed to a change in intrinsic myocardial function (Buccino et al. 1967; Peacock 
and Moray 1963: Morrow et al. 1963). The "resistance" to digoxin in thyrotoxicosis 
might be due t-o similar actions of thyroxine and digoxin in Na+ and K+ -dependent 
ATPase (Lindsay and Marker 1976) . However, alterations in glycoside kinetics 
is another possible explanation and have been evaluated by several investigators 
using either radioactive glycosides (Doherty and Perkins 1966; Eichenbusch et al. 
1970). or radioimmunoassay (Croxon and Ibertson 1975: Gilfrich and Meinertz 
1978; Shenfield et al. 1977) . Interpretation of results obtained with radioactive 
glycosides is difficult because the methods used in the isolation and quantitation of 
the various metabolite fractions differ in speci:6.cicy (Eichelbaum 1976). 
Dohercy and Perkins (1966) investigated digoxin pharmacokinetics in relation 
to thyroid function. Doses of 0.75-1.5 mg. tritiated digoxin were administered in­
travenously or orally to 13 hyperthyroid, 10 hypothyroid and 12 euthyroid patients. 
Levels of radioact ivity were lowest in hypothyroid, intermediate in euthyroid and 
highest iri hyperthy roid patients, suggesting that- these pharmacokinetic changes 
might- explain alt.ered sensitivicy. The serum half-lives in the 3 groups was not sig­
nificantly different .. nor were the half-lives for urinary excretion. In 2 hyperthyroid 
patients who became hypothyroid roi1owing treatment with radioiodine, and one hy­
pothyroid patient who became euthyroid following treatment with thyroid hormone; 
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no significant changes in serum half-lives for urinary excretion were observed. To 
explain the lower or higher plasma digoxin levels in thyrotoxicosis and myxedema 
respectively, Doherty and Perkins proposed an altered volume of distribution in 
these conditions. 
Ismail-Beigi and Edelman (1971) showed higher tissue levels of Na+ , K+ -
ATPase in thyrotoxicity. Therefore, the suggestion of changes in tissue concen­
tration or distribution of digoxin in thyroid dysfunction may be valid. Experiments 
with eutbyroid. hyperthyroid and hypothyroid dogs: however failed to demonstrate 
signjficant changes in tissue digoxin in relation to thyroid function, while the serum 
level changes were similar to those seen in patients (Doherty and Perkins 1966). 
Croxson and Ibbertson (1975) using radioimmunoassay (RIA) studied steady­
state serum digoxin concentrations in 17 hyperthyroid and 16 hypothyroid patients 
24 h after the final dose. These patients had been treated with 0.5 mg. digoxin daily 
for 7 days. Serum concentrations and plasma half-lives of digoxin were significantly 
different between the two groups. 
Since creatinine clearance is elevated in hyperthyroidism and decreased in hy­
pothyroidism: alterations in digoxin kinetjcs in thyroid disease may be attributable 
to changes in renal function (Bradley et al. 1974). These observations were con­
firmed by Lawrence et al. (1977) who administered trit.iated digoxin to 9 hyperthy­
roid and hypothyroid patients. Mean plasma radioactivity did not differ between 
the 2 groups, but digoxin clearance and glomerular filtr�tion rate (GFR) were sig­
nificant ly correlat.ed. 
:Reduced intestinal absorption in thyrotoxicosis is also a possibility. Huffman 
et al. ( l 9i7) showed an increase in serum digoxin concentration from 0.3-0.4 to 1.4 
ng/ml. and a similar increase in daily urinary excretion of digoxin, 3 months after 
treatment ':''ith 1 3 1  I in a patient receiving 0.25 mg. daily. Steady state levels of 
digoxin as we1 1  as daily urinary excretion were similar with 0.3 mg/ day i.v. and 
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0.75 mg/day orally. This suggests that only 35% - 40% of the dos,e was absorbed 
by this thyrotoxic patient compared to the usual value of 65% - 70%.  Lower levels 
of digoxin measured by RIA were also observed by Shenfield et al. (1977) in 4 
hyperthyroid patients after oral administration of a. 0.5 mg. dose as compared to 
normal patients. Gilfrich and Meinertz (1978) administered 1 mg. digoxin i.v. to 
8 patients with thyrotoxicosis. The same patients were studied after they became 
euthyroid with treatment. Urinary excretion half life was approximately 24 h in the 
thyrotoxic stat,e as compared to 40 h in the same patients after thyroid function had 
returned to normal. Cumulative urinary excretion of digoxin was appreciably lower 
during thyrotoxicosis (51% of dose) than after normalization of thyroid function 
(78%) .  Since the drug was given i.v. a decrease in the extent absorption during 
hyperthyroidism cannot account for these differences. 
Another possible explanation for the differences in levels are due to altered 
volumes of distribution (Doherty and Perkins 1966) . Increased volume of distribu­
tion in hyperthyroid patients and decreased volume of distribut.ion in hypothyroid 
patients were demonstrated by Shenfield et al. ( 19'iiL and Gilfrich and Meinertz· 
( 1978L showed a larger V d in hyperthyroid patients than in euthyroid patients. The 
findings of decreased serum and liver levels of tritium in the hyperthyroid group. 
but increased cardiac levels, supports the concept of changes in the distribution of 
d igoxin in hyperthyroidism. There is considerable evidence to suggest that there 
a.rr c hanges in glycoside receptors with altered thyroid status. The nature of the 
cardiac receptors remains unresolved but there is still doubt. that the Na+ , K+­
ATPase is intimately involved (Goltart 1978) and it has also been shown that there 
is an increase in Na+ ,K+-ATPase activity in hyp,erthyroidism (Curfman, Crawley 
and Smith 1977) . 
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Lindsay and Parker (1976) , showed that pre-treatment with thyroid hormones 
or digoxin in rats resulted in increase Na+ , K+-ATPase activity but that pretreat­
ment with both was not additive suggesting that T4 and digoxin both competed for 
the same pathway. Therefore with increased ATPase activity more digoxin may be 
needed to achieve the degree of inhibition necessary for a therapeutic response. In 
addition, increased Na+ K - -ATPase activity resulting in increased digoxin binding 
to tissues such as skeletal muscle could account for the observed differences in serum 
levels and V d of 3 H-digoxin. 
There is evidence of liver enzyme induction in hyperthyroidism for a number of 
drugs (Kato 1977, Crooks et al. 1973, Eichelbaum 1976) and an increase in biliary 
excretion of both unchanged digoxin and metabolites in hyperthyroid rats has been 
demonstrated (Huffman et al. 1978) . It is possible that in hyperthyroidism, digoxin 
metabolites are more avidly taken up into cardiac tissue than is the parent drug and 
this possibility has not been excluded by any of the present studies since 3 H-digoxin 
was used or digoxin was assayed by RIA both of which measure a fair amounts of 
metabolites. Liver enzyme induction is also suggested by Varadi and Foldes ( 1 976) : 
who observed increased D-glucaric acid secretion in most hyperthyroid patients as 
compared to normal subjects. Since an increased D-glucaric acid excretion is a 
result of the induction of the glucuronic acid pathway (Hunter et al. 1971) ,  it was 
concluded that in thyrotoxicosis the enzymes of the glucuronic acid sequence are 
s t imulated and the hepatic transformation of digoxin can be enhanced by thyroid 
hormones as endogenous enzyme inducers. 
The hyperdynamic state in hyperthyroidism may also be involved in the altered 
cardiac tissue level, heart rate for example has been implicated in glycoside binding 
(Lloyd and Taylor 1978, Roth-Schechter et al. 1970) and there is an increased heart 
rate in hyperthyroidism. 
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Thus there are several possible explanationis 10r the increased cardiac binding 
of digoxin in hyperthyroidism. The two most likely hypotheses are :- 1) Changes in 
sensitiv ity to digoxin with altered thyroid status are due to changes in serum level. 
2) Changes in sensitiv ity to digoxin with altered thyroid status are due to a direct 
effect of thyroid hormone of the heart inducing increased Na+, K+ -ATPase. As a 
result more glycoside is needed to achieve the same response. 
c)  Potassium Imbalance 
Potassium ions influence electrophysiologic events in the heart. Excess myocar­
dial potassium reduces conduction in ·the atria and subnodal system and depresses 
automaticity. Despite this, in cJinical situations, conduction disturbances during 
hyperkalemia are rarely seen, except in digitalized patients, indicating that inter­
action between potasium and the cardiac glycosides (F isch and Knoebel . 1966). 
Intracellular depletion of potassium appears to interact directly with the action of 
cardiac glycosides promoting toxicity (Lown et al .. 1951). 
Serum potassium poorly reftects intracellular pot_assium (Lown et al. 195 1 , 
Lown and Levine 1954a, Moore et al. 1954). Potassium ions also contribute to the 
t,ransmembrane resting and action potential of the myocardial cell. These facts may 
explain the relationship between hypokalemia and digitalis toxicity. Also, clinical 
benefit has often been achieved by the administration of potassium in patients 
with digoxin-induced arrythmias. The fact that hyperkalemia can also result from 
digoxin intoxication (Gaultier et al. 1968, Citrin et al. 1972, Rumrack et al. 1974) 
complicates the situation and stresses the importance of understanding the etiology 
behind the changes in serum potassium. The influence of potassium on inotropy 
is not well understood. In laboratory experiments, potassium was found to lessen 
the inotropic response (Prindle et al. 1971, Lee et al. 1977), but. this has not been 
confirmed clinically. 
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Steiness (1978) however has reported that digoxin toxicity in hypokalem.ic pa­
tients is compounded by a reduced active renal tubular secretion of digoxin in 
humans, an effect already observed earlier in dogs (Marcus et al. 1971). This may 
partly explain why hypokalemia pre-disposes to digoxin toxicity. All patients were 
receiving both digoxin and furosemide maintenance treatment and inulin clearance 
was used as the baseline for changes in clearance. When patients received potassium 
supplements, the tubular secretion was restored to normal. 
Cohn et al. ( 1967) , studied the effect of K + depletion on myocardial concentra­
tion of tritiated digoxin. He found that there was no significant differences between 
the myocardial 3 H-digoxin of the central and potassium-depleted groups at 0.5, 1, 
2, 6 or 16 hours but at 24 hours, a significantly higher concentration of digoxin was 
present in the potassium deficient mouse hearts (23.6 ± 5.2 µg/gm.) than in the 
control group (3.1 ± 1.5 µg/gm.). Potassium depl,eted mice with total renal failure, 
showed increased myocardial 3 H-digoxin levels at 20 hours as compared to mice 
with renal failure but without potassium deficiency. lt is thus evident that dimin­
ished renal function produced by potassium-depletion is not the sole mechanism of 
this retention of cardiac 3 H-digoxin. 
The mechanism by which digitalis inhibits the influx of potassium is still under 
investigation. However, it has been established t.hat the active transport of Na+ and 
K + across the cell membrane is associated with the splitting of ATP by membrane 
ATPase. It has been postulated that Na+ and K + activate ATPase by combining at 
sites which are more or less selective for these ions. The transport ATPase is readily 
inhibited by concentrations of the cardiac glycosides in the range from less than 
10-8M to more than 10-4M (Glynn 1964). At lower concentrations of digitalis, the 
degree of inhibition of K+ influx appears to diminish as extracellular K+ increase 
(Page 1964, Glynn 1956) . This observation may be explained by competition of 
cardiac glycoside and K + for a binding site, possibly on the cell membrane (Page 
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1964, Repke 1965, Glynn 1 95i). In addition, Ebert et al. (1967) , reported that 
K+ can displace digoxin from the heart. This is in agreement with the studies of 
Marcus et al. (1969) . The authors determined digoxin disposition in 2 groups of 
dogs. 1n group I hyperkalemia was produced prior to the injection of digoxin and 
was continued to 1 hour or 4 hours before sacrifice. In group 11 infusion continued for 
1 50 mins. Serum K+ was in the range of 6-9 mEq.jL. There was less digoxin in the 
myocatdium of hyperkalemic dogs in group I. There was a decrease in the amount in 
the kidney, but an increase in digoxin concentration in the skeletal muscle. Group II 
dogs displayed no difference in concentrations of digoxin in the myocardium, kidney 
and skeletal muscle. The authors postulated that the change in body distribution of 
digoxin in the dogs made hyperka]emic prior to the administration may be explained 
in part by competetive inhibition of K+ and digitalis for similar receptor sites. Once 
digitalis is bound to the cell, hyperkalemia does not alter its retention. Therefore 
the mechanism of K+ in reversing digitalis induced arrythmias may be other than 
physical displacement of digoxin from the heart. It is also possible that the portion 
of digoxin that is pharmacologically active is a minute portion of that present in 
the myocardium and that K+ displaces this fraction, diminishing pharmacologic 
activity but releasing amounts of digoxin which are not measureable by methods 
available then. 
d) Obesity 
Ewy et al. (1971) , studied the effects of obesity on digoxin distribution by 
administration of a single i.v .  dose to five obese patients before and after a mean loss 
of weight of 102 lbs. There was no significant difference in the blood concentration 
of digoxin before and after weight reduction. The finding is consistent with the 
hypothesis that fat-free body weight is a more important determinant of the blood 
concentration of digoxin than total body weight. 
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INTRODUCTION TO PHARMACODYNAMICS 
Pharmacokinetics involves the study of movement of drugs into, through and 
out of the body. It describes the processes and rates of drug movement from the 
,. 
site of absorption into the blood, distributio� into the tissues and elimination by 
metabolism or excretion. Pharmacodynamics refers to the description of drug effects 
once the drug has reached its site of action. · An aphorism that is appropriate 
is, "Pharmacokinetics is what the body does to the drug : Pharmacodynamics is 
what the drug does to the body." Therefore, to investigate the pharmacodynamic 
behavior of a drug the primary requirement is that the drug have a biological 
response that can be monitored. 
Biological responses 
Pharmacodynamic parameters that can be monitored with time following acute 
administration of cardioactive agents include blood pressure, heart rate and left. ven­
tricular ejection time (LVET) (Shapiro et al. 1970; Weisler et al. 1966; Hinderling 
and Garrett 197i6; Thiobonnier et al. 1984) . The extent of antagonism of isopro­
terenoJ action may permit the quantification of beta-blocker action. Ocular pressure 
is a measure of the action of carbonic anhydrase inhibition (Lehmann et al. 1970) , 
and pupil dilation is a proper measure of mydriatic action (Smolen et al. 1971 ) .  
Depth or duration of anesthesia can be measured for the action of anesthetics (Levy 
et al. 1966; Brodie et al. 1967) . 
However, in many cases, an acute pharmacodynamic response cannot be quan­
tified. Many drugs have cumulative effects that can only be appraised clinically with 
long term or chronic therapy. F.'or example it is not feasible to quantify anticancer 
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drug action (e.g. methotrexat.e, fluorouracil} wjtbin t.he body on acute adminis­
tration by following the regression of a solid tumor or loss of viable cancer cells 
(although it may be feasible to monitor the toxicity wit.h successive white blood cell 
counts). The diminution of a lesion by an anti-inflammat.ory drug is a slow process 
compared to the acute pharmacokinetics of the anti-inflammatory agent. Also, ap­
propriate pbarmacodynamic responses that can instantaneously reflect the action 
of an active agent at a receptor site are sometimes limited. An example is the long 
term effect in groups of pregnant animals acutely challenged with various doses of 
a. teratogenic agent. The frequency of anomalies in the lit.ter serves as an index of 
the toxicologicall effect (Jusko, 1972). In these instances correlation of plasma levels 
with biological action on chronic dosing may be the only effective procedure. 
Provided the drug under investigation does evoke a monitorable biologic re­
sponse, it should be possible to model the effect. Descriptions of pharmacokinetics 
and pharmacodynamics rely heavily upon the use of models. Models are usually 
mathematical equations, the parameters of which represent factors which we be­
lieve to be important in determining drug concentration effects. Models are pre­
f erred that not only describe the observations but also off er some insight into the 
underlying biological processes responsible. However, we are frequently  forced to 
use empirical models with no clear biological counterpart. 
Having decided upon a model, the values of its parameters quantify the phara­
macokinetic or pharmacodynamic differences and similarities among drugs and the 
influence of other factors, such as other drugs and disease states. As noted by Hen­
nis and Stanski ( 1985) : the factors influencing pharmacokinetic-pharmacodynamic 
models could therefore be simply classified as: 
1) Pharmacokinetic factors 
2) Pharmacodynamic factors 
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1) Pharmacokinetic factors : 
Immediately after an intravenous administration there is almost instantaneous mix­
ing of the drug into blood. This phase occurs within one or two drcu]ations of the 
drug in the body and is rapid. This very rapid mixing phase defines the peak drug 
concentration observed in blood one-half to two minutes after adminstration of the 
drug. After the peak blood concentrations are achieved. one or more phases are visi­
ble comprised of distributive and elimination phases where the blood concentrations 
decline at a slower rate. 
The distributive phases represent the equilibration of the blood concentration 
( after the immediate mixing phas1e that defines the peak concentratfon) with tissues 
that are less welJ perfused. During this phase, distribution equilibrium has not been 
established between the blood concentration and drug concentrations in most of the 
tissues of the body. Drug is being distributed and redistributed between various 
tissues, with several factors governing the rate at which the tissue concentrations 
equilibrate with the blood concentration. These include the perfusion of the tissues 
and the partitioning or solubility of the drug in the tissues. If the drug has limited 
ability to penetrate membranes (low lipid solubility, high degree of ionization, large 
molecular weight) , diffusion factors can also become rate limiting in the equilibration 
of t.he blood concentration with the tissues (Stanski et al. 1985) . 
Aft.er the drug has been distributed-redistributed throughout the body, the 
elimination phase becomes obvious. During this phase the decline of the blood 
concentr.a.tion is slower relativ.e to the distribution phase. The decline of the drug 
concentration is due to the irreversible removal of drug from the blood. This can 
be due to metabolism in the liver (blood or other tissues can also metabolize drug) 
to generally less ,active compounds and/ or excretion of the unchanged drug via the 
kidney or bile. Because the change of the blood concentration is relatively slow in 
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the elimination phase compared w ith the distribution phase. a pseudoequilibrium 
is said to exist between drug in the blood and drug in the Yarious tissues. 
Drug response is generally related to the steady state concentrations to em­
phasize the clinical implications of the defined relationsh ip. Steady state is defined 
as a situa�ion in which the blood concentration is constant because the rate of drug 
elimination is equal to the rate of drug administration . Since the steady-state blood 
<:oncentrat.ion is in equilibrium with all of the tissue drug concentrations, the bio­
phase, or she of action, concentrations will also be constant (an exception would be 
any organ that eliminates the drug) . Since the drug effect occurs in the tissues, at. 
steady state the drug concentration at the site of action (biophase) will be constant. 
2) Pharmacodynamic factors·: 
Some of the factors that can cause time delay between change in the blood 
concentration and the corresponding change in drug effect are: 
a) Perfusion or delivery of drugs to the biophase. 
If the perfusion to the biophase is high drug delivery will be enhanced: and 
therefore the rate of equilibration between the blood concent.ration and the biophase 
concentration will be enhanced. 
b) Diffusion of drug from the capillary lumen to the biophase. 
Once in the capillary lumen of the region of the biopha.se, the drug must diffuse 
into the specific tissue or site where it can act. If physiochemical factors (ionization, 
molecular size) significantly l imit. the rate of membrane penetration (diffusion) into 
t.he oippl)ase, this can translate into a t ime delay between change in blood concen­
tration and corresponding change in the drug effect. 
c} Par.tition�ng of the drug between the blood and the biophase. 
Once the drug has reached the biophase, several processes can occur. The drug 
can reach the receptor sites within the biophase and induce the drug effect . The 
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drug can also be nonspecific.ally bound to various (nonreceptor) proteins within the 
biophase analogous to the drug-protein binding that occurs in blood. H the drug is 
bound to proteins that are not relevant in creating drug effect .  the drug is effectively 
"unavailable" to induce a pharmacologic effect. 
d) Time f.o achieve receptor events and create the drug effect . 
After the drug reaches the biophase, the actual time of receptor association, 
dissociat ion and translation of the receptor events into a pharmac,ologic effect be­
come iµiportant. H the time to achieve receptor events is slow, then a significant 
delay between the change in blood concentration and the corresponding change in 
drug effect. will be obvious. 
Techniques of Pharmacodynamic Modelling 
The estimation of the par'ameters of pharmacodynamic models using obser­
vations of drug effect require, first of all, a description of drug concentratfons at 
the time of the effect. Usually this description is obtained from a pha.rmacokinetic 
model . H the model linking drug concentration to effect is known to be appropri­
ate, then in theory the observatiOJ11s of drug concentration and drug effect should be 
used simultaneously to estimate the parameters of both the pharmacokinetic and 
phramacodynamic model. However, most frequently the pharmacokinetic model is 
better defined than the pharmacodynamic model , and more reliable estimates of its 
parameters can be obtained from drug concentrations alone, because these are usu­
ally more precise and easier to obtain than measures of drug effect. It is therefore 
often easier to test different pha.rmacodynamic models by estimating parameters 
using fixed value,s for the pharmacokinetic parameters, which have been estimated 
from drug concentrations alone. 
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The use of computer-based model-fitting is strong!�· recommended for esti­
mation of the pharmacokinet.ic and pharmacodynamic parameters (Johnson, 1974 ; 
McIntosh and McIntosh .  1980). 
Selection of a suitable mode] is often helped by a plot of concentration against 
effect. Information about linearity. equilibration delays or tolerance may be ac­
quired by this simple method. 
Pharmacodynamic _Models 
The term 'pharmacodynami:c models' has been used to describe models that. 
utilize concentrations at the effector site (generally obtained from in: vitro or isolated 
organ studies) , whereas: the term 'pharmacokinetic-pharmacodynamic models is 
used to describe those models in which the drug concentrations at the effector 
site are not known or cannot be estimated without knowledge of the drug effect. 
(Holford et al. 1982). Pharmacodynamic models usually require the assumption 
that drug concentration, (e.g. in a tissue bath) is in equilibrium. or at steady state 
condition in vivo. H no assumption about equilibrium can be made, a combined 
pharmacokinetic-pharmacodynamic model is then required. 
Fixed Effect Model 
The simplest pharmacodynamic mode] relates drug concentration to a fixed 
effec,t. No assumptions have to be made about the form of the relationship between 
concentration and effect, because only one degree of effect is considered ,  and the 
effect 'model' has only one parameter: the concentration at which the effect occurs. 
The model may be improved to include the statistical probability of the occurence 
of effect. 
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The Linear Model 
The simplest relationship between cqncentration and E>ffect which can describe 
a range of effect is the linear function 
E = S · C . . .  ( 1 . 1 )  
where E is intensity of effect, C is concentration and S is the slope parameter. 
Implicit in this model is zero effect at zero concentration , H the measured effect 
has some value when drug is absent, e.g. b lood pressure. then the model may be 
expressed as 
E = S .  C + Eo . . .  (1 .2) 
where, Eo is the effect without drug. The parameters of this model are easily 
obtained by linear regression. However if Eo is known with much greater reliability 
than the measurements of E obtained in the presence of the drug, then £0 should 
not be estimated as a parameter, but used in the form 
(E - Eo) = S · C . . . ( 1 .3) 
to estimate S alone. This avoids the problem of estimating a value for Eo which is 
different from a reliably known effect in the absence of drug. Kramer et al. (1979) 
noted this and concluded that a linear mode] was not appropriate to describe the 
effect of digoxin on systolic time intervals, even though the relationship appeared 
to be linear in the presence of digoxin .  The linear mode] predicted a.n effect of 
digoxin at zero concentration which was nearly 40 % of the maximum change in 
electromechanical systole (QS2) observed in the presence of digoxin. 
A linear relationship between drug concentration and prolongation of the Q-T 
interval has been reported for disopyramide (Whiting et al. 1980) and quinidine 
35 
(Holford et al. 198 1 ) .  Eichelba.urn et al. ( 1 980) , have found a similar relationship 
for the effect of verapamil on prolongation of the P-R interYal . 
Transformation of drug effect. measurements may also allow the use of a lin­
ear model : Whitfield and Levy ( 1980) used the logarithm of the activated partial 
t.hromboplastin time (APTT)  and found a linear rela.t.ionship with heparin concen­
t ration. ThE' basis for the transformation is empirica.l . and is dictated by use of 
a response which tends towards infinity as the drug conc-entration increases. The 
use of an alternative transformation, e.g. the reciprocal of the APTT may also be 
considered in defining the effect of heparin because heparin action is directly related 
to inhibition of coagulation, and the prolongation of the APTT may be expected 
to be inversely related to this inhibition. 
A linear relationship between the area under the warfarin concentration t-•s. 
time curve and the area under the logarithm of prothrombin time vs. time curve 
has been used to compare the potencies of the R(4-) and S(-) enantiomorphs of 
warfarin (O'Reilly, 1974 ) .  The logarithmic transformation of response presumably 
was used to correct for the obviously nonlinear relationship between prothrombin 
time and the coagulation factors. 
Because the relationship between warfarin concentration and its effect is com­
plicated by the time course of coagulation factor synthesis and degradation, O'Reilly 
used t.he areas under the log prothrombin-time vs. time and warfarin concentra­
tion us. time after a single dose of each enantiomorph. This procedure effectively 
rf!m0ve.'i. the time dependence for the effect of warfarin on coagulation . 
Fal liers ( 1979) used a. linear relationship between forced expiratory volume, in 
one second, FEVi ( expressed as a percentage of predicted 'normal') and theophylline 
concentrations using the two-parameter model. The observations were made in a 
group of 18 patients over a cohc.entrati9n range of 2-18 mg/I. The intercept value 
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(Ee, ) was estimated as 58.2 <:=c'.: which is in agreement with the pre-drug mean FEVi 
of 55.2%. The slope of the line w_�- 1 .23% per mg/1 .  
The Log-Linear Model 
The concentration-response relationship of isolated tissues has formed the ba­
sis of cUTrent theories of pharmacodynamics (e.g. Ariens and Simonis, 1964a;b) . 
Graphical representation of responses, obtained over a wide range of concentrations, 
is conveniently obtained by using the logarithm of concentration, which effectivly 
compresses the scale of the abscissa. The log transformation has a second prop­
erty, that of l ineiarity of the log concentration-effect curve between 20-80% of the 
maximum effect. However, there are problems associated with this approach: The 
equation describing this relationship is given below: 
E = S - logC + I  . . .  ( 1 .4) 
where E, S and C are the same as in Eqn. ( 1 .1 ) ,  and / is a constant. The first obvious 
problem with this log-l�ear model is its inability to predict E when C is zero, and 
the second problem is its inability to predict a maximum effect. The estimation of 
the maximum effect and the influ�nce of interventions such as antagonists on the 
maximum is an inherent part of pharmacodynamic investigation. In addition, if the 
measurement of effect is to be restricted to the range of 20-80% of the maximum 
and the model used only to summarize the observations within these bounds, then 
the only problem is how to the estimate the maximum effect to assure only the 
20-80% responses are used . If it is not possible to estimate the magnitude of the 
maximum effect because of restrictions on the highest concentration possible to 
use, then there is no guarantee that the model is being applied within the 20-80% 
range. Shephard et al. ( 1979) compared the effects of warfarin in young and old 
people using the log-linear model . The effect of warfarin was expressed as the log 
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of the synthesis rate. and t he sJopPs of the straight lines fitt ed to the log of the total 
warfarin concentration were the same in both groups. The rate of prothrombin 
complex elimination was 50% lower in the older group, but the concentration of 
warfarin required to reach the same inhibition of synthesis (50%) was the same in 
both groups. 
Ishizaki et al. (1980) . who studied the beta blockade effects and absolute 
reduction of HR fol1owing exercise using sotalol in elderly hypertensive subjects 
found that the log-linear model adequately modeled the reduction in HR. 
The Emax Model 
This model incorporates the existence of a maximum effect. The model 1s 
described by the fol1owing hyperbolic function: 
E = Emax · C 
ECso + C 
. . .  ( 1 .5) 
where Emax is the maximum effect attributable to the drug and EC50 is the con­
centration producing 50% of the maximum effect. This model a:Jso predicts the 
absence of an effect when the concentration, C, is zero. It may be modified, like the 
linear models described above, with the addition of a constant term, E0, describing 
the baseline effect existing in the absence of drug 
E - E . 
Emaz · C 
o -
. ECso + C 
. . .  ( 1 .6) 
Irt this case, Emaz refers to the maximum effect attributable to the drug whereas 
the maximum absolute effect in the presence of drug is Ema.x + E0 • The Ema.x 
model may be justified not only on empirical grounds described above, but also as 
the expression of simple receptor theory ( e.g. Ariens and Simonis, 1964a). However, 
the Emaz model cannot be used to prove the existence of a specific receptor and 
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estimates of the receptor dissociation constant obtained iri vivo (ECso) are unlikely 
to reflect the the events a.t. the receptor sites (Holford and Sheiner, 1982) .  
If the drug effect. i s  inhibit ion of a physiological phenomenon e.g. lowering of 
exercise heart rate by a ,B-blocker: then Eqn. ( 1 .6) can be modified 
E - E .:... 
Ema,:, . C 
-
0 lCso + C 
. . .  ( 1 .7) 
where IC sci is now the concentration producing- 50% inhibition of Emax . The study 
of Mitenko and Ogilvie ( 1973) on the effects of theophylline on airways obstruction 
in asthmatic patients illustrates the value of the Ema.x model. They determined 
the change in forced expiratory volume (FE'V1 ) over a range of theophy l line serum 
concentrations in a group of six patients. The effect was expressed as a percentage 
of the expected FEVi in a normal patients. The maximum effect predicted by the 
model was 63%. This suggests the presence of a non-reversible component of airway 
obstruction, which would be a reasonable expectation in this group of patients. The 
concentration required to achieve 50% of this max.imum was 10 mg/1: doubling this 
concentration to 1-he upper l imit of the therapeutic range (20 mg/1 .L predicts two 
thirds of the maximum achievable response. The biggest increases in expiratory 
flow rate were observed at concentrations up to 10 mg/1 . 
The Ema.x model may also be applied to the data of Singh et al. (1980) , 
who studied the effects of timolol on exercise and resting heart rate. The workers 
used the log-linear model to correlate the effect to timolo1 serum concentration 
and concluded that there was only a weak correlation. However t when the results 
are plotted in a non-logarithmic fashion: the existence of a maximum response is 
evident. The lowest heart rat,e achievable by beta-blockade (Eo ) ,  estimated during 
maximal exercise, was 68 beats/min, and at rest was 56 beats/min . E0 reflects the 
influence of factors affecting the heart rate other than ,B-receptor activation . 
39 
The Sigmoid Ema:r: Model 
This is a modification of the Ema.x model and is useful in that it al1ows for 
differences in the concentration -1effect relationship as defined by the Emax model. 
The equation is described by 
E = 
Ema.:r: . en 
ECn 
+ 
en 50 
. . .  (1 .8) 
where, n is a new parameter affecting the shape of the curve. IT n is greater than 
I then the curve will be S-shaped, and if it is less than 1 the initial portion has a 
slope greater than the hyperbola and beyond the E Cso the slope is less. 
This function was proposed on an empirical basis by Hill ( 1910) to describe the 
association of oxygen with hemoglobin. The sigmoid Emax mode] can be derived 
from receptor theory where n is the number of drug molecules combining with 
each receptor molecule. However, non-integer values of n are sometimes found in 
practice. This does not detract from the model's value as an empirical description 
of the interactions of the drug with its effect site (Wagner, 1968) . 
The work of Stanski et al. ( 1979} has shown that the in-vivo effects of d­
tubocurarine on muscle strength in patients undergoing surgery may be described by 
a sigmoid Ema:r: model with a value of 2.3 for n. Although the receptor basis for the 
mechanism of action of &-tubocurarine is well established, no physical interpretation 
of this number in terms of the drug-rec�ptor interaction seems feasible. Meffin et 
al. ( 1977) used the Sigmoid Ema,x model to describe the antiarrythmic effects of 
tocainide in man. They found a very steep concentration-response curve requiring 
values of n from 2.3 to 20. 1 .  Interpretation of these values is not possible in terms of 
a tocainide receptor, but they do serve to quantify the steepness of t:he relationship. 
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PharmMukinetic-Pharmacodynamic Models 
Pharmacokinetic-pharmac.odynamjc models provide insight into the properties 
and nature of that body compartment. that contains the biophase. The biologically 
active receptor sites reside within the biophase, a volume where the effect of drug 
on a site_ is only limited by its free diffusion. Optimum dosage regimens can be 
designed to give biophasic compartmental levels of the active drug necessary for 
the proper magnitude and duration of the desired pharmacological response with 
minimum toxicities. 
If such compartmental levels that provide effective pharmacodynamic activity 
are the same for all species, optimum dosage regimens for humans can be effectively 
predicted from animals by the use of appropriate scaling factors. 
Conc·entration is the link between the pharmacokinetic model (PK) ,  relating 
dose to the concentration, and the pharmacodyna.mic model. PD: relating concen­
tration to effect. Some of the models used to link the PK and the PD models are 
d iscussed below: 
a) The Direct Link 
The simplest link is achieved by a direct relationship between the measured 
c:oncentration and the observed effect. If the effect is measured at the same time 
as drug concentration is measured, e.g. in plasma., then no formal pharmacokinetic 
model is required. The compartment where the receptor sites reside and where the 
drug exercises its pharmacodynamic action could be either the central : shallow or 
deep compartment (Garrett 1977) . 
The central compartment is defined as that volume in the body where an 
amount of drug is instantaneously homogenously distributed on administration. 
An example is when an intravenously administered bolus of a drug is monitored in 
the plasma with time and the highest plasma level is observed as close to time zero 
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as is practically possible and the apparent volume of distribut-ion is the administered 
dose divided by the initial concE'n�ration at time zero. The central compartment 
would then consist of the plasma wat,er and all instantaneously equilibrating body 
tissues which may include plasma protein, erythrocytes and in many cases, the 
extracellular water a-ecessible to i.he well-vascularized tissues. 
The shallow compartment is that apparently homogenous volume which readily, 
but not instantaneously, equilibrates with the central compartment. It frequently 
contains the intracellular water. It is characterized by a relatively rapid decrease of 
drug concentration in the equilibrated central compartment associated with plasma. 
The decline is ]argely due to the rate determining elimination of drug from the 
body where the re-equilibration between the central and shallow compartment is a 
relatively fast process. 
The deep compartment consists of that volume within the body which slowly 
equilibrates with the central and/or shallow compartment at rates comparable to 
rates of elimination . It's presence is indicated by the fact. that the monitored cumu­
lative urine or excreta demonstrates a prolonged and slow increase. It may contain 
non-vascularized fatty tissues, tightly binding enzymes or tissues: or bone. 
It is also possible that no pharmacokineticaUy significant amount of drug is 
in a deep compartment that contains the biophase, since only small amounts of 
drug may be necessary to give biological activity and this small amount may be 
i nsignificant relative to the total mass balance. 
Biophase in the central compartment 
A relatively instantaneous onset of pharmacodynamic action which decreases 
rapidly and parallels the loss of drug from the central compartment, indicates that 
this compartment contains the biophase. An example is thiopental (Stanski, 1984) , 
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a short acting drug. whose half-life of pharmacodynamic action is  much shorter 
than the plasma. half-life generally obt,ained from the dispostion curve. 
It may be considered that there is no blood-brain barrier to thiopental, that the 
drug in the central compartment and the brain a.re in relatively instantaneous equi­
libration. The primary cause of dimunition of brain concentrations of drug a.re its 
loss, through the central compartment, to the relatively rapid equilibrating tissues 
of the shallow compartment. Slow infusions or oral administrations of thiopenta.1 
are thus contraindicated since large doses would be necessary to maintain effec­
tive drug concentrations in the central compartment. If toxicities were engendered 
in the peripheral comparment, adverse reaction would result from such routes of 
administration. 
The drug concentration in the central compartment of a pharmacokinetic model 
may be linked to a pharmacodynamic model by simple substitution for C in one 
of pharmacodynamic models described before. Using a linear pharma.codynamic 
model for simplicity and the sum of a series of exponentials to describe the central 
compartment concentration of drug we obtain, for example 
E(t) S · L Ciexp(-Ai · t) . . .  ( 1 .9) 
i=l  
where E(t) is  the effect at time t and Ci and Ai are the constants of a sum of n 
exponentials. 
b)  The Indirect Link 
Graphical display of the relationship between plasma or central compartment con­
centrations and drug effect may reveal a counter-clockwise hysteresis loop when 
the points are joined in time sequence. This form of hysteresis is characteristic of a 
delay in equilibration between plasma drug concentration and the concentration of 
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active substance at the effect s i te .  The active moiety maybE:> t.he drug, its metabolite 
or some other indirect effect,  e.g. protein synthesis. leading to the observed effect. 
Biophase in the shallow compartment 
Garrett (1979) , noted that if the time course of pharmacodynamic action par­
allels the time course of drug in the shallow compartment , a tissue component of 
this compartment is the biophase. The classical half-life of this phase is equal to 
the biological half-life of the active agent and denotes that plasma level is a proper 
determinant of drug efficacy on both acute and chronic administration. When the 
pathogenic organisms are in the readily available tissues, plasma levels of antibi­
otics on acute as well as chronic administration are proper criteria of antibacterial 
efficacy. 
Hinderling and Garrett { 1977) , showed that the pharmacokine'tics of 8-methyl 
digoxin can be characterized by a three compartment body model. The time course 
of the average decrease in heart rate paralleled the time course of chug in the shallow 
compartment on both intravenous and oral administration and the biophase was 
definitely not in the central or deep compartments. 
If a multicompartmental model is used to describe plasma drug concentration , 
it is possible to calculate the time course of a quantity proportional to drug concen­
tration in the peripheral or tissue compartments of the model (Benet 1972) . With 
the assumption of unit partition coefficient between compartments and no loss of 
drug_ frqm the tissue compartment, then the amount of drug in the tissue com­
partment can be used directly used to estimate the model parameters. The time 
course of the tissue compartment 'concentration' can then be linked to a suitable 
pharmacodynamic model by the use of an expression such as Eqn. 1 .9 to describe 
the tissue compartment. 
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The major drawback of the tissue compartment link is the requirement that the 
equilibration of drug with the effect site must have the same time course as drug con­
cent.rations in a compartment derivab)e from measurements made in plasma and/or 
some other compartment, e.g. urine. The time course of equilibration is governed 
by t.he perfusion, diffusion and partition properties of the effect site. H the organ 
�. in wh ich this resides is large or shares properties with a pharmacokinetically sig-
nificant organ or tissue, then the tissue-compartment l ink may be valid. But there 
is no a priori reason to expect this to occur. Neverthless: the tissue compartment 
approach has been used with some success to describe the time course of lysergic 
acid (LSD) on mental performance in human volunteers (Wagner et al. 1968) . The 
peripheral compartment of a two-compartment pharmacokinetic model for LSD , 
l inked to a linear pharmacodynamic model, adequately described the time course of 
drug effect. A similar approach was used by Reuning et al. ( 1973) , to describe the 
time course of the effect of digoxin on electromechanical systole of t.he heart (QS2 )  
after a single i.v. bolus dose. Although the time course of effect. was dearly related 
more closely to the concentrations predicted in the tissue compartment, systematic 
time-related deviations (from a linear pharmacodynamic model) were seen . This il­
Justrates the l imitations of the tissue compartment approach� which cannot account 
for equilibration with the effect site, when the latter is either faster or s lower than 
equilibration with one of the identifiable pharmacokinetic compartments. The use 
of a three-compartment model to describe digoxin pharmacokinetics by Kramer et 
al. ( 1979) improved the ability of the tissue compartment to describe the effects 
of digoxin on QS2 , The concentrations in the more superficial of the two tissue 
compartments had a time course similar to that of drug effect, but the interpreta­
tion of the data is made difficult by the use of pooled observations from a group of 
subjects. 
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Biophase in the deep compartment 
A delay in the appearance and maximum of drug a<'tion in contrast to the 
plasma level data and the amount of drug in t�e shallow <'Ompartment implies that 
t-he biophase is in a deep compartment. The quantification of pharmacodynamic 
activit;r ."."7ith time would follow the time course of the drug in the deep compart­
ment. Such a deep compartment may not be pharmacokinetically discernible since 
insignificant amounts of drug may be responsible for the pharmacodynamic action 
and the actual blood level on acute administration would have no direct relation­
ship with the activity of the drug. However, the magnitude of the activity at any 
time would still be dose related and mediated by the time course of the drug in 
the observable compartments. In general, there would be no strict proportionality 
between pharmacodyna.mic activity and plasma level on acute drug administration 
until the rate determining step of drug elimination from the body is the release of 
drug from this deep compartment. Only if the deep compartment can be equili­
brated with the plasma on chronic administration would plasma level be indicative 
of drug action at all times. 
A pharmacokinetically observed deep compartment is not necessarily the same 
ac;. or equivalent to, the biophase which may be in a deep compartment. However, 
evidence of paraUelism in the tune course of biological activity and drug amounts 
i n  such a compartment is indicative. Levy et al. (1969) , observed that LSD phar­
macodyna.mic action paralleled the time course of drug in a slowly accessible phar­
macokinetic compartment. 
Another example of a deep compartment biophase occurs with .B-methyldigoxin 
when the pharmacodynamic �arameter monitored in healthy hum�s· was the per 
cent decrease in left ventricular ejection time index (LVETI) . The t�e �ourse of 
LVETI action correla.ted with the time course of .B-methyldigoxin and its active 
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metabolite, digoxin . in their deepest pharmacokinetic compartment and not their 
plasma levels on acute dosing (!Underling and Garrett, 1 977) . 
Kelman and Whiting ( 1980) have proposed a. method using a multicompart­
ment model to describe drug concentrations in each compartment to partition dif­
ferent . fractions of the effect among the separate compartments. However, this 
a.pproach requires the acceptance of the theory that. single drug effect is mediated 
by drug concentrations at different effect sites. 
Short comings of the above methods: 
The above classical methods suffer from the following drawbacks in that it 
cannot adequately model pharmacodynamics in the following cases: 
1 )  When the amount of drug necessary to evoke a response is pharmacokineti­
cally negligible, the observed effect over time may not correlate with observed 
disappearance from any of the pbarmacokinetically discernible compartments. 
2) When the biological receptor sites are saturated the response will not corre­
late with the concentration in any of the kinetic compartments although the 
biophase may kinetically correspond to one of the same compartments. 
3) When there is a delay in equilibrium with the receptor sites the time delay to 
onset. of action or time to maximal action is not re-adily explained by c lassical 
met.hods. 
The E�ect Compartment Model 
Forrester et al. ( 1974) realized that the time course of the effect could .be used 
to define the rate of drug movement to the effect site. This concept was used by 
Forrester et al. to explain the observations of Sllapiro et al. ( 1970) of the time 
course of effect of various cardiac glycosides. Forrester and co-workers used the 
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onset of drug effect to est imate the halftime for achievement of peak effect, which 
varied from a few minutes (oubain) to nearly an hour (d igitoxin) .  
Holford and Sheiner ( 1982) , noted that if drug concentration in the plasma is 
suddenly changed from zero to some value C, the effect E. will increase in proportion 
to the c�ncentration at the effect site until the plasma and the effect site come into 
event.ua] equilibrium at the effect Ee . If drug loss from the effect site is controlled 
by a rate constant keo , then the half time for achievement of Ee will be 1n 2/keo ­
More often , however, we are concerned with changing concentrations in the plasma 
and hence at the effect site. In this case the pharmacokinetic model can be used 
as an input function to the effect site, to describe the time course of drug effect. 
An ingenious way of doing this has been proposed by Sheiner et al. ( 1979) which 
used an effect compartment as an extension of the pharmacokinetic compartment 
model . The rate of change of drug amount in the hypothetical effect compartment 
( Ae) can be expressed as 
. . .  ( 1 . 1 0) 
where A 1 is the amount in the central compartment of a pharmacokinetic model : 
lined to the effect model, with rate constants k 1 e and keo (Fig. 1 .2) . The exact 
form of the pharmacokinetic model is irrelevant as long as it adequately describes 
the central compartment concentration . A generalized deriv�tion of the relevant 
equations for the effect compartment model follows. 
For a drug whose concentration vs. time profile in the central compartment fol­
lows exponential kinetics, the amount of drug in the central compartment following 
the administration of an i .v .  bolus may be represented as 
A 1 = DLXie-a;t 
i= l 
. . .  (1 . 1 1 )  
Dos = D 
Effect 
compartment 
Fig . 1 : 2 -THE EFFECT COMPARTMENT MODEL 
3 
• • 
• • 
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where Xi and Oi are constants: � is the dose and A 1 is the amount of drug in the 
central compartment any tjme t .  The amount of drug in the effect compartment at 
any time is then given by: 
. . .  (1 .12) 
The concentration of drug, Ce , in the effect compartment is obtained by dividing 
Ae by the effect compartment volume, Ve 
... ( 1 .13) 
At equilibrium, the rates of drug transfer between the· central and effect compart­
ments are equal, i.e. 
. .. ( 1 . 14 )  
or 
... (1.15) 
If the partition coefficient, Kp , equals Cef C1 at equilibrium� then we rearrange 
Eqn. (1.15) to obtain, 
Substituting for Ve in Eqn. (1.13) 
n X ·  
C k D K � i [ -oi·t - k  .ut1 e = eCI • • p  V (k ) e • - e � J . 1 1 ·eo - O:i i= 
Since, Kp = Ce/C1 , substituting for Kp in eqn. (1.17) gives, 
n X 
C k DL i i -oi,t -k,-otJ 1 = eC• • V (k  ) t e - e 1 • o - a · i=l e i 
. . .  ( 1 . 16) 
... (1.17) 
... (1.18) 
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where, 01 is now the equivalent steady state concentrat-ion of drug in the central 
c.ompartment for a corresponding steady state concentra.tion Ce in the effect com­
partment. 
Also, 
. . .  (1 .19) 
where, Emax is the maximum response, Cp88(so) is the concentration that produces 
50% of the maximal response and E is the response. The value of EC50 then, as 
estimated from the data, will be the central compartment concentration producing 
50% of the maximum effect at equilibrium and at steady state conditions. Clinically: 
this is more important than the concentration at the effect site producing 50% 
of the response. This model has been used extensively in recent years to mode) 
the pharmacokinetics-pharmacodynamics of d-tubocurarine (Hennis et al. 1985; 
Sheiner et al. 1979) , thiopental (Stanski et al. 1984) and .6-9-tetrahydrocannabino) 
(Chiang and Barnett� 1984) . 
Scott et al. (1985) studied the effects of fentanyl and alfentanil on EEG changes 
in humans. They observed a temporal lag (or hysteresis) between changes in serum 
narcotic concentration and changes in spectral _edge. They therefore coupled the 
pharmacologic model with a pharmacokinetic model with a separate effect compart-
ment .  
They noted that hysteresis could be due to: 
1 )  perfusion ( drug delivery to the brain) 
2) diff�sion (crossing the blood brain barrier and cell membranes to reach the 
opoid receptors) 
3) receptor events (affinity, dissociation constants) 
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c-)  The Model Independen1 Link 
The methods described above have used pharmacokinetic models to describe 
the concentrations at the effect site : and linked this to the pharmacodynamic model .  
Model-independent methods hav,e been described by Smolen et al. and Smolen 
( 1 976a,b) . This approach is based on the assumptions tha.t the pharmacokinetic 
processes i�volved are linear, and secondly, that the same concentration at the 
effect site produces the same response. The approach· uses convolution and de­
convolution techniques. The dos,e-concentration-effect relationship is obtained by 
convolution of the drug input with the pharmacodynamic processes . The techniques 
of numerical deconvolution are powerful tools although they are complex and not 
readily understood by many pharmacokineticists. 
Tolerance and Sensitization 
Tolerance and sensitization are the phenomena of increased and decreased re­
sponses by the animal when rechallenged with the same drug under identical con­
ditions respectively. These are usually due to adaptive changes by the receptor in 
its number and affinity. The term "down-regula:tionr. is now used to describe a 
decrease in receptor number. The opposite process of increased sensitivity to drug 
action with continued exposure .to the drug is not well defined. A likely  mechanism 
for this event is the accumulation of an active metabolite of the parent drug or a 
physicochemical change in the receptor . Mathematical models to describe tolerance 
and sensitization have not been developed. A clockwise hysteresis lloop on plotting 
the response vs. concentration is indicative of tolerance or is due to the cumulation 
of an antagonistic metabolite. 
Applications of Pharmacodynamics 
Duration of Effect 
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Pharmacokinetic-pharmac-odynamic models predict the time course of drug 
effect. These models can hence be used to predict the duration of effect for any 
dosage regimen. If the concentration in the effect site parallels the concentration 
in the central compartment, then the pharmacokinetic model suffices to predict the 
duration of effect. If the concentration in the effect. compartment does not paralJel 
the concentration in the central compartment, then the duration of effect will not 
be related simply to the dose, especially when repeated doses are administered. 
For example, if the pharmacodynamics of a drug can be described by an Ema.x 
model, then we can identify three phases of the time course of drug action during 
the terminal elimination phase of the drug from the body. When concentrations 
are much larger than the ECso , the effect will be close to the maximum effect. and 
concentrations in the plasma may change several-fold with little change in effect: 
e.g. a ten-fold change in concentration from 90 to 9 times the EC50 will reduce 
the effect by less than 9%. When concentrations lie between 20% - 80% of of the 
EC5c, then effect will be almost directly proportional to the concentration. Below 
these concentrations, effect will be almost directly proportional to concentration, 
and will decline in an exponential fashion. 
lnjl.uence of Dosing Regimen 
With pharmacokinetic-pharmacodynamic models it is now possible to ade­
quately describe the influence of dosing regimen on overall drug effect. Wagner 
( 1968) pointed out that a dosing regimen producing wide fluctuations in concen­
trations would have a reduced overall drug effect as compared to a dosing regimen 
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producing minimal fluctuat-ions in concentration. This cari be explained by observ­
ing that for the Ema,x model . t,he cumulative drug effect. ( E )  is an integral of the 
effect term (Eqn. 1 .5) as given below: 
- I C (t) E = Ema:r. ECso + C (t)  . dt . . . .  ( 1 .20) 
H C is constant, e.g. at steady state following a continous infusion of drug, 
then t,he integrated effect will be the same as the instantaneous effect predicted by 
the average steady state concentration of the drug. H dosing is now changed from 
a constant infusion to intermittent dosing, the same daily dose will produce the 
same average steady state concentrations, but concentrations will fluctuate about 
this average. It can be shown mathematically that the increased effect at con­
centrations above the average will not fully compensate for the decreased effect at 
concentrations below average. The total effect for the day will therefore be less with 
intermittent dosing than for continous infusion , for the same average steady state 
concentration . Holford et al. ( 1982) , have noted that the differenoes are not large 
if the concentrations are always above the region of ECso: but becomes marked 
when the concentrations are in the region of ECso, Clinical experience with dosing 
regimens of various drugs have confirmed these predictions. e.g. in the treatment of 
c rania! arteritis, efficacy is much worse when prednisolone is administered on alter­
nat,e days, compared with the same averge daily dose given every day (Hunter et al. 
197 5} . On the other hand, efficacy in the treatment of the nephro:tic syndrome ap­
pears to be the same when alternate-day and daily dose regimens are compared, but 
toxicity is reduced compared with the alternate-day regimen (Hunter et al. 1975) . 
Holford et al. ( 1982) , hypothesize that this could be explained if the concentrations 
of prednisolone are around the ECso for the treatment of nephrotic syndrom,e and 
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in the region of the ECs,:i for J.he toxicity. The¥ further hypothesized that it is pos­
sibly for similar reasons that the reduction in creatinine clearance in dogs produced 
by gentamicin or tobramycin is g1,eater when a constant. infusion is given, compared 
with aminoglycoside concentration resulting from the same daily dose given every 
24 hr. lt was implied that the average aminoglycoside concentration produced by 
the infusion ·must be in the EC20 to ECso range for renal toxicity. In general, the 
influence of dosing regimen can be expected to be of greatest significance when the 
average concentration is in the neighborhood of the EOso and the dosing interval 
is several times longer than the drug elimination half-life. 
Metabolite Activity 
The metabolite of a drug may contribute to the observed effect.  This may be 
challenged by comparing the time course of the activity with that of the time course 
of the metabolite obtained on drug administration. The correlation of the pharma­
cokinetics of the administered metabolite and the time course of pharmacodynamic 
act.ivity is demanded. This could be confounded by the fact that the contribution 
may be agonistic or antagonistic. These factors need to be understood and incorpo­
rated into the pharmacodynamic model. Examples of drugs where the metabolite 
may be active are guinidine (Holford et al. 1981) ,  disopyramide (Whiting et al. 
1980) , lorcainide (Meinertz et al. 1979), verapamil (Eichelbaum et al. 1980) and 
8-methyldigoxin (Hinderling and Garrett, 1976) . 
Drug Combinations 
Pharmacodynamic models can be derived that incorporate the effect of drug 
combinations and the receptor mechanisms involved. 
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Separat.e Receptor-Separat e lvfecha.nism 
When two drugs act by different mechanisms and contribute to the same overall 
response, their combined effect can be described as the sum of their individual 
effects 
E _ Ema.x.,A · A + Ema.x.,B · B AB - ECso,A + A ECso B ..... B ( 1 .21)  
where the subscripts A and B stand for the Emax. model parameters for the drug A 
and drug B respectively. Equations for cases involving seperate receptor-common 
mechanism and common receptor-common mechanism have been described by Hol­
ford et al. ( 1982) . 
REVIEW OF DIGOXIN RESPONSES 
Systolic Time Intervals 
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The responses most commonly measured clinically as indices of cardiac funtion 
are the sytolic time intervals .  It was therefore intended to monitor systolic time 
intervals in the piharmacodyna.mic studies to be conducted with digoxin. 
The term 'systolic time intervals' (STI) is generally used to describe time in­
tervals or measurements obtained from an electrocardiogram, a phonocardiogram, 
a carotid pulse tracing, or from simultaneous recordings of one or more of the 
same. Some of the STI are: a) left ventricular ejection time (LVET) b) duration of 
electromechanical systole (QS2) c) duration of heart sounds (S1 S2 ) d) pre-ejection 
period (PEP) e) iso-volumic contraction time (ICT) f) P-R interval g) R-R interval. 
T he P-R and R-R intervals are measured from the electrocardiogram. The 
P-R interval is measured as the time interval from the start of a P-wave to the 
immediately following R-wave, and the R-R interval is measured as the time inter­
val from one R-wave to the next. Measurement of other STI mentioned above is 
discussed later. STI corrected for heart rate are viz ., left ventricular ejection time 
index (LVETI), pre-ejection time index (PEPI) and QS2 index (QS2 I). 
Although it is difficult to pinpoint the first use or application of systolic time 
intervals (STI)_ ,  Garrod (1874-75) .can be credited with the first graphic recording 
of the pul�e to determine the relationship between HR and the duration of left 
ventricular ejection. From then on the development of STJ progressed. Katz et 
al. ( 1921 ) ,  'using the then modern electronic techniques, simultaneously  recorded 
the EKG, phonocardiogram and the subclavian pulse. T his set the stage for the 
techniques we apply today. 
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Systolic time invervals (STI) measurements are sensitive indices of myocardial 
contractility. They reflect a number of factors such as stroke volume, aortic and 
left ventricular, end-diastolic pressures (Diament and Kippip, 1970), or the level 
of adrenergic activity which may affect the measured values in opposing directions 
(Lewis et al. 1972). 
Attempts to use STI in complex situations - for instance in the course of acute 
myocardial infarction - has proved not very satisfactory. The most useful appli­
cation appears to be in the documentation of the e_ffect 9f positive and negative 
inotropk a.gents in patients who can act as their own controls and who are hemo­
dynamically stable. 
As an archetype of positive inotropic drugs, digitalis has been extensively stud­
ied with the use of the STI. The first cardiac glycoside was studied almost four 
decades ago by measuring the changes in STl during treatment with strophanthin . 
In the 1960's Weissler and co-wo:rkers led the revival of this technique for use in 
clinical-pharmacologic testing of digitalis (Weissler et al. 1964,1966,1968). 
Other cardiac glycosides more recently studied were strophanthin K (0. 125 0.25 
mg, i.v.) and lanatoside G (0.4, 0.8 and 1.6 mg). STI and impedance plethysmo­
graphic (IP) values were recorded in ten patients with compensated coronary heart 
disease (Matos et al. 1975). The heart rate decreased significantly during the 2-
hr. study in the supine position for both the glycoside and placebo groups; blood 
pressure remained unchanged. 
The QS2I ,  the LVETI and the PEPI showed no change after placebo. The 
indices were obtained from the measured values · by using the regression equations 
for heart rate by Weissler et al. (1969). The glycosides caused no change in LVETI. 
QS21 was significantly shortened only after 1 .6 mg of lanatoside C. PEPI and iso­
volumic contraction time (ICT) were significantly shortened by both doses of stro­
phanthin K and by all doses of lanatoside C;  the effects were dose-related. 
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The amplitude of the IP curve and the relative pulse volume showed positive 
and negative changes without any trend following administration of placebo or gly­
coside. It was suggested that the usual therapeutiic doses of cardiac glycosides do 
not cause significant changes in the peripheral circulation in patients with compen­
sated coronary heart disease. Yet their action on STI is quite marked, showing a 
positive inotropic effect. 
Our present know ledge about the effect of drugs acting on the autonomic ner­
vous system in man is based to ·a considerable extent on data based on STI measure­
ments. Matos et al. (1976) , studied the chronotropic and inotropic efffects of i .v. 
administration of 5 µg. of isoproterenol and of 0.5 mg of atropine in 12  patients (4 
men and 8 women; mean age 55 years) with symptomatic sinus bradycardia {SSB) , 
and 12 match-paired subjects. Heart rate, blood pressure, and STI were measured 
before and after drug administration. 
There was no difference in the baseline STI values between the SSB patients 
and the controls. The two groups differed significantly only in heart rate. 
Isoproterenol had a significant positive chrono-and inotropic action on patients 
with SSB as well as the controls: PEPI, PEP /LVET, and ICT / QS1 values were 
shortened. The effects were of similar magnitude in both groups. There was an 
increase in heart rate following injection of atropine in both groups. There was no 
significant difference in the response of the two groups. QS1 lengthened significantly 
after atropine in SSB patients but remained unchanged in the controls. 
In this wel1-defi.ned and selected SSB subgroup of sick sinus syndrome, the 
response to is·oproterenol and atropine was uniform and reproducible. According 
to the STI values,  myocardial contractility and the response to isoproterenol and 
atropine were no different in patients with SSB as compared with control subjects 
of the same age and sex. 
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Despite the early introduction of the method, clinical application of the STI 
recieved little attention until recent years. Their acceptance as useful quantitative 
measures of left ventricular performance in individual patients has: indeed evolved 
slowly. In part, this reflects the dif erent nature of the STI as a physiologic measure, 
one which denotes the timing of the events of the cardiac cycles rather than the 
more conventionally applied dimensions of pressure, flow, and volume. In addition, 
the fact that STJ changes occur with sudden alterations in ventricular loading, such 
as changes in end-d'iastolic wall stress and impedance to systolic emptying (as do 
virtually all other physiologic measures of chamber performance) , has discouraged 
some from accepting these measures as stable physiologic expressions. Probably the 
major deterrent to the more rapid clinical applications of STI is the fact that until 
the recent decade, the significance of the STI in a quantitative sense had not been 
critically tested. 
Clinical applications of STI: 
Weissler et al. (1980) , determined the relative frequency of residual symptoms 
and signs and of abnormal STI among 37 patients who had convalesced from a 
previously documented injury to the left ventricular myocardium. The patients 
had recovered from acute transmural myocardial infarction occuring 3-6 months 
previously. 
Compared with the values for a group of 25 normal subjects studied concur­
rently, the pre-ejection period index (PEPI) was prolonged, the left ventricular ejec­
tion time index (LVETI) was shortened, and the PEP /LVET ratio was increased. 
For each of these indices, the differences between the controls and patients were 
statistically significant (P<0.001) . Of the three, PEP /LVET allowed best discrimi­
nation between normal and abnormal groups. Of interest was the observation that 
in asymptomatic patients - that is, those who did not have dyspnea, fatigability, 
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or angina pectoris, but all of whom had convalesced from a previously documented 
myocardial infarction, the majority exhibited abnormal left ventricular performance 
as defined by the PEP /LVET measurement. 
Having defined this high incidence of abnormality in left ventricular perfor­
mance among asymptomatic patients, Weissler et al. attempted to detect this 
abnormality by other common clinkal iJ?.dicators viz. ,  the presence of an 83 or 84 
gallop or of cardiomegaly on chest X-ray. The presence of 83 or 84 could not reli­
ably detect the patients with abnormal left ventricular performance. Thus among 
the patients who had convalesced from a previous insult to the myocardium, the 
STI revealed the presence of residual abnormality when clinical and radiological 
evidence for such cardiac abnormality is absent. 
STI and other methods of assessing left ventricular performance: A com­
parison 
Weissler et al. studied 29 patients with angina pectoris who had not experi­
enced myocardial infarction (MI). These patients were evaluated by conventional 
and by STI methods in 54 patients with angina pectoris who had survived an acute 
attack of MI. Among the patients with a normal coronary arteriogram and a nor­
mal left ventricle, the EF was 0.68 ± 0.08 (mean ± SD) .  Among the same patients 
the PEP /LVET was 0.34 ± 0.04 (mean ± SD). These values correspond to norms 
previously established for these measures. Highly significant deviations (P<0.001) 
in EF, PEPI, LVETI, and PEP /LVET from the normal occured among the patients 
with coronary artery disease who had a previous myocardial infarction. Iil contrast, 
among patients with documented coronary artery disease but without a record of 
a previous myocardial infarction, there was no significant difference from normal 
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in these measures. The STI and the EF were therefore accurately predicted in pa­
tients ( except for patients with coronary artery disease and a previous history of 
myocaridal infarction) . 
The final test of the accuracy of the STI is provided in a determination of 
the agreement between the EF and the PEP /LVET in defining the presence of an 
abnormal ventricle among various subsets of patients with coronary artery disease. 
The data indicated that the prevalence of abnormal left ventricular performance as 
detected by the PEP /LVET in the four group of patients was virtually identical to 
that determined by EF. Agreement between PEP /LVET and EF in estimating the 
prevalence of abnormal function exceeded 90% in each subset. 
It was evident that PEP /LVET as a noninvasive measure of left ventricular 
performance is superjor to current clinical appro,aches in detecting the presence 
of normal or abnormal ventricular performance in patients with coronary artery 
disease. 
Limitations of Systolic time intervals for evaluation of cardiac function 
STI are influenced by several anthropometric. hemodynamic, and pharmaco­
logic factors which cari limit the usefulness of STI for the evaluation of cardiac 
function in individual patients. The hemodynamic factors are largely unknown in 
individual patients. To appropriately use STI the following facts have to be kept in 
mind. 
Regression Equations 
No universally acceptable regression equation is as yet available for the relationship 
between the PEP, LVET, and QS2 (interval between the onset of depolarisation and 
onset of aortic component of the second heart. sound, on one hand and the heart 
rate (HR) , on the other. No large randomized population group has been studied 
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taking into account age, sex, blood pressure, anthropometric factors, the supine or · 
upright positions etc. 
Different equations have been published regarding the relationship between 
LVET and HR. Significant differences in the slope of the regression equation exist, 
resulting even at HR's between 60 and 90 beats/minute (bpm) in important dif­
ferences in the calculated LVET. In heart failure LVET, expressed as a percent of 
normal, also differs depending on the regression equation used for the comparison. 
At an HR of 60 bpm, LVET would still be within normal limits, i.e., ± 10% of 
normal. 
Different slopes have been calc-ulated for the relationship between LVET and 
HR between men and women (Willems and Kesteloot, 1967), after digitalis admin­
istration (Kesteloot et al. 1969), and duri�g exercise (Vanderhoeven et al. 1973� 
Gleichmann et al. 1976) . 
Age and systolic blood pressure have been shown by multiple regression analysis 
to have independent influence on LVET when HR is included, (Willems et al., 1967) . 
Different slopes have been calculated for the relationship of QS2 and HR (Weissler 
et al. 1968, Kesteloot 1968) . 
Nearly all authors have found that PEP is virtually independent of HR. A 
logarithmic relationship between LVET and R-R interval has been described during 
atrial fibrillation in patients with mitral disease (Keteloot and Dene£ 1970, Baragan 
et al. 1976). Different slopes have been calculated for the relationship of LVET and 
QS2 to HR during consecutive days in myocardial infarction (Spodick and Kumar, 
1968). As a result of the above observations, no single equation can be used to 
correct LVET or QS2 for HR changes in different clinical situations. 
There is evidence which indicates that even between HR's of 60-100 bpm, a 
linear regression equation is not the best fit. The relationship is better character­
ized by a polynomial or hyperbolic regression equation as shown by Willems and 
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Kesteloot ( 1967) . This could explain the differences in slope between males and 
females; the lower slope can be predicted in normal groups with a higher mean HR. 
However, between HR's of 50-110 bpm the deviation becomes important, when the 
regression equations are used for the extrapolation or correction of the data. 
The correlation coefficients of the relationship between LVET and HR vary 
between 0. 75 and 0.85. This means that 30-45 % of the total variation of LVET and 
QS2 remains unexplained. As a consequence, the confidence with which conclusions 
can be made in an individual case is reduced. Multiple regression equations with 
the introduction of other relevant parameters besides HR can increase the predictive 
power of the reg:ression equation. 
Interactions of influencing factors 
Increases in. the HR due to physiologic variations, emotions, exercise, atrial 
pacing, atropine, isoproterenol, and like have different influences on preload, after­
load, sympathetic tone and cardiac output. Interactions between different factors 
influencing STI can make the interpretation difficult. 
The only reported study of ST I in dogs is by Zamella et al. (1980) . 27 anes­
thetized mongrel dogs were studied and correlations were obtained between various 
measures of cardiac function and STI. The regression equations were extremely su­
ceptible to pre-load changes and were applicable to 2 to 3 dogs, but none to all the 
dogs. 
Wolf ( 1980) , in an excelJent review of correction methods for STI indicated that 
the relationship between HR and STI is curvilinear and not linear. The R-R interval 
(RRI) and HR are connected by a simple inversion, the graph of the relation being 
a hyperbola. Thus if there is a linear dependency from one of these parameters, 
e .g. RRI, the dependency on the other one, e.g. HR, will be hyperbolic . Because of 
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Weissler's great influence (Weissler et al. 1974) , many assume a linear relationship 
between HR and STI. 
Card us et al. ( 197 4) , demonstrated the linearity of the dependency of RRI and 
STI and the hyperbolic curve for HR and STI. Kesteloot and Willems ( 1967) , also 
discussed the possible models for the relationship. The data support the hypothesis 
of the nonlinear relationship for HR and STI, the linear function of RRI and STI 
and the hyperbolic curve for HR and STI. Statistical analysis by these authors did 
not show a significantly better fit for any one of several different functions. Linearity 
between HR and STI was therefor,e retained. Data of Wolf et al. ( 1978) point in the 
same direction . It is sometimes possible that the assumption of the linear relation 
between HR and STI could lead to incorrect results. For example, in a study by 
Belz et al. ( 1978) , 12 groups of 10 persons were given different doses of cardiac 
glycosides. The first analysis was done using the correction formula of Weissler 
and statistical analysis of varian�e. Overall differences between the groups was not 
s ignificant. The second analysis used analysis of covariance with RRI as covariate. 
The differences then were significant. Thus an analysis of covariance using RRI as 
covariate instead of linear regresion using HR is the better method. 
SUMMARY 
In summarizing the value of the STI as a predictive, diagnostic and research 
tool it is appropriate to include the concluding comments of Weissler at the Inter­
national conference on systolic time intervals (Weissler et al. 1980) . Weissler noted 
that the current methods for assessing the duratioin of the sequential phases of the 
cardiac cycle in man are quite accurate. Thus, whether the duration of the STI are 
measured by the conventional triple recording of the electrocardiogram, phonocar­
diogram and carotid arterial pulsation, or by the echocardiographic approach, the 
measurements derived yield data that are indistinguishable from that determined by 
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direct interventions in the cardiac chambers. There remain some differences of view 
as to the most appropriate mathematical expressions for denoting the relationship 
between HR and the duration of STI. However, the linear regression relationships 
between HR and QS2 , LVET are quite adequate for clinical applications. 
The relationship of the pre-ejection period (PEP) to HR is somewhat more 
controversial. Although it is likely that the PEP diminshes with increasing HR, 
the magnitude of change with increasing HR is certainly less than that for the 
q·s2 and LVET intervals. The minimal slope of the regression relationship between 
PEP and HR limits our capacity to demonstrate a close correlation between those 
two variables. However, it is generally agreed that the ratio PEP /LVET requires 
no correction for HR:_ for _clini�al a;eplication . It is possible that this ratio, of two 
intervals, each of which is influenced by HR, must also be influenced by HR. But, 
for practical purposes, in the HR range of 50 to 110 bpm, the correction is not 
employed because of the minimal influence of the HR. 
]t is evident from a number of papers mentioned before that both the PEP 
and STI are influenced by ventricular loading. In this respect, the STI behave no 
differently than other noninvasive and invasive methods. Because of the influence 
of loading conditions, changes in STI cannot be readily interpreted as reflecting 
changes in the intrinsic contractility of the myocardium. However in chronic disease 
states the LVET and changes in STI accurately reflect the level of left ventricular 
performance. 
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DIGOXIN AS THE INVESTIGATIONAL DRUG 
Digmcin was selected as the investigationa] drug due to the following reasons: 
1) Digoxin has measureable pharmacodynamic responses: 
The systolic time intervals (STI) , have been used extensively to monitor the 
pharmacodynamic responses of digoxin for clinical and investigational purposes 
since its introduction in 1921 by Katz et al .. A revival of the technique by Weissler 
et al. ( 1964, 1966, 1968) , has led to the now prevalent use of STI for c linical, in­
vestigational testing of cardiac glycosides. A more extensive review of STI and its 
applications has been presented earlier. 
2} Lack of correlation between ST] and digoxin serum levels. 
The first study in which it was attemped to study digoxin pharmacokinetics 
and pharmacodynamics simultaneously was in 6 normal subjects by Shapiro et al. 
( 1970) . The authors found a negative correlation between LVET and plasma digoxin 
values (r = 0.77, P<0.01 ) .  Significant decreases in LVETI and QS2 were seen 
30 min. after injection. The LVETI shortening progressed to its maximum at 3 
and 4 hours. While the 24 and 48 hr values were significantly less than control, 
they were returning toward the initial value. A similar pattern of change was noted 
in the QS2 interval . The mean PEP decreased within the first 2 hours, but was 
not materially dif erent from control afterward .  Heart rate, ejection fraction, 81 82 , 
isovolumic contraction time, and Q1 were not significantly altered. The t112 of the 
.6.LVETI derived from the slope of these values was approximately 29 hrs. 
The authors observed that the maximal inotropic effects seen at 3 and 4 hours, 
as determined from the maximum .6.LVETI, occurred as plasma dfgoxin declined 
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into a slow excretion phase. During the rapid early fall of the plasma level, inotropic 
effects began. During the subsequent slow decline, the inotropic effects, as reflected 
in shortened LVETI and QS2 , paralleled the plasma digoxin values. This was in 
contrast to earlier views that plasma concentration of digoxin may be of little im­
portance concerning myocardial ef ects, particularly since the plasma to myocardial 
ratio of digoxin is large i .e., at least 1:30 (Doherty and Perkins, 1966; Binion et al. 
1969) . 
However Reuning et al. (1973), showed that simultaneous experimental deter­
minations of the change in the left ventricular ejection time index (ALVETI) as a 
function of time, do not correlate with the plasma level-time curve when digoxin is 
distributing between plasma and tissues . In contrast, levels of digoxin predicted for 
the tissue compartment correlate closely with the .b..LVETI during the distribution. 
They observed a good correlation between values of these two parameters ( correla­
tion coefficient=0.91) . A similar analysis of the change in the QS2 interval ,  AQS2, 
as a function of time after a single intravenous dose of digoxin indicated that th is� 
measure of pharmacologic effect does not correlate with changes in digoxin plasma 
levels during the distributive phase. 
That the pharmacodynamic re�?_�S�� o� q_igpxin are possibly related to tissue 
levels and not to serum levels was further borne out in a study by Forester et al. 
(1974) , who studied the onset and magnitude of the contractile response of cedilanid­
D, oubain, digoxin and digitoxin in normal volunteers after i.v. administration of 
the glycosides . The onset of QS2I shortening on a mole basis was described by an 
exponential equation for the g]ycosi<ies. The maximum shortening of QS2 1/mole 
assuming no excretion and metabolism in the first hour was the same for all the 
glycosides. However the time c0nstant for the maximal effect ( the time at which 
63% of the total response has been achieved) was 5.8. 7.2, 23 and 56 mins. for 
oubain, cedilanid-D, digoxin and digitoxin respectively. The observed .time lag to 
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peak effect may reflect the fact that the receptors for the observed effect are in 
a shallow or deep compartment and could therefore be an indication of the time 
required for the concentration of glycoside in the biophase to reach the minimum 
concentration required to elicit a response. 
In another study Jogestrand et al. (1981), related the plasma and skeletal mus­
cle levels of digoxin to the response. The authors had previously shown ( Jogestrand, 
1980) , that highly significant correlation exists between the digoxin concentration 
in skeletal muscle and the right atrial myocardium using biopsies taken during open 
heart surgery. The approach was meritorious considering the following 3 reasons: 
1) The major depot for digoxin is the skeletal muscle. About 50% of the total -
body content of digoxin is bound to this tissue. 
2) The effect of cardiac glycosides on skeletal muscle is similar to that on the heart, 
with an increased contractile force being produced by a high concentration of 
glycoside in the tissue (Smulyan and Eich 1976) . 
3) The percutaneous needle biopsy technique proposed by Bergstrom (1962) al-
lows sampling of skeletal muscle for digoxin assay without surgical intervention. 
The results of the study indicated that a significant correlation between �QS2I and 
skeletal muscle digoxin concentration exists. There was also a comparatively high 
r-value (-0.58) for the correlation between dLVETI and skeletal muscle digoxin con­
centration, although this correlation was not statistically significant. In all subjects 
in the present study, in whom the serum and skeletal muscle digoxin concentrations 
were measured at two different dose levels, the increase in serum and skeletal muscle 
digoxin concentration was associated with shortening of QS2J and the shortening 
QS2I was significantly greater at the higher than at the lower dose. 
Hinderling and Garrett (1977), modeled the pharmacokinetics - pharmacody­
namics of digoxin and ,8-methyl digoxin in seven normal subjects. They qbserved 
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significant decreases in LVET and HR after an oral and i.v. administration of /3-
methyl digoxin. The time course of this action correlated with the time course 
of /3-methyl digoxin and its active metabolite, digoxin, in their deepest compart­
ments and not with their plasma levels. The relative peak effect and area. under 
the ejection time-time curves (for doses of 0.3 and 0.6 mg.) indicated a linear dose­
response relationship on intravenous administration. The time course of HR action 
correlated (8.3 and 12.5% decreases with 0.3 and 0.6 mg. i.v ., respectively; 6.5 and 
9.5% decreases with 0.3 and 0.6 mg. p.o. , respectively) with the time course of 
{3-methyldigoxin and its metabolite digoxin in shallower pharmacokinetic compart­
ments (peaks at approx. 80 min. i.v. and 135 min. p.o.). Significant effects had 
disappeared by 10 hr. after drug administration. This finding indicated that the 
biophases differ for ejection time and heart rate action. 
The authors observed that the time course of the apparent negative chrono­
tropic effect observed from heart rate measurements was remarkably different from 
LVETI measurements after /3-methyldigoxin administration. Therefore the authors 
suggest that these two receptor-sites containing b:iophases are kinetically different. 
The most extensive study on modelling digoxin pharmacokinetics - pharmaco­
dynamics was by Kramer et al. (1979) who conducted pharmacokinetic - pharma­
codynamic studies with digoxin in 12 volunteers.. The authors fitted the digoxin 
concentrations vs. time to a 3-<:ompartment model. The levels of digoxin in the 
deep compartment that were predicted from this fit were found to relate closely 
to the intensity of the response as measured by QS2I. The authors found that a 
nonlinear relationship (langmuir type), between l!.QS2I and the level of digoxin 
in the more slowly equilibrating tissue compartment yielded a better simultaneous 
fit than the linear relationship attempted. The results of their study established a 
close relationship between digoxin levels in the slowly distributing (deep) peripheral 
compartment and the inotropic response (as estimated by AQS2I) . 
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Although the data in their study established a relationship between digoxin 
levels in the deep peripheral compartment and .6QS2I, several aspects related to 
the work require further substantiation or improvement. The variability inherent in 
the response measurement, both intrasubject and intersubject limits the quantita­
tive treatment of .6QS2I data. Although the relationship is established for averaged 
data from 12 subjects, the same relationship has not been established for individual 
subjects. Also, the limited range of the changes in .6QS2 l coupled with the inter­
subject variability makes it difficult, even for averaged data, to distinguish among 
different possible mathematical relationships between drug level and response. Thus 
the results of this study suggest that further efforts designed to develop more re­
producible response measurements for digoxin would be desirable. A second aspect 
of the response measurements that requires further substantiation is the relation­
ship between the .6QS2I and the degree of inotropy obtained after administering 
digoxin. Although a linear relationship has been clearly demonstrat,ed in a previous 
study between .D.QS2I and the direct measurement of the rate of pressure change 
in the left ventricle obtained after digoxin administration, further studies designed 
to test this apparent link between l:l.QS2I and inotropy are needed. 
Repke, et al. have pointed out that any proposed mechanism for digitalis action 
must explain both the lag phase of myocardial response and the absence of a direct 
correlation between gJycoside level in blood and glycoside acti ity. There appear 
to be at least two possible mechanistic explanations for lack of direct correlation of 
digoxin serum levels with response the lag phase of myocardial response, and the 
observation in their study of an apparent correlation of inotropy with digoxin levels 
in the d�ep compartment of a three-compartment pharmacokinetic model. One 
possibility is that the receptor for digoxin is sufficiently remote from the diioxin 
in serum so tha.t the time needed for distribution to the receptor is similar to that 
needed for distribution to the deep compartment. A second possibility is that the 
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mechanism of the inotropic response to digoxin involves a sufficient delay such that 
the time course of inotropy is similar (perhaps fortuitously) to the time course of 
drug levels in the deep compartment. Repke et al. have presented evidence that 
the mechanism consisting of an inhibition of transport ATPase by cardiac glycosides 
followed by an increase in intracellular calcium is at least consistent with the idea of 
a response mechanism involving considerable delay in the development of inotropy. 
S) Altered pharmacokinetics-pharmacodynamics of digoxin in altered physiological 
states. 
A comprehensive review of altered digoxin pharmacokinetics in. disease states is 
given earlier in the review on digoxin pharmacokinetics. The implications of these 
altered physiological states to pharmacodynamics is as follows. 
a) Renal Function: 
Results of studies in patients and in normal subjects compiled by Reuning et al. 
( 1973 ) ,  indicate that the apparent volume of distribution obtained by extrapolation 
(V d) , is �bout 5?% as large in subjects with severe renal insufficiencyis as compared 
to the V d in normal subjects; with the exception of the studies of Ueda et al. ( 1967) 
in Jap'anese subjects. In these subjects the V d of subjects with renal insufficiency 
was ohly 1 6% of that observed in subjects with normal renal function. Reuning et 
al. further suggested that although the extensive data of Doherty et al. ( 1964) ,  
did not permit a numerical calculation of V d, their results suggest that the V d in 
subjects with renal failure is about one third that of normal subjects. Since the 
apparent volume of distribution relates the plasma concentration of drug to the 
amount of drug in the body, it is evident. from the results that the relationship 
between plasma level and body level of d igoxin is altered considerably in subjects 
with severe renal impairment. Since the decreased numerical value of V d in renal 
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failure·could be a direct kinetic result of the decreased rate of digoxin elimination, a 
second measure of the apparent volume of distribution V d88 , was determined. The 
value of tbis parameter, which is independent of the degree of renal impairment, was 
also depressed in subjects with severe renal insufficiency to about 65% of normal. 
The apparent volume of the central compartment, V c, was depressed to a similar 
extent. The apparent volume of distribution in all the cases was very large (up to 
2100 liters) , indicating extensive binding of digoxin in tissues. 
The implications of this observed differences in V d of patients with renal failure 
compared to those with normal renal function is significant. These differences in V d 
may be diff'E�rences at the biophase, or in a peripheral storage site. Pharmacokinetic­
pharmacodynamic models need to be developed that can discern these differences 
in V d and indicate the adjustment in dosage required. 
b) Potassium imbalance 
Potassium ions influence electrophysiologic events in the heart. Excess myocar­
dial potassium reduces conduction in the atria and subnodal system and depresses 
automaticity. Despite this, in clinical situations, conduction disturbances during 
hyperkalemia are rarely seen, except in digitalized patients, indicating interaction 
between potasium and the cardiac glycosides (Fisch and Knoebel, 1966). Intracel­
lular depletion of potassium appears to interact directly with the action of cardiac · 
glycosides promoting toxicity (Lown et al. 1951) . 
Steiness (1978) , however has reported that digoxin toxicity in hypokalemic 
patients is compounded by a reduced active renal tubular secretion of digoxin in 
humans, an effect already observed earlier in dogs (Marcus et al. 1971� . This may 
partly explain why hypokalemia pre-disposes to digoxin toxicity. All patients were 
recieving both digoxin and furosemide maintanenoe treatment and ;inulin clearance 
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was used as the baseline for changes in clearance. When patients recieved potassium 
supplements, the tubular secretion was restored to normal. 
Cohn et al. (1967) ,  studied the effect of K+ depletion on myocardial concentra­
tion of tritiated digoxin. He found that there was no significant differences between 
the myocardial 3H-digoxin of the control and potassium-depleted groups a.t 0.5, 1,  
2: 6 or 16 hours, but at 24 hours, a significantly higher concentration of digoxin was 
present in the hearts of potassium deficient mice (23.6 ± 5.2 µg/gm.) than in the 
control group (3.1 ± 1.5 µg/gm . ) .  Potassium depleted mice with total renal failure, 
showed increased myocardial 3H-digoxin levels at 20 hours as compared with mice 
with rena] failure but without potassium deficiency. It is thus evident that dimin­
ished renal function produced by potassium-depletion is not the sole mechanism of 
this retention of cardiac 3H-digoXin. 
The mechanism by which digitalis inhibits the influx of potassium is stilJ under 
investigation. However, it has been established that the active transport of Na + and 
K+ across the cell membrane is associated with the spJitting of ATP by membrane 
ATPase. It has been postulated that Na+ and K+ activate ATPase by combining at 
sites which are more.or Jess selective for these ions. The transport ATPase is readily 
inhibited by concentrations of the cardiac ,glycosides in the range from less than 
1 0- il.l\1 to more than 10-4M (Glynn 1964) . At lower concentrations of digitalis , the 
degree of inhibition of K -t- infiux appears to diminish as extracellu)ar K+ increase 
1(Page 1964, Glynn 1956) . This observation may be explained by competition of 
cardiac glycoside and K+ for a binding site, possibly on the cell membrane (Page 
1964, Repke 1965, Glynn 1957) . In addition, Ebert et al. (1967) , repor�ed that K+ 
can displace digoocin from the heart. 
Marcus et al. ( 1969) postulated that the chang:e in body distribution of digoxin 
in the dogs made hyperkalemic prior to the administration of digoxin as compared 
to normal dogs may be explained in part by competetive inhibition of K + and 
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digitalis for similar receptor sites. Once digitalis is bound to the cell, hyperkalemia 
does not alter its retention. Therefore the mechanism of K+ in reversing digitalis 
induced arrythmias may be other than physical displacement of digoxin from the 
heart. It is also possible that the portion of digoxin that is pharmacologically active 
is a minute portion of tha.t present in the myocardium and that K+ displaces this 
fraction : diminishing pharmacologic activity but reieasing amounts of digoxin which 
are not measureable by methods available then. 
Serum potassium poorly reflects intracellular potassiuJ?l (Lown et al. 1951, 
Lown and Levine 1954a: Moore et al. 1954) .  Potas ium ions also contribute to the 
transmembrane resting and action potential of the myocardial cell. These facts may 
explain the relationship between hypokalemia. and digitalis toxicity. Also: clinical 
benefit has often been achieved by the administration of potassium in patients 
with digoxin-induced arrythmias. The fact that hyperkalemia can also result from 
digoxin intoxication (Gaultier et al. 1968. Citrin et al. 1972. Rumrack et al. 1974) 
complicates the situation and stresses the importance of understanding the etiology 
behind the changes in serum potassium. The influence of potassium on ionotropy 
is not weJl understood. In laboratory experiments, potassium was found to lessen 
the ionotropic response (Prindle et al. 1971, Lee et al. 1977) : but. this has not been 
confirmed clinically. 
The results indicate the need for the development of pharmacokinetic - phar­
macodynamic models to better characterize the effects of K+ in altering the phar­
macokinetics and pharmacodynamics of digoxin. 
c) Thyroid dysfunction 
Hyperthyroid patients appear to require larger doses of digitalis (Watters and 
Tomkin 1975; Klassen et al. 1977) . Unusually high doses may be needed to control 
ventricular rate in atrial fibrillation due to thyrotoxicosis (Boas 1931; Barker et 
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al. 1932; Frye and Braunwald 1961; Morrow et al. 1963) . However, hypothyroid 
patients need smaller doses of cardiac glycosides to treat congestive heart failure 
(CHF) (Morrow et al. 1963) . 
The altered sensitivity to digitalis in patients with thyroid disease has been 
attributed to a. change in intrinsic myocardial function (Buccino et al. 1967; Peacock 
and Moray 1963i Morrow et al. 1963) The "resistance" to digoxin in thyrotoxicosis 
might be due to similar actions of thyroxine and digoxin on Na+ , K+ -dependent 
ATPase (Lindsay and Marker 1976) . However, alterations in glycoside kinetics is 
another possible explanation and has been evaluated by several investigators using 
either radioactive glycosides (Doherty and Perkins 1966; Eichenbusch et al. 1970) 
or radioimmunoassay (Croxon and Ibbertson 1975; Gilfrich and Meinertz 1978; 
Shenfield et al. 1977) . Some of these studies have been reviewed earlier. 
The hyperdynamic state in hyperthyroidism may also be involved in the altered 
cardiac tissue level. Heart rate for example has been implicated in glycoside binding 
(Lloyd and Taylor 1978, Roth-Schechter et al. 1970) and there is an increased heart 
rate in hyperthyroidism. 
Thus there are several possible explanations for t.he increased cardiac binding 
of digoxin in hyperthyroidism. The two most likely hypotheses are :- 1 )  Changes in 
sensitivity to digoxin with altered thyroid status are due to changes in serum level. 
'2) Changes in sensitivity to digoxin with altered thyroid status are due to a direct 
effect of thyroid hormone on the heart inducing increased Na.+ , K-r -ATPase. As a 
result more glycoside is needed to achieve the same response. 
Another possible explanation for the differences in levels are due to altered 
volumes of distribution (Doherty and Perkins 1966) . Increased volume of distribu­
tion in hyperthyroid patients and decreased volume of distribution in hypothyroid 
patients were demonstrated by Shenfield et al. ( 1977) and Gilfrich and Meinertz 
(1978) , showed a larger Vd. in hyperthyroid patients than in euthyroid patients. 
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The findings of decreased serum and liver levels of 3H-digox.in in the hyperthyroid 
group, but increased cardiac levels supports the concept of changes: in the distribu­
tion of digoxin in hyperthyroidism. There is considerable evidence to suggest that 
there are changes in glycoside receptors with altered thyroid status. The nature of 
the cardiac receptors remains unresolved but there is still doubt that the N a+ , K+­
ATPase is intimately involved (Coltart 1978) and it has also been shown that there 
is an increase in Na+ , K+-ATPase activity in hyperthyroidism (Curfman, Crawley 
and Smith 1977) . 
The existing body of l iterature on the effect of thyroid dysfunction on d igoxin 
kinetics and disposition are far from conclusive and indicate the need for devel­
opment of pharmacokinetic-pharmacodynamic models to determine whether the 
changes in digoxin effects due to thyroid dysfunction are due to altered pbarmaco­
kinetics, altered levels at the biophase, or both. 
4) Lack of a specific assay for digoxin 
Finally, there is the possibility that metabolites of digoxin may interfere with 
the radioimmunoassay of digox.in serum levels if these metabolites are present in 
serum at a sufficient concentration. It has been demonstrated that the active 
metabolites digoxigenin bis-digitoxoside and digox.igenin mono-digitoxoside and the 
inactive metabolite dihydrodigoxin are all capable of interfering with the RIA to 
varying degrees (Stoll et al. 1972; Kramer et al. 1976) . It has not been established 
whether there are significant concentrations of these metabolites in serum because 
of the extremely low concentrations of assayable compounds achieved after d igox.in 
administration in man . Also, most of the pharmacokinetic and pharmacodynamic 
studies have been conducted using these non-specific assays for digoxin so that the 
contribution of the parent drug to the response has not been reliably determined. 
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5} Use of the dog as an experimental model 
Although the dog bas b�en used extensively as an experimental model for 
digoxin pharmacokinetics and pharmacodynamics using invasive techniques (Za­
mella et al. 1980; Horwitz et al. 1977; Rubenson et al. 1984) ,  there has been 
no study yet that has used non-invasive techniques of measuring STI in the dog. 
Further there has been no study in the dog where the pharmacokinetics and phar­
macodynamics have been simultaneously studied for pharmacodynamic model de­
velopment. Most studies that have measured digoxin responses in the dog, have been 
pharmacologic studies, where · the objective usually has been the demonstration of 
an observable pharmacologic effect, rather than pl1armacodynamic model ling. 
Altered physiologic states may be easily induced in the dog, and could pro­
vide insight into altered pharmacokinetics-pharmacodynamics due to these altered 
physiological states. The dog_ thus seemed to be an adequate experimental model 
for our current and future studies. 
6) Lack of pharmacokinetic-pharmacodynamic studies in existing literature 
Toxicity occurs in over 20% of the pat.ients receiving digoxin. Also, patients 
with altered rena[ function have varying needs of digoxin. Resistance to digoxin is an 
accepted phenomenon in hyperthyroid and hyperkalemic patients, while sensitivity 
to digoxin is common in hypokalemic. and hypothyroid patients. In spite of these 
existing problems in digoxin dosing adequate pharmacokinetic-pharmacodynam.ic 
models have not yet been developed to assess digoxin needs in such patients. Studies 
that have attempted to model digoxin pharmacokinetics-pharmacodynamics suffer 
from the following drawbacks: 
1 )  Use of a non�specific assay for digoxin since lack of a specific assay confounds 
the contribution of the cardio�tive metabolites of digoxin to the response. 
78 
2) Previous studies have not monitored the plasma levels and response of digoxin 
simultaneously over time :thus preventing mathematical definition of the rela­
tionship between the levels and responses. 
It is for all of the above mentioned reasons that digoxin was chosen as the investi­
gational drug in the dog. 
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REVIEW OF EXISTING ANALYTICAL METHODS 
Analytical methods for digoxin can be divided into 2 groups. In the µg. range, 
t.he classical methods of photometry and chromatography still have an established 
place in the pharmacoepoeias and in control laboratories for the quantative de-­
termination of cont.ent and purity. Pharmacokinetic investigations utilize methods 
that wilJ detect digoxin in the ng. range. Some of the methods used are isotope 
assays, gas chromatography (GC), gas chromatography - mass spectrometry (GC­
MS), high pressure liquid chromatography (HPLC) , radioimmunoassay (RIA) and 
rubidium (Rb)-uptake by erythrocytes. 
I. Chemical and Chromatographic methods 
Initial methods involved co�verting digoxin to colored products by the Baljet or 
Keller-Kiliani react.ions which were measured by photometry. Or, digoxin was 
treated with strong acid and t�en measured by fiuorimetry. The fluorimetric method 
was the most sensitive. These methods are no longer used because of their lack of 
specificity and lack of sensitivity. Since 1950's chromatographic methods have been 
used for qualitative and quantative analysis of digoxin. Initial methods used paper 
chromatography and subsequently thin layer chromatography (TLC) . Here again 
the major drawback was lack of sensitivity. Some of the TLC procedures were those 
by Fuch et al. 1958, Stahl 1961 1 and Carvalhas and Figueira 1973. 
II. Gas Chromatography 
The first GC analyses of digoxin (Jelliffe and Blankenhorn 1963, Wilson et al. 
1967), were effected by converting digoxin to its trimethylsilyl ether derivative. 
Watson and Kalman (1971) ,  deve]oped a GC assay for digoxin. Although this assay 
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enables analysis of ng. levels of digoxin in plasma, it requires 10 ml of plasma and 
elaborate processing and deri�atization with hepta:fluorobutyrate prior to injection. 
Neverthless GC in conjunction with MS is of great value. The technique enables 
metabolites to be identified and quantified. (Watson et al. 1973) . 
III. Liquid Chromatography 
Gravity column c.hromatography with silica-gel and aluminium oxide has been em­
ployed for many years. Other column filling materials have been used including 
Sephadex LH-20 (Gault et al. 1976) and DEAE-Sep�adex LH-20 (Sugden et al. 
1976) . Due to its accuracy, reproducibility and speed of operation HPLC has been 
the preferred choice over liquid chromatography (LC) , at normal pressure. A num­
ber of HPLC procedures for digoxin and its metabolites have been published using 
various columns including .silica-gel, ion-exchangers and reversed phase columns. 
IV. Double Isotope Dilution Derivative Assay 
This method originally used for the analysis of amino acids and steroids has also 
been applied to the analysis of digoxin (Lukas 1973 ) .  
The sample i s  spiked with 3H-digoxin for recovery calculations. The sample 
is extracted and converted to its acetate derivative with 1-14C-acetic anhydride. 
Finally� the digoxin c.ontent is calculated from the carbon-14 and tritium content of 
the acetate derivative. the specific activity of the I-14C-acetic anhydride and fraction 
of tritium recovered . Several extractions and chromatographic clean-up procedures 
are necessary before and after derivatization. The precision of this assay is poor at 
levels of 2 ng/ml. of digoxin or lower. 
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V. Enzyme Immunoassay 
The enzyme-immunoassay technique (EIA) , differs from RIA in that an enzyme­
labeled drug (i.e. a drug covalently attached to an enzyme) rather than an isotope­
labeled drug is used as the antigen competing with the unlabeled drug to be analyzed 
( Rubenstein et al. 1972). The antibody bound to the labeled drug then sterica.lly 
inhibits the enzyme activity; the higher the concentration of unlabeled drug: the 
more competition there is for binding sites on the antibody and thus more release 
of enzymatic activity, which serves as the indicator for immunologic competition. 
This technique was introduced for the determination of digoxin by Chang et al. 
( 1975) , and made commercially available. The kit bas been evaluated (Rosenthal 
et al. 1976) � and compared· to RIA (Rosentahl et al. 1976: Sun and Spiehler 
1976) . Comparison of digoxin concentrations determined with both EIA and RIA 
revealed no systematic differences. A bout 20 specimens can be analysed within 
2.5 hr. However, the antibody used in EIA also crossreacts with digoxin metabolites 
viz. ,  digoxigenin, digoxigenin mono-digitoxoside and digoxigenin bis-digitoxoside 
(Lin day and Dra:,ver. 1983) . 
VI. Radioactively Labeled Digoxin 
Most of our present knowledge on the pharmacokinetics and biopharmaceutics of 
digoxin is due to the use of radioactive labeled cligoxin (MaTcus et al. 1 976; 
Doherty et al. 1961. 1966, 1967; Harrison et al. 1966; Hernandez et al. 1963) . 
The technique is easy, inexpensive, highly sensitive and extremely precise. However 
its 2 major drawbacks have curtailed its use in recent years. viz ., 1) non-specificity, 
i.e., radioactivity of a plasma or urine sample collected after a�ministration of a 
labeled drug may not only rep.resent the drug but the sum total of different species 
formed by chemical , or biologic decomposition or by metabolic transformation. 2) 
Restrictions on the use of radioactive materials. 
VII. Radioimmunologic methods 
Basic principles: 
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Based on the work of Yalow a.pd Berson (1959) on ·the detection of insulin, radioim­
munoassay (RIA) has now developed to be the most widely used method for the 
detection of_ trace amounts of ·biologically active substances (antigens) . 
In the assay a constant �ount of antibody (which is selected in order to bind 
only part of the amount of added antigen) is incubated with a constant amount of 
tracer and antigen to be determined. In the course of the competetive reaction more 
labeled antigen will be bound by the antibody with decreasing amounts of unlabeled 
antigen present in the system· and vice versa; according to the law of mass action. 
After a set time, ideally at equilibrium - the antibody-bound antigen is separated 
,; 
from the free antigen and the' radioactivity in one of the fractions is measured, in 
.: . 
order to determine the unknQwn concentration of the antigen from the measured 
,count rates. This requires that both the antigen present in the standard and the 
unknown displac,e antigen from an antibody-labeled-antigen immune complex, but 
identical behaviour of tracer �d unknown or standard antigens is not necessary. 
Antibodies: 
Digoxin is a_ small molecule (mol. wt. 780.92) , and is too small to be immuno­
genic by itself. To obtain antipodies it is therefore nece�sary to couple it to protein 
carriers or haptens. Butler and Chen (1967) were the first to succeed in obtain­
ing antib<;>dies against digoxin. Antibodies have also been develop,ed by Smith et 
,al. (1970) . The process involves oxidation of the OH groups on the digitoxose 
molecules by metaperiodate, yielding a dialdehydie derivative. The dialdehyde is 
then coupled to albumin to yi�ld a conjugated� immunogenic molecule. Antibodies 
against, dihydrodigoxin have also been developed (Butler et al. 1982) , although 
they have not been commercially marketed. 
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Tracers 
The original digoxin RIA method (Smith et al . 1969) employed 12-a-3H-digoxin. 
3H- as a beta-emitter requires quench correction; so that the unit cost per assay 
is higher compared with lab�ls that allowed gamma-counting. For these reasons 
1 25 I-labele? _qigoxin is used in virtually all digoxin RIA kits today. The shorter 
half-life of 1 251 (62 days) does: not present a serious restriction. 
VIII. Radioimmunoassay 
T he first published RIA for digoxin (Smith et al . 1'969) employed high-affinity anti­
digoxin antibody, 3H-digoxin as tracer and dextran-coated charcoal (DCC) as the 
separation system. A serum volume of 1 ml. was required with a 15 min. incubation. 
Centrifugation of the free digoxin bound to DCC, denaturation of antibodies by 
heating at 60 °C, and quench corrections had also be be carried out. In contrast 
modern assays use less serum: (0.1 ml or less) and by the use of iodinated tracers 
the counting process has become much more convenient. T he general capabilities 
and limitations of digoxin RIA have been summarized (Shapiro et al. 1975, Rave] 
1976) . Considerable difficulty has been encountered due to the lack of specificity of 
1 25 1-digoxin kits. The antibody cross reacts with some of the digoxin metabolites 
(Stoll et al. 1972) including dihydrodigoxin (Kramer et al. 1976) . 
IX. ATPase for the Determination of Cardiac Glycosides 
T he existence of an Na+ , K+ - activated ATPase (Mg++ - dependent, N a+, K+ -
activated ATP-phosphohydrolase) was discovered by Skou in 1957. Soon afterwards 
he discovered cardiac glycosides are able to inhibit ATPase activity by binding to 
the enzyme (Skou 1960) . This enzyme is specifically associated with active cation 
transport, and becomes phosphorylated during the transport reactiO!n. The ATPase 
molecule also possesses a binding site for oubain. 
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Both reactions - The dephosphorylation of ATP and the binding of oubain 
- may be employed as tools to measure the concentration of cardiac glycosides. 
The first method measures the inhibition of ATP hydrolysis; the second is based 
on the displacement of radiolabeled oubain from its binding site by other cardiac 
glycosides. 
Comparison of the results obtained by ATPase activ ity and RIA 
Since some known metabolites of digoxin are able to inhibit ATPase and to bind 
the antibodies respectively, both methods lack specificity. However with respect to 
the minor extent to which the metabolites occur in plasma (Marcus et al. 1966; 
Vohringer and Reitbrock 1974) the results obtained by both assays should be compa­
rable. Results obtained from urine samples by both methods might show differences 
since polar and nonpolar metabolites occur in remarkably high concentrations in 
the urine (Marcus et al. 1966; Vohringer and Reitbrock 1974) . 
After administration of a dose of 0.5 mg. tritiated digoxin to each of 5 human 
volunteers the total radioactivity was determined in the polar and in the chloroform­
extractable fractions of the urine. Measurements using ATPase activity as well as 
RIA's were performed for the same samples (Gundert-Remy et al . 1978) . No 
systematic deviat ion could be detected between the results obtained from the three 
different assays. This indicates that both radioimmunologic. and enzymatic assays 
are non-specific to the same extent since the results are not statistically different 
from the data obtained by measurement of total radioactivity. 
Comparison of ATPase and RIA methods 
The ATPase enzyme is not stable for more t.han 3 months and hence it is neccessary 
to prepare batches of enzyme from time to time to characterize them for use in the 
assay procedure. Using ATPase according to Booka and Jelliffe ( 1972) , it takes 
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60 mins. and according to M�dh (1973) 90 mins. to run a sample by displacement 
and activity assay respectively. Large series of plasma samples can. be determined 
more conveniently using RIA �ue its short incubation times and because an extrac­
tion procedure is not neccessaty. However with the ATPase enzyme, more than one 
cardiac drug or its metabolit� can be measured using the same enzyme system. 
X. Rubidium Uptake in Erythrocytes 
Active uptake by human erythrocytes of potassium measured by flame photometry 
has been demonstrated to be inhibited by cardiac glycosides (Schatzmann 1953) . 
This effect. was shown to be due to an inhibition of membrane Na+ - K+ - ATPase 
activity (Post et al. 1960; Dunham and Glynn 1962; Glynn 1957) . 
Therefore Lowenstein (1965) introduced the principle of inhibition of active 
cation uptake by erythrocytes= to measure plasma concentrations of cardiac glyco­
sides. Potassium, however had to be replaced by rubidium, since available potas­
sium isotopes are impractical for standard laboratory techniques. Since 86Rb has 
a half-life of 19.7 days and emits beta and gamma-rays it is very appropriate for 
routine laboratory use. 86Rb is taken up by human erythrocytes in the same way 
as potassium (Love and Burch, 1953). 
Some of the disadvaniages of the assay, are: 
1. Variability in batches of erythrocytes - since uptake of 86Rb is dependent on 
the source of the erythrocytes e.g. blood group, age, race, and disease states 
of the donor. 
2. The assay requires 8 hrs., which is much longer than the time required to do 
RIA's. 
3. Has a dichloromethane extraction step, which can contribute to errors. 
4. Large volumes of plasma ar� required to assay low digoxin concentrations. 
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XI. Recent HPLC Assays 
Initial studies measured digoxin concentrations by administration of 3H-digoxin 
to patients (Beall et. al. 1963; Doherty et al. 1961; Doherty et al. 1969; 
Hernandez et al. 1963). �11 subsequent studies have used RIA for measuring 
digoxin concentrations (Biddle et al. 1978; Coltart et al. 1974; Gorodischer et al. 
1976; Gullner et al. 1974 ; Jusko et al. 1974; Karjalainem et al. 1974; Krasula 
et al. 1974; Park et al. 1982) . 
It has been demonstrated that the digoxin metabolites: digoxigenin, digoxi­
genin mono-digitoxoside, digo�igenin bis-digitoxoside; cross-react extensively using 
RIA (Stoll et al. 1972) . Kramer et al. (1976) , showed that dihydrodigoxin also 
cross-reacts with the commerically available RIA 's. 
Recent methods have separated digoxin from its metabolites by HPLC . By 
collecting the digoxin fraction at the end of the HPLC column, and by either apply­
ing RIA or measuring radioactivity (when radiolabeled digoxin is administered ) :  
specific assay methods for digoxin have been made available (Eriksson et al. 1 981 ;  
Loo e t  al. 1977 1981 ; Morais e t  al. 1981 ; Nelson et. al. 1979) . 
Gibson and Nelson (1979� 1980) reported that plasma digoxin concentrations 
measured by specific HPLC assay and direct 1 25 1-RIA are essentially identical when 
glomerular filtration rate is 40 ml/min . or more; in contrast: the ratio of HPLC­
RIA/RIA values was 0.83 ± 0.12 in renal failure patients. Wagner et al. (1981) , 
reported no significant differences between results with a specific assay and RIA 
with groups of 17 randomly selected plasma samples and 34 randomly selected urine 
samplef: fi:om a study in normal adult male subjects. Loo et al. (1981), reported 
a mean ratio of HPLC-RIA/RIA digoxin in serum of 0.84 ± 0.12 in 14 digitalized 
patients of unknown renal status. Wagner et al. (1983), reported a mean ratio of 
HPLC-RIA/RIA digoxin in a mean and range 0.74 (0.23 to 2.63) in serum and 0.81 
(0.068 to 1 .38) for atrial tissue. 
CHAPTER 2 
EXPERIMENTAL 
An Improved Method For Assaying Digoxin In Serum 
Using HPLC-RIA 
The following section describes the developed HPLC-RIA assay for digoxin in 
the presence of its major metabolites using information detailed in the prelimi­
nary studies. Details of these preliminary studies which include, the development 
of HPLC procedures, and validation of the selectivity of the RIA kit (Diagnostic 
P_roducts Corporation) to digoxin in the presence of dihydrodigoxin may be found in 
appendix B. References to the_ various materials used may be found in appendix A. 
Introduction: 
Most of the existing 'specific' assays for digoxin have inherent drawbacks .  Pro­
cedures involving gas chromatography - mass spectrometry although sensitive are 
expensive and tedious. The HPLC methods by Loo et al. ( 1977) and Nelson et al. 
( 1979) , Gault et al. and Sugden et al. require 3H-digoxin as an internal standard: 
or require _3H-digoxin be administered to patients. 
The developed assay has some advantages over currently available procedures. 
The extraction of digoxin from serum is over 90%,  from serum as compared to 
previous assays where the extract:ion varied from 54% - 78% (Nelson et al. 1979) . 
Loo et al. {1974) and Gault e� al. ( 1976) , also reported mean extraction percentages 
of around 70% - 80% . The assay does nqt require 3H-digoxin to be administered 
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to the subjects or patients, or to be used in the assay, except for 1251-digoxin used 
in the RIA procedure. 
Kuhlman et al. 1973, and Sternson et al. 1978, have shown that digoxin hy­
drolyses to give rise to digitoxosides, viz., digoxigenin bis-digitoxoside, digoxigenin 
mono-digitoxoside and digoxigenin . There is a possibility that digoxin hydrolysis 
may occur in assays using reverse phase HPLC (Morais et al. 1981, Eriksson et al. 
1981, Nelson et 1al. 1979, Loo et al. 1981, Wagner et al. 1983), since the mobile 
phase in such systems is comprised largely of water. Use of a normal phase HPLC 
system (where the mobile phase i� comprised of organic solvents) eliminates the 
possibility of hydrolysis during the assay. Furthermore, after coUection of eluate 
fractions, the solvent can be _easily evaporated to dryness prior to reconstitution 
for RIA. Evaporation of aqueous solvents (in reverse phase HPLC) is extremely 
cumbersome and further enhances the possibility of degradation. 
Morais, et ail. (1977), Loo et al. (1981) and Eriksson et al. (1981),  have re­
ported partial or complete separation of dihydrodigoxin from digox:in using HPLC. 
Little success was had in reJ?roducing this separation. Due to its very low ab-
sorbance, nanogram quantitie� of dihydrodigoxin cannot be monitored using ultra-
violet (UV) spectrophotometry. Hence, during the developmental stages of the as­
say the retention times for dihydrodigoxin were monitored using spectrofluorometry 
(Wells and Myers, 1961) . 
Experimental: 
Materials: 
All solvents used for the �xtraction or chromatography were HPLC grade from 
Fisher Scientific Co. (Pittsburgh, PA, USA). Digoxin was obtained from Sigma 
Chemical Co. (St. Louis, M9, USA). Digoxigenin, d�goxigenin mono-digitoxoside 
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and digoxigenin bis- digitoxoside were purchased from Boehringer Mannheim Bio­
chemicals (Indianapolis, Ind., USA) . Dihydrodigoxin was a gift from H.Hull (Bur­
roughs Wellcome, Research Triangle, N.C, USA). RIA was performed using the 
Digoxin RIA kit (Diagnostic Products Corporation LA, CA, USA). 
Methods: 
Extraction: 
1 ml. of serum was extracted with a combination of 0.5 ml. methylene chloride and 
4 ml. chloroform in a screw-capped 10 ml. glass tube. The tube was agitated for 
15 mins. on a rotary mixer and then centrifuged at 1000 g for 5 mins. The organic 
layer was pipetted into a 12 ml. conica] centrifuge tube. The aqueous layers were 
re-extracted and centrifuged again using the procedure above. The aqueous layer 
was aspirated and the organic layer was pipetted _out. The combined organic extract 
was evaporated to dryness on a vortex evaporator. The residue was reconstituted 
in 170 µl. of mobile phase and was injected on to the HPLC column using a fixed 
volume 100 µl. loop injector. 
Chromatography 
The HPLC system was a Waters M - 6000 A solvent delivery system. The separation 
was acquired with a Lichosorb 81-100 silica column (Hewlett Packard: 5 µm. par­
ticles, 20 em. length, 3 mm. internal diameter) . The mobile phase was comprised 
of 75% hexane: 1 8% ethanol and 7% methylene chloride. The flow rate was mon­
itored at 3 ml./min. and pressures ranged from 1,500 to 3,000 psi. The retention 
times for digoxigenin, digoxigenin mono-digitoxosiide, digoxigenin bis- digitoxoside 
and digoxin varied slightly with each batch of mobile phase that was prepared but 
typically were 5.2, 7 .2, 9.8 and 13.2 mins. respectively. Dihydrodigoxin is not sepa­
rated from digoxin using the above procedure. Retention times during development 
of the assay were monitored by injecting a mixture cont�ining 2.5 µg. of digoxin 
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and its metabolites on the column and detected using a Gilson variable wavelength 
UV spectrophotometer at 230 nm. Retention times (prior to assaying each batch 
of samples) were determined by injecting 20 ng. of each of the metabolites in the 
mobile phase on the column and collecting 1/2 min. fractions of the eluant over a 
period of 20 �s. Each fraction was evaporated to dr:y-ness, reconstituted in 0.5 ml. 
of blank plasma and assayed by RIA to confirm that digoxin was indeed separated 
from its metabolites 
Digoxin can ot be detected spectrophotometrically in the ng./ml. range, but 
can be assayed by RIA. Hence, post injection, the eluant fraction corresponding to 
the retention time of digoxin was collected off the HPLC column. This fraction was 
evaporated to dryness. The residue was reconstituted in 0.5 ml. of blank plasma 
and this was assayed for digoxin using the ra.dioimmunoassay kit mentioned before. 
Radioimmunoasay 
RIA was conducted on the 1eluant fractions. The fraction corresponding to 
digoxin (typically 12-15 mins.) was collected in 12 ml. centrifuge tubes and was 
evaporated to dryness on a vortex evaporator. The residue was reconstituted in 
0.5 ml. plasma and assayed by RIA. The RIA kit used was found to be highly 
selective for digo:rin in the presence of dihydrodigoxin. 
Analyses: 
The standard curve and samples were done in duplicate. The standard curve 
was constructed using serum stai.ndards containing 0.5, 1.0, 2.0 and 4.0 ng/ml. 
digoxin. The st,andards ( containing known concentrations of digoxi,i in serum) 
were extracted and assayed by HPLC-RIA to obtain measured concentrations. The 
standard curve was then obtained by regression of the measured and the known 
concentrations. A set of controls (frozen serum s:amples spiked with 0.50 ng/ml. 
and 3.50 ng/ml. digoxin) was run before and after each bat�h of 12-13 samples to 
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be assayed. The concentrations of the samples �d controls were obtained from the 
standard curve for that day. 
Results: 
Chromatography: 
Digoxiii was separated from its metabolit�s (except dihydrodigoxin) on the 
column. A typical chromatogram showing separation of digoxin from its major 
metabolites is shown in Fig. 2.1. 
Extraction: 
Various solvents were tried for optimizing extraction of digoxin from serum. Most of 
the systems exhibited nonlinearity, low recoveries or non-reproducibility. A double 
extraction using 4 ml. chloroform and 0.5 ml. of methylene chlodde gave almost 
complete extraction which was reproducible. A typical extraction curve is given in 
Fig. 2.2. The regression line has a slope of 1.04 ± 0.11 and a mean value for the 
the intercept not significantly different from zero (The hypothesis H0 : Mean = 0 
was not, rejected. p = 0.6) . The correlation coefficient for the regression line was 
0.99 The slope of the line indicates an extraction efficiency of around 100% While 
the extraction procedure is tedious, it is accurate and reproducible, and requires no 
internal standard. Furthermore the organic solvents used are easily evaporated. 
Linearity: 
A typical standard curve is shown in fig. 2.3. The slopes and intercepts are given 
in Table 2.1. It is evident that the standard curve remained essentially constant over 
a eight month period. The low standard deviations for the slope and the intercept 
indicate that the standard curve remained essentially constant over a eight month 
period. 
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TABLE 2.1 
Reproducibility of the standard curve. 
NO. OF STDS. 
5 
5 
4 
5 
5 
MEAN 
± 
s.d. 
SLOPE 
1 .096 
0.974 
0.865 
0.88 
0.997 
0.96 
0.09 
INTERCEPT 
-0.044 
-0.106 
-0.06 
0.023 
0.053 
-0.03 
0.06 
95 
CORR. COEFF. 
0.99 
0.99 
0.99 
0.99 
0.99 
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Recovery: 
The precision of the method is estimated from the coefficients of variation 
for the repeated measurements made on two sets of controls. This was achieved 
by running a control from each set at the start and completion of each batch of 
samples. The recovery for these repeated measurements is given in Table 2.2. 
The recovery at a. spiked concentration of 3.5 ng/ml. was 99.91 % ± 8.97% ng/ml. 
The overall day to precision is indicated by the low standard deviations associated 
with the recovery of the controls. The mean recoveries of 100.1 7% and 99.91 % 
at 0.50 and 3.50 ng/ml. is indicative of the accuracy of the assay. The in-day 
precision is obtained from the recovery (calculated for day 2) and is 107.5 ± 3.0 
and 98. 71 ± 9.69 at concentrations of 0.50 and 3.50 ng/ml. _respectively. The values 
for the controls compared well with the values for the same controls obtained by 
direct RIA. 
Application: 
Serum samples obtained from beagle dogs administered digoxin for pharmacoki­
netic and pharmacodynamic studies ( described later in this chapt,er) were assayed 
using both HPLC- RIA and by direct RIA. Over 40 samples were assayed by both 
methods. A linear relationship was observed between the values obtained by both 
methods, with a slope of 1 .02 and a mean intercept not significantly different from 
zero (The hypothesis H0 : Mea.n = 0 was not rejected p = 0.78) .  Values obtained 
by using_ direct RIA were plotted on the abscissa. (Fig. 2.4) . 
The results are similar to those of Gibson and Nelson (1979, 1980) in patients. 
They reported the values obtained by direct RIA and those obtained by HPLC-RIA 
were essentially identical in patients wit.h glomerular filtration rates of greater than 
10 ml imin. They observed that the differences in the values may be significant 
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TABLE 2.2 
Recovery of controls. 
CONTROLS BY HPLC-RIA 
(Spiked cone. = 0.5 ng/ml.) (Spiked cone. = 3 .5 ng/ml.) 
DAY Measured cone. Recovery % Measured cone. Recovery % 
1 0.44 88.00 3.22 92.00 
0.39 78.00 3.25 92.86 
0.43 86.00 3.31 94 .57 
** 3.72 106.28 
2 0.55 1 10.00 3.05 87.14 
0.55 1 10.00 3.30 94.28 
0.52 104.00 3.74 106.86 
0.53 106.00 3.73 106.57 
3 0.54 108.00 4 .05 1 1 5.71  
0.54 108.00 3 .92 112 .00 
4 0.48 96.00 3.25 92.86 
0.55 1 10.00 3.54 101.14 
0.49 98.00 3.38 96.57 
Mean 0.50 100.1 7  3.50 99.91 
± 
s.d. 0.05 10.97 0.31 8.79 
· "' indicates lost sample due to spillage. 
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in patients with renal failure pr,esumably due to accumulation of cross-reacting 
metabolites. 
Conclusion: 
Described here is an accurate and precise method for assaying digoxin in serum. 
The assay has major advantages over existing assays, viz.: 
1 )  The extraction procedure has high recovery and a high degree of reproducibility. 
2) The possibility of cross-reactivity to metabolites has been minimized by: (a) an 
HPLC procedure that separates digoxin from its metabolites and (b) by using 
a RIA kit that is highly selective for digoxin in the presence of dihydrodigoxin. 
3) Hydrolysis of digoxin on column is minimized since the mobile phase for the 
HPLC procedure is comprised of organic solvents. 
These represent substantial improvements over existing assays. T he improved se­
lectivity of the assay could be of clinical value in patients with renal failure and 
accumulation of metabolites of digoxin. This assay was developed for application 
to pharmacodynamic studies in dogs, to assure that cardioa.ctive metabolites were 
not present in sufficient quantities, to contribute significantly to the pharmacody­
namic response being monitored. 
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METHODS 
Initial Pharmacokinetic Studies . 
Initial studies were done in 3 normal beagle dogs (Dog no.1, 13.2 kg., Dog no.2, 
10.0 kg. and Dog no.3, 9.75 kg.) . These studies were essentially pilot phamiacoki­
netic studies conducted to determine digoxin dispostion in these dogs. Information 
pertaining to materials used in these studies may be found in appendix A. These 
studies were conducted with the dogs in a conscious, unanesthetized state. The 
forelegs of the dogs were shaved. A tourniquet was applied above the elbow and a 
heparin lock was introduced into the saphenous vein. After removal of the tourni­
quet the lock was kept patent at all times by flushing it periodically with a solution 
of heparin (100 Ujml.) in normal saline. The dogs were administered 0.05 mg/kg. 
digoxin (Lanoxin'( R ) , 0.25 mg/ml.) i.v as an infusion (manually) over 5 mins. The 
Jock was then flushed with 3 ml. of normal saline to rinse the syringe and the 
tubing (associated with the heparin lock) of residual digoxin. Blood samples were 
drawn at specific times as follows: Using a st.erile 3 ml. syringe, 2 m1. of blood 
was drawn via the heparin lock. This syringe was discarded a.nd 5 m1. of blood 
was again drawn via the heparin Jock using a 10 ml. sterile syringe. The lock was 
flushed with 2 ml. of heparin. The contents of the 10 ml. syringe was transferred 
to a sterile vacutainerCR) (10 ml., red top). Typically the sampling times were 0.5, 
1.0, 1.5, 2.0, 3.5, 5.5, 7.5, 9.5,  16.0, 24.0, 32.0, 48.0 hrs. post-infusion. After each 
blood sample was withdrawn, 10 mins. was allowe� for clotting. The samples were 
then centrifuged for 10 mins. and the serum was pipetted out into polystyrene 
tubes (FalconCR) ) _and frozen for future analysis. Prior to being assayed the serum 
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samples were thawed to room temperature and assayed for digoxin content using 
RIA (Diagnostic Products, LA, CA.). Compartmental analysis was conducted on 
the concentration vs. time data using the nonlinear regression program, NONLIN 
(Metzler et al. 1974) . 
Pharmacodynamic studies 
Responses measured 
Dogs used in these st,udies were normal dogs as determined by blood tests 
and tests conducted for detection of heart worm. The responses recorded were 
electrocardiograms (EKG) , heart sounds and carotid pulse tracings. The electro­
cardiogram used was a VS4 Portable Electrocardiograph . The electrodes for the 
electrocardiogram were placed as follows: The insides of the dogs fore and hind legs 
were shaved. Cambridge electrode jelly was then applied to the inside of the legs 
where the electrodes were to be placed. A small amount of electrode jelly was also 
applied to the electrodes. The electrodes were kept in position by rubber straps 
that attached to pairs of hooks on the electrodes. The straps were tightened just. 
enough to hold the electrodes in position and to facilitate conduction of the body's 
electrical currents. Standard Lead I and Lead II electrocardiograms were usually 
recorded. 
Heart sounds were measured using a microphone pick-up unit. This high fidelity 
microphone was usually placed_ externally in between the 3rd or the 4th intercostal 
space in a position optimal to measuring the high frequency vibrations of the heart 
sounds. The optimal position was also determined by listening to the heart sounds 
with a stethophone. 
Left ventricular ejection times (LVET's) were obtained either invasively (initial 
studies) or non-invasively (later studies) . The LVET's may be non-invasively ob­
tained in humans by rp.easurements made on the carotid pulse recording obtained by 
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the placement of a pressure transducer externally over the carotid artery. A similar 
procedure could not be used in dogs by virtue of the fact that the carotid artery is 
not as superficial in dogs as compared to humans. In fact, the carotid artery is very 
deep-seated in the dog's neck, being in a deep paratracheal position. Therefore the 
pulsations in the carotid artery could not be obtained by external pick-up. LVET's 
were therefore obtained by invasive catheterization of the left auricle. Invasive mea­
surement of the LVET involved introduction of a pigtail catheter (5  french) into the 
left auricle after introduction via the femoral artery. The catheter was connected to 
a strain-gauge transducer through a dome. The pressure changes in the left auricle 
were recorded on an Electronics for Medicine EKG recording system. 
Evolution of methodology Jed to methods for the non-invasive measurement of 
the LVET. This involved exteriorization of the carotid artery in dogs by surgery. 
The carotid pulse tracings were then obtained by placement of a strain-gauge type 
pressure transducer with a funnel-shaped pickup unit placed externally over the 
exteriorized carotid artery. The LVET's could then be obtained by measurements 
made on the carotid pulse tracing. 
The procedure used for exteriorization of the carotid artery was basically that 
of Dueck et al. , ( 1 982) . The retaining suture used was 2-Prolene (cutting needle 
blue monofi.lament polypropylene suture, 50 cm) . The suture used for closure of the 
incision was 00 black silk. The procedure involves making a longitudinal incision 
in the neck of an anesthetized dog. The carotid a,rtery is then transferred from a 
deep paratracheal position to a ventrolateral subcutaneous position and is protected 
from the underlying mattress sutures by the sternomastoid muscle. 
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Responses measured 
The responses monitored by measurement and/or calculations on the record­
ings obtained are: LVET (left ventricular ejection time), S1 S2 (duration of heart 
sounds) , QS2 interval (duration of total electromechanical systole), P-R interval, 
R-R interval, Q-1 and the PEP (pre-ejection period) . The measurements were made 
as described by Weissler et al., (1968) . However the the heart sound tracing, the 
carotid pressure tracing and the standard EKG tracing were not recorded simulta­
neously. The VS4 electrocardiograph possesses a single writing channel. However, 
any two tracings may be simultaneously recorded by superimposing them on each 
other. Therefore the heart sound tracing and the carotjd pulse tracing, or the stan­
dard EKG and the carotid tracing, or the standard EKG tracing and the heart 
sound tracing may be recorded together simultaneously. Therefore in the stud­
ies conducted the carotid pressure tracing and the standard EKG and the heart 
sounds were recorded singly and the heart sound tracing and the standard EKG 
simultaneously recorded was also obtained. The following systolic time intervals 
were measured from the recorded tracings: 
1 )  The R-R interval was obtained from the standard EKG tracing. It was mea­
sured from the uppermost tip of the QRS wave (i.e. the R wave) to the R wave 
immediately following it (Fig. 2.5). 
2) S1 S2 which is the interval between the heart sounds, was obtained from the 
heart sounds tracing. It was measured from the onset of the first heart sound 
to the begining of the high amplitude of the second heart sound (Fig. 2.6) . 
3) LVET was obtained from the carotid pressure tracing. It was measured from 
the beginning of the upstroke to the dicrotic notch or the incisura (Fig. 2. 7) . 
4) The QS2 interval was obtained from the simultaneously recorded tracing of 
the heart sounds and tlie standard EKG. Jt was measured from the onset of 
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the Q-wave to the beginning of the high amplitude of the second heart sound 
(Fig. 2.8) . 
5) The isovolumk contraction time (JCT) , is derived by subtracting LVET from 
81 82.  
6) The pre-ejection period is obtained by subtracting LVET from Q82 
7) The time between the beginning of depolarization to the first heart sound ( Q­
I ) ,  is obtained by subtracting S1 S2 from QS2. 
All measurements were an average of ten simultaneous recordings. Only well 
defined waves were used to obtain the measurements. Al] recordings were carried 
out at a chart speed of 100 mm/sec. 
Study No. IA 
Dog no. :  4 
Weight: 20.45 kg. 
Sex: Male 
This was a pilot pharmacokinetic-pharmacodynamic study conducted in a mon­
grel dog. The dog was anesthetized using 30 mg/lkg. pentobarbital. The femoral 
artery was catheterized and a pig-tail catheter (5 fr.) was introduced and threaded 
into the left auricle. The catheter was hooked to a strain gauge pressure transducer 
so that the LVET could be measured invasively as described before. Digo,cin (0.05 
mg/kg.) was administered i.v. as a (manually administered) uniform infusion over 
5 mins. Blood samples were drawn at. 0, 15, 30, 45: 60, 75, 90, 120, 180, 210, 240 and 
270 mins. post infusion from the catheter. The blood samples drawn were treated as 
described as before. The pressure tracings, heart sound tracings and Lead II EKG 
tracings were recorded each tim,e a blood sample was drawn. After the completion 
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A standard EKG trac i ng .  
F ig. 2 . 5  
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Superimposed �tandard EKG and heart sounds tracing 
(simultaneously recorded) • 
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F ig. 2 . 7  A carotid pressure tracing .  
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of the study the dog was sacrificed by i .v administration of a saturated solution of 
K Cl in normal saline. 
Dog no.: 5 
Weight: 19.3 kg. 
Sex: Female 
Study No. lB 
This was again a pilot pharmacokinetic-parmacodynamic study and hence was 
conducted using a mongrel dog. The dog was conscious and in a sling. The 
LVET was measured using the non-invasive techniques (after adequate recovery 
from surgery) described previously. In contrast to the previous study blood sam­
ples were drawn and the pharmacodynamic responses measured simultaneously over 
a period of 78 hrs. 
Study no. 2 
Dog no. :  2 
Weight: 10 kg. 
Sex: Female 
Study no. 9 
Dog no. :  1 
Weight: 13.0 kg. 
Sex: Male 
Study Nos. 2, and 3 
These studies were conducted in beagle dogs. The studies were conducted after 
the dogs had adequately recovered from surgery, for exteriorization of the carotid 
artery. The dogs had recovered with no infection and seemed quite normal in their 
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behavior and seemed to have the same friendly disposition they had before un­
dergoing surgery. T he study was conducted after the dog was anesthetized with 
pentobarbital (30 mg/kg.) . After the dog was anesthetized an endotracheal tube 
was introduced in the trachea of the dog. The balloon in the endotracheal tu be was 
inflated to keep the tube in position. Whenever necessary, the dog was maintained 
on artificial respiration by attachment of the external end of the tube to a respira­
tor pump which delivered 200-300 cc/stroke at the rate of 15 strokes per minute. 
inflated Digoxin (0.05 mg/kg) was then administered as an i .v.  infusion over a pe­
riod of 5 mins. through a heparin lock placed in tbe saphenous vein of the forearm 
of the dog. The EKG electrodes and the heart sound microphone were placed in 
position. The priessure transducer was connected to the electrocardiogram but the 
funnel pick-up was not placed in position until just before recording the carotid 
pulse tracing. This is because a perfect seal is required between the funnel pick-up 
of the pressure transducer and the surface where the pulsations of the carotid artery 
are measured. This could only b,e accomplished manually, since the use of a belt 
resulted in excessive pressure around the neck region. Also, use of a belt resulted 
in minute changes in the position of the funnel piick-up, resulting in deterioration 
,of the quality of the carotid pulse tracing obtained . Blood samples were drawn 
and the Lead I or II electrocardi!ograms, phonocardiogram and the carotid pulse 
tracings were simultaneously obtained at specific time intervals over a period of 72 
hours. The dog was given maintenance doses of pentobarbital on the first day until 
collection of the 12 hour sample. Pentobarbital was then discontinued and the dog 
recovered from the anesthesia. The dog was again anesthetized with pentobarbital 
each time before blood samples were drawn and the pharmacodynamic responses 
simultaneously measured at 24, 32, 48, 56 and 72 hrs. F ive ml.'s of blood were 
drawn at each of the pre-determined intervals. T he resulting serum was used to 
assay for digoxin content by RIA. After assaying by RIA, aliqu9ts of the serum 
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were diluted with blank serum so that their digoxin concentrations were between 
0.5 and 4 ng/ml. These samples were then assayed using HPLC. 
In a similar study dog no. 3 died of respiratory depression prior to digoxin 
administration. 
Study No. 4 
Dog no. :  1 
Weight: 13 kg. 
Sex: Male 
This study was conducted similar to studies 2 and 3. The most important dif­
ference between this study and the previous studies is in the sampling times. Blood 
samples were drawn frequently and the pharmacodynamic responses measured si-
multaneously over a period of 10 hrs. As in previous studies the dog was under 
anesthesia through the 10 hrs. of the study. After administration of anesthesia the 
heart rate (HR) was allowed to stablize. HR was monitored frequently and after it 
had reached a stable value (usually after 30-60 mins.L digoxin was administered. 
The dose of digoxin administered was 0.05 mg/kg. i.v. given over a period of 5 
mins. 
Dog no. :  2 
Weight: 11 .5 kg. 
Sex: Female 
Study No. 5 
Dog 2 died of respiratory depression after administration of pentobarbital and 
prior to the administration of digoxin. 
Study No. 6 
Dog no.: 1 
Weight: 13.0 kg. 
Sex: Male 
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This study is  identical to study no. 4 .  Dog no. 1 was again used in the study. 
The study was aborted 2.5 hrs. after adminstration of digoxin because sites could 
not be found in the fore and hind legs for placement of a heparin lock. The dose of 
digoxin administered was 0.025 mg/kg. i .v. over a period of 5 mins. 
Study No. 7 
Dog no. :  1 
Weight: 13.0 kg. 
Sex: Male 
Since study no. 6 was prematurely aborted, the study was repeated ( a month 
later) using dog no. l .  The procedures used were identical to those used in study 
no. 6 The dose of digoxin administered was 0.025 mg/kg. i.v . as an infusion 
over 5 mins. Blood samples were drawn and pharmacodynamic responses measured 
frequently over a period of l O hrs. 
Study No. 8 
Dog no. :  6 
Weight: 17.0 kg. 
Sex: Male 
This study is identical to that of study nos. 2 and 3. The digoxin dose admin­
istered was 0.05 mg/kg. i.v. as an infusion over 5 mins. followed by 3 ml. of saline 
to flush the tubing. 
Study No. 9 
Dog no. :  7 
Weight: 9. 75 kg. 
Sex: Female 
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The study is identical to that of study nos. 2 and 3. The dose of digoxin 
administered was 0.05 mg/kg. i.v . as an infusion over 5 mins. followed by 3 ml. of 
normal saline. 
Dog no.: 6 
Weight: 16.4 kg. 
Sex: Male 
Study no. 10 
This study was a. repetition of  study no. 8 .  The study was repeated since 
analysis of the data from study no. 8 revealed that the HR of the dog was not 
stable at the time of administration of digoxin. Therefore, in this study the HR 
was frequently monitored after induction of anesthesia to determine that the HR 
had indeed stabilized and did not show any large fluctuations over time. After this 
was verified digoxin was administered (0.05 mg/kg. i.v .  as an infusion over � mins. 
followed by 3 ml. of saline to flush the tubing) .  
Pharmacokinetk modelling 
CHAPTER 3 
RESULTS 
Computer programs are generally used to conduct regression procedures on 
the concentrat.ion-time data obtained from pharmacokinetic studies. These proce­
dures permit characterization of the po]yexponential equations used to describe the 
concentration-time profile. They also permit accurate determination of parameters 
used in the polyexponential equat�ons. 
Nonlinear regression procedures (NONLil'\ - 1976) were conducted on the 
plasma concentrations ( Ct) as a function of time obtained from the initial phar­
macokinetic studies. The digoxin plasma concentration vs. time data obtained 
in the initiaf pharmacokinetic studies are tabulated in tables 3.1, 3.2 and 3.3 Bi­
exponential and tri-exponential equations were fit to the data. The tri-exponential 
equation was found to best fit the data. The following bi-exponential and tri­
exponential equations were fitted to the data: 
C A -0tt . B -- 8t . c - -rt t =  e - e - e 
. . .  (3.1 )  
. . . (3.2) 
A typical' NONLIN "deck" (excluding the data) submitted to the computer is given 
in table 3.4 The values of the parameters obtained by nonlinear fitting are listed in 
table 3.5 
The model was selected base_d on on t,he F-test (Boxenbaum et al.,1974) AIC 
{Akaike information criterion, Akaike H. 1973,1976: Yamaoka K. et al.,1978) and 
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Dog no. : 1 
TABLE 3.1 
Initial Pharmacokinetic Studies 
TIME CONC. 
(hrs.) (ng./ml) 
0.50 31.30 
1.00 12.94 
1 .50 8.20 
2.00 6.38 
3.50 4 .04 
5.50 3.56 
7.67 3.28 
9.58 3.02 
1 6.92 2.31 
24.20 1 .36 
30.75 1 .25 
47 .83 0.86 
Plasma concentration vs. time data following administration of 0.05 mg/kg of 
digoxin i.v. (uniformly over a period of 5 mins.) to a 13.2 kg normal beagle dog. 
TIME = time post-infusion 
1 14 
Dog no. :  2 
TABLE 3.2 
Initial Pharmacokinetic Studies 
TIME CONC. 
(hrs.) (ng./ml) 
0.25 34.80 
0.50 21.32 
1.00 12.20 
1.50 9.95 
3.50 6 .28 
7.50 3.86 
11 .00 3.24 
17.07 1.94 
23.92 2.08 
31.00 1.64 
38.00 1.16 
54 .00 0.96 
77.00 0.55 
Plasma concentration vs. time data following administration of 0.05 mg/kg. digoxin 
i .v. (uniformly over a period of 5 mins.) to a 1 0.0 :kg normal beagle dog.  
TIME = time post-infusion 
1 15 
Dog no. :  3 
TABLE 3.3 
Initial Pharmacokinetic Studies 
TIME CONC. 
(hrs.) (ng./ml) 
0.25 35.62 
0.50 18 .55 
1 .00 9.38 
1 .50 6.26 
3.50 4.13 
7.50 3.32 
11.00 2.49 
17.00 1 .94 
24.13  1.04 
31.03 1 .08 
38.00 0.87 
54 .50 0.81 
78.00 0.41 
Plasma concentration vs. time data following administration of 0.05 mg/kg. digoxin 
i .v (uniformly over a period of 5 mins.) to a 9.75 kg. normal beagle dog. 
TIME = time post-infusion 
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TABLE 3 .4 A typica l  NONLIN "deck" submi tted for fi tti ng a tri ­
exponenti a l  equation to the data . 
DOG NO.  3 
-2-COMP. 
TABLE 3.5 NONLIN A NA L YSES Initial pharmacokinetic sf.tidies 
2 
3-COM P. 2-COMP. 3-COMP . 
1 
2-COMP . .  3-COMP. 
. . . .. . --··· . .  ·- ··· ·- --·- · · ·-- - - - ··--·-- · ·· ·-· · -·-·- - ·· · ·  · ·------ . - ·····- - ·- ···· . .  ·-·· ·- ··-·-·-- ·--···· -.. -----
A ( 1 1g/rnl . )  7 .49(2 . r n) · 
H ( 1 1g/m l . ) I A2 (0.2x) 
C ( ni,t/ m l .) 
!';2.06 ( 1 1 .32) 
4 .62(0 .92) 
1 .51 (0.28) 
a (hr·· I )  
{J (h.r- 1 ) 
"Y (h.r
·- 1 ) 
SSW 
0 . 17 (0.05�) . 2.65(0.43) 
d .f. 
N 
H2 
CO R H  
(i' 
A IC 
WT. 
0.01 4 (0.0053) 0. 1 3 (0.018)  
1 .3n 
9 
rn 
0.99 
0. 7� 
1 2.0 
J /
Y 2 
0.01 r>(o.oo:m) 
cu r, 
7 
13 
1 .00 
0.997 
28.23 
-12.66 
1/Y2 
AIC = Aikaike information criterion 
SRW = weighted sum of square deviations 
·· nu mbers in brackets are standard deviations 
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3,1 .2:l (� .4 2 )  
4 . 42 (  1 .21 ) 
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0. 19(0.037) 1 .44 (0.32) 
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66.56 ( 1 2.33) 
4 .32(0.39) 
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0.0 15 (0.016) 0.074 (0.01.4 ) 
3.41 
8 
l2 
0.99 
0.78 
22.72 
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2 
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1 2  
1 .00 
0.998 
53.43 
-8.6 
1 /Y 2 
. .. - ... - .. .. . _. _____________ _______ _ 
� 
� 
-..J 
1 18 
the SSW (weighted sum of squared deviations) . The criteria for the selection of 
models is discussed in greater detail later in this chapter. The value for AIC was 
calculated as follows: 
AIC = 1'•.t · ln(SSW) + 2p 
where, 
N is the total number of observations used for regression, 
p is the number of paramet,e1s in the equation, and, 
SSW is the weighted sum of square deviations 
The best. fit was obtained using a tri-exponential equation. It is evident therefore 
that digoxin follows tri-exponential kinetics in the beagle dog. This is in agreement 
with existing pharmacokinetic studies of digoxin in humans (Kramer et al . .  1974 : 
Sumner and Russell, 1976; Balant et al. , 1980) and dogs ( Kuhlman et. al . .  1 979; 
Bruznock 1973; Morgan and Binnion 1970) . 
Similar nonlinear regression fitting was conducted on the data obtained in 
studies 4 ,  7, 8, 9 and 10. The results are summarized in table 3.6. 
Again using the F-test, AIC and SSW the tri-exponential equation was found to 
give the best fit. Regression analysis was not cond uct.ed on the serum concentration 
as a function of time data obtained from Study no. 6. due t,o a lack of sufficient 
number of data points required for such analyses. The values in the last column in 
table 3.6 are the mean and standard deviations of t.be pharmacokinetic parameters 
listed for st.udies 4 .  8 .  9, 10. The small standard deviations indicate that the . . . 
pharmacokinetic profile of digoxin in the 3 beagle dogs is quite similar and constant. 
Pharmacodynamic Modelling 
The plasma concentration vs. time data and the response vs. · time data for 
studies IA, lB, 2-4 and 6-10 are given in tables 3.7-�.16 respectively. 
TABLE 3.6 
NONLIN A NALYSES 
(St.ud ies 4 ,  7-10) 
- -- ·- ---- ... ... _._ .. _________ .. _____ _ �.. .... . . . .  ., ... .. ...... ..  , . . ·--···- ·--·· ·--� ... ... _, · ··'" . ___ ,,. ___ . - ·------· 
OOG NO. 
STUDY NO.  4 
] 
7 
DOSE (mg/kg.) O .Of> 0.02:, 
A ( ng/ m l . )  <l0.98 {f> ,1I !; )  33 .5 1 (2 .69) 
n (ng/ml.) 24 .97 (2.112 )  1 1 .20 (0.nr,) 
C ( ng/ml.) 5.02(0.4 1)  2.29(0.03) 
a (min. - J )  0.064 (0.0072) 0. 1 1 (0.005) 
f3 (min.- 1 ) 0.012(0.00049) 0.0 1 7 (0.006) 
6 
8 
0.05 
27.3X(9.7) 
:i l .fi 7 ( 5.  78) 
6:06(0.40) 
0.053(0.0094 ) 
0.018 (0.0016) 
7 
9 
0.05 
65.24 (3.09) 
l l .97( 1 .09) 
7.53(0.35) 
0.044 (0.0016) 
0.01 2(0.0005) 
6 
1 0  
0 .0!; 
3r,_1>:i (n . :i2) 
,1 1 .79(2 . :rn) 
3. 73(0. J 1 )  
0 .10(0.0 14)  
0.0 18(0._00057) 
(4,8,9,10) 
0.05 
40.88(5.49) 
3 1 .04 (2.29) 
5.37(0.23) 
0.061(0.0049) 
0.01 6(0.00068) 
1 (min . ·· 1 ) 
RSQUART!' 
CORR . 
�SW 
0.00099(0.00019) 0.00057(0.00004) 0.0012(0.000 1 6) 0.00 1 8 (0.000099) 0.00043(0.000059) 0.0011 (0.000087) 
· WT. 
A UC 
Vt (ml/kg.) 
1 .00 
0.99 
1 .62 
I i },. z 
. I 
8 1 04 .35 
549.56 
0.09 
!Um 
0. 1 1  
1 / Y 2 
498 1 .00 
53.1..90 
,. numbers in brackets are standard deviations 
0.99 
0.99 
-1 .X 
I 1 }-' 2 I . 
7:320.49 
rnn. 1 1  
AUC = area under the plasma cone .  t ime curve (ng. m i n ./ rn l . )  
S S W  = sum of wieghted square deviations 
1 .00 
cum 
O.i7 
I i  F 2 
666:L.'>6 
574 .89 
1 .00 
0.99 
l .80 
l / Y 2 
1 1351 .38 
620.65 
0.99 
0.99 
29.96 
l / Y 2 
7684. 16(2350.85) 
609.22(95 .4 1 )  
-· --· . - . ---------------------------
..... ..,.. 
TIME 
(mins.) 
-5.0 
15 
30 
45 
60 
75 
90 
120 
210 
240 
270 
... 
. . 
CONC. 
(ng. i ml) 
0.0 
53.17 
12.72 
7.85 
5.88 
4 .6 
3.78 
3.06 
1.93 
1.64 
1 .5 
- .. ·-· --· ·-· .. - . 
TABLE 3.7 
Study lA 
LVET QS2 
(± s.d.) (± s.d.) 
(msec.) (msec.) 
121.7 190 
2.89 0 
119 193 
3. 9,l 4 .83 
147.5 215 
3.59 7. 07 
143 194.5 
4 .83 . 2. 8,l 
147.5 190 
4 .25 2.36 
145 188.5 
4. 71 2.42 
131.5 183 
3. 97 5. 37 
100.5 167 
5. 99 2. 58 
125 169.5 
6. 67 1.58 
1 1 8  170 
2.58 0 
120 
RR PR S182 
(.l. s.d.) (± s.d.) (± s.d.) 
(msec.) (msec.) (msec.) 
335 78.33 170 
21. 21 7. 6,l 0 
349 85 178.5 
3.16 0 3. 37 
350 85 190 
353 86 176 
4 ,83 f!. 1 1  5.16 
346.5 80 170 
4.12  0 0 
330.5 82 166.5 
1 . 58 2.58 4.12 
32 1 75 160.5 
3.16  5.27 1 .28 
280.5 80 148.5 
1.58 0 3. 37 
306.5 80.5 153 
4. 14 1.58 4.22 
298.5 80 145 
3.37 0 0 
Plasma concentration vs. time and response vs. time data following administration 
of 0.05 mg/kg digoxin i.v. (uniformly over 5 min ) to  a anesthetized normal mongrel 
dog. TIME =: t.im� post-infusion, LVET = left ventricular ejection time, QS2 = 
duration of total electromechanid systole, RR = R-R interval: PR = P-R interval 
and 81S2 = duration between first and second heart sounds. - indicates intervals were not measured. 
TIME CONC. LVET 
(± s.d.) 
( hrs.) (ng /ml.) (msec) 
-·· ·---- --
-0.08 0 240.00 
0. 0 
0.33 33.28 320 
0. 0 
1 .33 7.65 268.57 
19.51 
1.83 5.36 21 2.5 
18.92 
3.08 3.76 212.5 
10.95 
4.92 3.30 213.33 
1 7. 92 
7.00 3. 10 231.42 
27. 94 
23.33 l .70 200 
0. 0 
30.83 2.00 224 
8. 94 
48.0 1 .20 238.18 
10.99 
54 . 75 0.91 246.67 
24.49 
72 .42 0.71 245 
9. 04 
78.5 0.49 237.1 4  
1 7. 99 
. .. --·---·· 
TABLE 3.8 
Study lB 
QS2 RR PR S 1S2 
(± s.d.) (± s.d.) (± s.d.) (± s.d. )  
(msec) (msecJ (msec ) (msec) --- -·--
888.00 1074.67 246 .15  440.00 
126. 67 129.06 15. 02 0. 0 
1 003.33 1 280 266 445.45 
91 7.,1 7 190. 69 16.,16 1 8. 09 
990 1231.11  257.78 400 
82.11 76. 88 21. 08 0. 0 
1246.67 1 480 280 443.64 
190. 01 197. 58 0. 0 21.57  
1280 1 460 268 4 1 5  
1 14 . 61 110.45 16. 86 29. 76 
] 256 1464 266 448.89 
1 79.,14 18,1 .61 18.97 1 7. 64 
1065 1285 265 400 
157.8  1 79.11 10. 0  0. 0 
1 1 55.56 1 371.11 245.45 404 
219. 02 207. 63 15. 72 8.94 
1112.73 1327.2i 240 440 
227.56 ·· · •,£,lS.16 0. 0 0. 0 
1245 
178.1 6  
1047.69 
110.62 
1034.28 
135. 74 
11 38.67 
19,I. 71 
1 40-5. i l  250 440 
114 .14 ilS.12 0. 0 
1263.68 i�.3.08 444.62 
118.56 7. '!JJ 27. 27 
l 24 1 .23 248\ 440 
122. 65 18.75 0.0 
1 354.67 253.33 424 .44 
193. 09 1 7. 99 19 . . U 
·-- ---·--· ·--- -
121 
Plasma concentrat.ion vs. time and response vs. time data following administration 
of 0.05 mg/kg digoxin i.v. (uniformly over 5 min) to a normal female mongrel dog. 
TIME= time post-infusion. LVET = left ventricular ejection time, QS2 = duration 
of total electromechanicl systole, RR = R-R interval. PR = P-R interval and S 1S2 
= duration between first and second heart sounds. 
1 22 
TABLE 3.9 
Study 2 
TIME CONC. LVET RR PR QS2 S 1S2 
(z s.d . )  (±  s.d.) (± s.d . )  (=  s.d.) (± s.d.) 
(hrs.) (ng. 1 ml )  (msec .)  (msec.) (msec.) (msec.)i (msec.) -- ---
-0.08 0 1 85 .60 808.88 13:2.50 380.00 320.91 
1. 77 16.16 2. 64 0 9. 02 
0.33 35.53 230.9 882.33 129.58 401.82 330 
9. 1 7  18.12 9.5 6.15 0 
0.63 19.25 195.71 750.77 1 23.00 386 300 
15.12 18.12 3. 5 6.15 0 
0.92 55.22 220.5 873.75 12: 1  398. 1 2  31 7.22 
9.69 80.52 9. 94 10. 39 6.18 
1 .50 7.58 183.57 1010.56 1 45 444.5 376.5 
12.,1.9 59.76 4 .08 5.99 9. 97 
3.83 4 .54 254 1470.6 137.22 455.71  371 .36 
2.11 952. 85 9.69 9. 92 5. 04 
7 .50 3.4 7  292 1 34 1.87 135.5 476.5 381.67 
9,4 9  305.55 9. 69 11.92 6.12 
24.83 1.68 1 50 465 123.5 325 290 
0 0 4. 74 61.97 6. 92 
3 1.83 1.65 1 39.28 523.75 1 1 3.33 314.54 213.63 
1 0. 1 7  29. 61 5. ,'J6 6.50 0 
48.00 1 . 1 1  160 634.28 1 32 .08 339. 17 210 
0 79. 79 8.98 9. 79 0 
55.58 0.t�l  151  500.5 123.5 293 203.5' 
e.11 15.54 4 .12 .1 6.96 7.,1. 7 
72.83 0.69 141 .42 537.73 131.5 319.5 220.5 
14. 64 12.52 !J. 97 9. 6.9 1 .58 
Plasma concentration vs. time and response vs. time data following administration 
of 0.05 mg/kg digoxin i.v .  (uniformly over 5 min) to a normal beagle dog. T IME= 
time post-infusion. LVET = left ventricular ejection time, QS2 = duration of to-
ta] electromechanic1 systole, RR = R-R interval : PR = P-R interval and S 1S2 = 
duration between first �nd second heart sounds. 
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TABLE 3.10 
Study 3 
TIME CONC. LVET RR PR Q82 8182 
(± s.d.) (± s.d.) (± s .d.) (± s.d.) (±  s.d.) 
(hrs.) (ng./ml) (msec.) (msec.) (msec.) (msec.) (msec.) 
-0.08 0.0 135.00 440.40 140.42 347.92 191 .36 
7.07 9,4 LU 6. 2 12. 6 7  
00.25 31.50 189.50 551 .00 151 .50 223.75 220.50 
1.58 27.96 5.R 6.94 9.69 
00.45 16.83 200.00 488.33 143.88 21 1 .43 
0.0 19.69 4.1 7 0. 78 
00.92 * � �  144.17  502.00 150.00 220.00 208.57 
4.91 13. 16  4. 11 0 9. 78 
1.25 5.58 140.00 468.00 140.00 338.00 192.00 
0 9.48 0 11.95 8.88 
1 .75 3.24 132.27 470.00 144.09 341 . 1 1  198.18 
2.61 9. 87 5. 84 8.58 4.04 
3.58 1 .62 140.00 461 . 1 1 140.00 214.44 230.00 
5. 0 5.46 0 5.27 4.69 
7.75 2.48 161 .67 550.00 135.00 249.00 222.78 
2. 5 0 2.96 9.07 3. 69 
12.00 2.01 207.27 625.50 149.50 400.50 243.00 
6.07 9.69 1.58 12.12 4 . 89 
16.00 1 .99 205.45 642.00 150.00 297.00 255.55 
6.87 4.22 0 4.89 5.27 
24.33 1 .55 1 12.72 371.36 157 .73 180.45 163.57 
5.18 9.29 9 . .  u 1.51 9. 78 
36.00 1 . 1 2  130.00 472.00 149.50 204.00 1 78.50 
0 15.91 5. 85 5. 91 8.51 
48.00 0.61 133.00 461 .67 140.55 214.00 196.67 
2.58 8. 66 1 . 67 2.24 12.25 
60.25 0.49 133.18 461 .82 143.64 204.09 183.63 
9. 97 11.4 7 6.96 6.64 9. 93 
72.00 ().37 132.78 500.50 1 -51 .50 212.00 181.50 
9.69 9,4.52 2.,12 4.22 4 . 14 
Plasma concentration vs. time and response vs. "ITine data following admm1strat1on 
of 0.05 mg/kg digoxin i.v. (uniformly over 5 min ) to a normal beagle dog. TIME 
= 
time post-infusion� LVET = left ventricu lar ejection time, QS2 = duration of 
total electromechanicl systole. RR = R-R interval. PR = P-R interval and S1S2 = 
duration between first and second heart sounds. ( u *)  indicates not. monitored and 
(-) indicates no1. measureable due to ill-defined landmarks on recording. 
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TABLE 3.11 Study 4 
TIME CONC. LVET RR PR QS2 S 1 S2 
(± s.d.) (± s .d . )  (± s.d . )  (± s.d . . )  (± s.d.) 
(mins.) (ng.iml) (msec.) (msec.) (msec. )  (msec.) (msec.) 
-45 0.0 1 87.50 507.78 143.50 245.00 201.40 
4 .25 6.2 4 . 7 7.1 10. 9  
-40 0.0 1 88 593.9 133 257.5 225 
2.6 18.9 5.4 9.9 5.5 
-10 0.0 209 638.6 145.9 290 281 
5.2 91.9 4 .9  8.2 6.5 
10 58.01 233 810 156.5 312.8 ·293 
4 .8  40.9  10.9  9.9 6. 7 
20 40.56 255 989.4 152 331.2 293.3 
5.9 290.2 4 .2 6.9 5. 8 
30 31.76 257.5 1067.7 159.2 320 291 .4 
12. 7 189. 7 5. 6 5.9 4 .5 
40 26.64 249.3 895 1 58.1 319.4 291.4 
6.1 118.1 5. 9 6.8 16. 0  
50 21 .36 251.5 1 009.4 155 336 301 .7 
8.2 1 78. 7 9.5 8.9 7.5 
60 19.76 266 1060.4 1 57.5 342.1  301.4 
5.2 '25S.6 6. 3 7. 6 9.0 
70 16.08 244.4 892.8 1 52.8 338.1 296.2 
12.6  89. 0 4.4 10.0  12. 7 
80 15.04 250.7 775.6 1 50 303 .3 278.6 
5. 9 42. 7 0.0 8. 7 8. 7 
90 12.24 245.7 791.5 1 50.6 308.8 279 
5.9 42. 7 1 .8 4 .8 10.2 
100 12. 1 6  277.2 1110 1 60.5 346 321.4 
8.9 91.2  6.0 19.,I 97. 6  
110 11 . 12  281.1 1 153.8 157.2 358.7 363.3 
11.4 954 .9  5. 0 15.5 15.0 
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TABLE 3.11 (contd.) 
TIME CONC. LVET RR PR QS2 S 1 S2 
(± s.d.) (± s .d . )  (± s .d. )  (± s.d.) (± s.d.) 
(mins.) (ng./ml) (msec. )  (msec .) (msec.) (msec.) (msec.) 
120 1 1 .36 236.7 728. 1 147.8 287.5 
.4 - 9 15.1  7.9 11 .6 
130 10.16 272.1 832 145.9 342.2 308.6 
4 . 9  41.0 44 .2 6. 7 19.4 
150 7.95 231.5 680.5 145 3 15.6 293.5 
6. 7 25. 7 5.0 10.4 8.8 
1 70 8.01 250.5 803.1 150 332.7 305 
4 .4 97.8 6. 7 2.6 7.1 
190 7.22 237.5 853.6 143.5 333.5 298.5 
4 .2  162.4 9. 7 10.0  15. 9  
210 6.44 242.7 743.6 143 324.4 301.1 
6.5 62.4 6. 3 9.2 6. 0 
230 5.82 234 .5 685 1 53 330 286 
6.8 18,4 12. 9  4.1 5. 7 
250 5.51  233 633 143 309 280 
4.2  6.9 8. 9 7.4 ,f 7 
270 5 . 1 7 238 675.5 160.5 320 280 
7. 9 4.4 12.8  3.3 9.2 
290 4.69 240 688 150.5 328.5 291 
0 6.3 2.8 2.4 9. 7 
310 4.48 238.5 627.5 150 307.5 279 
2.4 2.6 0 9.5 5.2 
330 4 . 18  232 633.5 148.5 310.5 280 
4 .2  5.8 6.2 1 .6  9.4 
350 3.62 231 640 148 310 313.9 
9.2 0 2. 7 14 .6  9.1 
390 3.43 232.5 704 .5 1 50 310 282.5 
8. 9 6.0 4.1  5.8 4 .2 
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TABLE 3.11 (contd.) 
TIME CONC. LVET RR PR QS2 S1S2 
(± s.d.) (± s.d.) (± s.d.) (± s.d.) (± s.d.) 
(mins.) (ng./ml) (msec.) (msec.) (msec.) (msec.) (msec.) 
410 3.33 240 730.5 152 324.5 281.5 
0 1.6 6.9 7.6 2.4 
450 3.22 244 784.5 158.5 330 314 
5. 7 19.8 5.8 2.9 5. 7 
470 3.28 250 767.5 154.5 342.5 308.5 
0 2.6 2 .. 8 5.9 5.8 
510 3.1 4  247.5 729 153.5 336.1 301 
4.2 5.2 4. 1  4.8 9.2 
530 3.1 7 249 697.1 150.6 325 295 
2.1 4.9 5 .. 6 5.0 5.8 
550 3.10 238 656.9 1 54.4 313.5 288 
4.8 10.0 6.8 6.2 6.9 
570 2.92 240.5 685 1 50 320 291 .5 
5.0 26.2 1.1 2.4 4. 1 
590 2.89 240 713.6 1 47.1 328 287 
4.1 7.5 9.9 9.5 4.9 
610 2.77 248 689.4 1 49.5 328.5 292 
6. 7 9.9 2.8 2.4 4.2 
P lasma concentration vs. time and response vs. time data following administration 
of 0.05 mg/kg digoxin i.v. (uniformly over 5 min) to a normal beagle dog. TIME 
= time post-infusion . LVET = left ventricuJar ejection time, QS2 = duration of 
total electromechanicl systole, RR = R-R interval, PR = P-R interval and 8 182 = 
duration between first and second heart sounds. 
(-) indicates that interval could not be measured due to ill-defined landmarks on 
recording. 
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TABLE 3.12 
Study6 
TIME CONC. LVET RR PR QS2 s1s2 
(± s.d.) (± s.d.) (± s.d. )  (± s.d.) (± s.d.) 
(mins.) (ng./ml) (msec.) (msec.) (msec.) (msec. )  (msec. )  
-55.00 0.0 187.00 558.30 140.56 266.25 250 
2. 73 7.07 9. 91 5.18 8.66 
-45.00 0.0 176.11 569.00 141.50 275.50 243 
6.51 14. 9  4 .12 4 .97 9.5 
-35.00 0.0 190.00 606.5 138.5 247.5 250 
7.07 28.48 5.9 2. 69 0 
-25 0.0 175 570.83 138·.o 248 234 
4 .08 90.59 ,I.BS 4 .22 9. 94 
-15 0.0 178 542:27 134.17 250 234.58 
2.58 14.21 4 .11  0 2.57 
0 *** 174.44 574.38 136.11  257.14 242.22 
1.67 21. 78 4 .86 9. 06 4.41 
10 27.6 934.64 151.5 287.86 247 
929. 95 5.8 5. 67 18.14 
20 *** 2) 3.75 1068.18 145.56 298.12 274 
8.54 427.27 4 .64 5.90 15.16  
30 11.6 195 1050.5 153 298.57 274 
7. 07 905.48 9.19 6.27 5. 98 
40 7.6 212.5 1036.07 151 .07 297.14 274.44 
6.12 920. 75 8. 81 8.59 11 . 90 
50 5.76 195 844 1418 295.56 275 
1 7. 61 186.16 9.5 4 . 64 5. 98 
70 *** 223.75 600.45 138.18 276.25 229.44 
4 . 79 19. 09 3.97 9.54 6.82 
85 5.44 737.78 144 281.43 228.33 
69.69 8.49 9. 78 7. 07 
100 3.8 200 691.67 145.56 281.25 24 1.67 
0.0 1 8.97 9.91 6. 94 9.01 
1 28 
TABLE 3.12 (contd.) 
TIME CONC. LVET RR PR QS2 S1S2 
(± s.d.) (± s.d.) (± s.d.) (± s.d.) (± s.d.) 
(mins.) (ng./ml) (msec.) (msec.) (msec.) (msec.) (msec.) 
1 15 *** 188.89 588.12 141.88 262.14 228.89 
7.,1.1 2.59 2.59 5. 67 7. 82 
130 *** 187.5 661.5 139.44 276.88 237.78 
,1.1.2,1. 96.52 7.68 7.0,I 8. 99 
145 ***  209 247.86 
2.11 11.19 
Plasma concentration vs. time and response vs. time data following administration 
of 0.025 mg/kg digoxin i.v. (unifo;rmly over 5 min) to a normal beagle dog. TIME 
= time post-infusion, LVET = left ventricular ejection time, QS2 = duration of 
total electromechanicl systole, RR = R-R interval, PR = P-R interval and S1S2 = 
duration between first and second heart sounds. 
(***) indicates serum concentrations wer� not monitored. 
(-) indicates intervals could not be measured due to ill-defined peaks on recording. 
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TABLE 3.13 
Study 7 
TIME CONC. RR 
(±  s.d.) 
(mins.) (ng./ml) (msec.) 
-54 0.0 384.28 
1.82 
-45 0.0 403.57 
6.99 
-35 0.0 393.33 
4.44 
-25 0.0 381.15 
9. 0 
-20 0.0 396.54 
9.15 
-5 0.0 392.86 
4 .69 
8 24.72 476.92 
7.29 
15 18.08 480.77 
10.58 
25 11.84 528.33 
14.2 
35 8.48 503.21 
7.5 
45 7.86 545 
19.84 
55 6.73 586.43 
26. 94 
65 5.42 617.14 
92.45 
75 5.63 603.85 
1 6. 6  
1 30 
TABLE 3.13 (contd.) 
TIME CONC. RR 
(± s.d.) 
(mins.) (ng./ml) (msec.) 
85 4.88 660 
51. 96 
95 4 .52 662.31 
97.28 
1 05 4 .37 683.75 
98 .. U 
115 3.66 718.46 
98. 92 
125 3.42 684.62 
40. 8 
140 3 .26 673.46 
15.99 
155 2.98 607.31 
29. 97 
170 2.58 593.85 
96.29 
185 2.53 525 
99.58 
200 2.26 505 
11.,48 
215 2.46 508.08 
10.92 
230 2.08 467.86 
8. 92 
250 2.27 432.5 
12. 52 
270 2.11 444 .5 
7. 76 
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TABLE 3.13 (contd.) 
TIME CONC. RR 
(± s.d.) 
(mins.) (ng./ml) (msec.) 
290 1.98 421.15 
2.19  
310 * * *  437.08 
,1 .5  
320 1.88 423.75 
10.9  
330 * * *  418.08 
5. 6 
340 ***  416.92 
9.25 
350 '1.83 413.46 
10.68 
360 ***  424.23 
9. 97 
370 ***  412.69 
5. 99 
380 1.78 410 
11.18 
395 ***  415.77 
1,1 . 98 
410 1.91 386.53 
10.28 
440 1.97 390 
8.55 
460 ***  396.92 
5. 22 
470 1.84 381.15 
15.9 
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TABLE 3.13 (contd.) 
TIME CONC. RR 
(± s.d.) 
(mins.) (ng./ml) (msec.) 
485 * * *  378.85 
15.9 
500 1.75 377.86 
12.96 
515 ***  379.23 
14.84 
530 1.63 396.67 
4.88 
545 * *"' 393.93 
4.46 
560 1.66 386.92 
2.59 
575 *** 383.21 
4.64 
590 1.59 372.5 
s.46 
605 *** 366.78 
9. 1 7  
620 ***  356.67 
9.26 
637 * * *  350 
4.08 
650 *** 340.77 
2. 77 
690 ***  320 
0 
Plasma concentration vs. time and response vs. time data following administration 
of 0.025 mg/kg digoxin i.v. (uniformly over 5 min) to a normal beagle dog. TIME 
= time post-infusion, RR = R-R interval. 
(***) indicates serum concentrations were not monitored. 
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TABLE 3.14 
Study 8 
TIME CONC. RR 
(± s.d.) 
(mins. )  (ng./ml) (msec.) 
- 1 05 0.0 463.82 
6.5 
-90 0.0 527.06 
91. 82 
-80 0.0 578 
,1 7. 08 
-70 0.0 572.69 
65.53 
-60 0.0 615.29 
54.4 1 
-45 0.0 654.21 
61.22 
-35 0.0 679.12 
80.45 
-20 0.0 728.57 
,19. 08 
-10 0.0 766.78 
197. 04 
10 53.5 827.31 
76.04 
20 34.8 907.67 
119.15 
30 27.8 910 
119.19 
40 25.3 944.06 
8,J.25 
1 34 
TABLE 3.14 (contd.)  
TIME CONC. RR 
(± s.d.) 
(mins.) (ng./ml) (msec.) 
50 19.4 610.48 
29. 91 
60 20.49 742 
6,1 . 28 
70 18 . 1  919.23 
1 71.22 
80 12.9 703.75 
1 7.27 
90 1 1 .3 91 2.33 
59.,19 
100 10.6 909.06 
185. 4 7  
1 10 9.8 610.94 
20. 89 
125 9 . 15  524 .83 
94 .11 
140 7.3 620.29 
12. 91 
1 55 5.8 668.66 
10. 99 
1 70 7.33 669.06 
28.4 7 
185 6 .85 639.05 
51 . 95 
205 5.71 704.06 
41.01 
230 5.37 668.33 
51 . 01 
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TABLE 3.14 (contd.) 
TIME CONC. RR 
(± s.d.) 
(mins. )  (ng./ml) (msec.) 
250 4 .94 715.28 
64.89 
260 ***  623.53 
8.49  
270 4 .5 568.95 
95.18 
280 * * *  606.47 
27. 08 
290 4 .55 623.12 
.,12. 98 
300 * * *  610.28 
.,16.51 
310 4.32 650.36 
15.12 
330 4 .05 602.89 
25.29 
340 ***  537.14 
24.0  
350 3.8 559.44 
96. 76 
360 * **  577.63 
5.10 
370 3.78 520.87 
11.93 
405 4 .i8 569.38 
7.99 
420 ***  547.67 
29.82 
1 36 
TABLE 3.14 (contd.) 
T IME CONC. RR 
(± s.d.) 
(mins.) (ng. /ml) (msec.) 
435 3.29 589.33 
4.21 
450 **"' 601.92 
9.02 
465 3.27 585.62 
s,1:18 
485 *** 592.14 
14. 64 
495 3.33 634 .33 
19. 01 
510 *** 532.25 
18.24 
525 3.21 542.5 
28. 6 
540 *** 407.04 
6. 69 
555 3 .10 493.04 
26.45 
570 ** * 562.81 
40.21 
585 3 .11  601.67 
50.15 
600 *** 4 10.26 
8.24 
615 2.8 532.81 
92. 66 
630 *** 346.54 
5. 96 
Plasma concentration vs. time and response vs. time data following administration 
of 0.05 mg/kg digoxin i.v. (uniformly over 5 min) to a normal beagle dog. TIME 
= time post-infusion: RR = R-R interval . 
( * **) indicates serum concentrations were not monitored. 
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TABLE 3.15 
Study 9 
TIME CONC. RR (± s.d.) 
(mins.) (ng./ml) (msec.) 
-142 0.0 575 
4 . 08 
-130 0.0 540.5 
16.41 
-120 0.0 629.5 
19. 6,I 
-110 0.0 696 
95. 5 
-100 0.0 678 
21. 88 
-90 0.0 681.S 
24.6  
-80 0.0 615.S 
49. 81 
-70 0.0 664 
96.12 
-60 0.0 620.S 
28. 72 
-50 0.0 708 
52.4 
-40 0.0 637 
28.5 
-30 0.0 676 
40.4  
-20 0.0 694 
97.18 
-10 0.0 738.5 
76.05 
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TABLE 3.15 (contd.) 
TIME C ONC. RR 
(± s .d.) 
(mins.) (ng./ml) (msec.) 
10 61.6 704.5 
9.56 
20 42.99 668 
11.89 
30 31.98 727 
20.16  
40 25.63 730 
1 6.99 
50 21.00 756 
26.12 
60 16.31 839 
89. 96 
70 15.25 796 
4 6.96 
80 12.89 826 
29.14 
90 1 1 .62 894 
195.99 
100 10.10 81 1 .5 
39. 94 
1 10 9.56 903.5 
90. 89 
120 9.03 902.5 
70. 91 
1 35 8.70 824 .5 
28.52 
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TABLE 3.15 (contd.) 
TIME CONC. RR 
(± s.d.) 
(mins.) (ng./ml) (msec.) 
150 7.83 808.89 
1 7.,16 
165 7.22 996.11 
48.84 
180 6.6 1193 
181.1 7  
195 6.36 913.5 
66.25 
210 5.69 1 010.5 
91. 66 
22-5 5.62 956.5 
,1 7. 9  
240 5.46 931 
37,4 
260 5.48 1035.5 
165. 84 
270 ***  944.44 
216.12 
280 4.89 918 
32. 93 
290 ***  861 .5 
23.58 
300 4.54 827.5 
32. 77 
310 * "' *  1015.5 
114.4 1 
320 4.2 818 
32.51 
140 
TABLE 3.15 (contd.) 
TIME CONC. RR 
(± s.d.) 
(mins.) (ng. /ml) (msec.) 
330 ** *  926.5 
56.97 
340 4 .47  921 
196.8 
350 ***  972 
248.19 
360 4 .05 881 .5 
16.84 
375 ***  822.5 
12. 96 
390 3 .8 664 .5 
19.89 
405 ***  803.5 
1 7.96 
420 3.58 784 .5 
22. 78 
435 ***  750 
75.46 
450 3.54 947 
4 1 .. u 
465 ** �· 788 .5 
12.92 
480 3.1 5 870.5 
69. 79 
515 *** 652 
5. 97 
510 2.84 646 
12. 87 
TIME 
{mins.) 
525 
540 
555 
570 
585 
600 
TABLE 3.15 (contd.) 
CONC. 
(ng./ml) 
***  
2.77 
* * *  
2.64 
*** 
2.62 
RR 
(± s.d.) 
(msec.) 
830 
109.14 
625.5 
14 . 62 
721.67 
30.21 
595.5 
22. 78 
563 
7. 15 
495 
4 . 71 
141 
Plasma concentration vs. time and response vs. time data following administration 
of 0.05 mg/kg digoxin i.v. {uniformly over 5 min) to a normal beagle dog. TIME 
= time post-infusion, RR = R-R interval. 
( * ** )  indicates serum concentrations were not monitored. 
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TABLE 3.16 
Study 10 
TIME CONC. RR 
(± s.d.) 
(mills. )  (ng./ml) (msec.) 
-150 0.0 343.5 
8.89 
-140 0.0 346 
5.16 
-130 0.0 365.5 
4 .97 
- 120 0.0 359.5 
9. 69 
-110 0.0 364.5 
5.5 
- 100 0.0 344 
1. 14 
-90 0.0 335 
5. 77 
-80 0.0 352 
6. 92 
-70 0.0 375 
7. 07 
-60 0.0 386 
6. 99 
-50 0.0 375.5 
4 . 98 
-40 0.0 375.5 
1.24 
-30 0.0 351 .5 
5. 9 
-20 0.0 361 .5 
6. 69 
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TABLE 3.16 (contd.) 
TIME CONC. RR 
(± s.d.) 
(mins.) (ng./ml) (msec.) 
10 57.3 392 
6. 75 
20 35.34 427 
4 .22 
30 28.62 373.5 
5. 78 
40 23.60 365.5 
7. 98 
50 22.44 380 
9. 99 
60 20.26 359 
5.16  
70 15.8 391 .5 
4.12 
80 13.4 445.5 
12.8  
90 1 1.53 425.5 
4 . 97 
100 10.97 443.5 
6. 69 
1 10 10.04 496.5 
16.17  
120 9.21 441 .5 
9. 31 
130 8.02 499 
6.58 
1 44 
TABLE 3.16 (contd.) 
TIME CONC. RR (± s.d.) 
(mins.) (ng./ml) (msec.) 
1 50 6.7 494.5 
7. 98 
165 5.7 497.5 
20 .. u 
180 5 .00 474.5 
14. 99 
195 4 .5 4 73.5 
1 7.99 
210  4.25 493.5 
10. 29 
225 3.88 466.5 
9. 79 
240 3.86 535 .5 
19.4 9 
260 4.03 504.5 
4. 98 
270 * * *  479 
6. 58 
280 3.8 436 
5. 68 
290 ***  439.5 
9. 69 
300 3.8 434 
10.49 
310 * * *  468 
4.89 
320 3 .64 436.5 
9.14 
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TABLE 3.16 (contd.) 
TIME CONC. RR (± s.d.) 
(mins.) (ng./ml) (msec.) 
330 ***  416.5 
1. 09 
340 3.59 437.5 
1.1 1  
350 * * �- 443 
5.81 
360 3.3 387 
20.44 
375 * * �- 433 
,I .BS 
390 3.25 433 
16. 36 
410 ***  382.5 
5. 89 
420 3.22 430.5 
3. 69 
435 * * *  415.45 
13.12 
450 2 .92 451.5 
10. 55 
465 * * *  396.5 
6.25 
480 2.95 408.5 
1. 83 
495 * * >I- 365 
6. 61 
510 3.04 378.18 
9.56 
TIME 
(mins.) 
525 
540 
555 
570 
585 
600 
TABLE 3.16 (contd.) 
CONC. 
(ng./ml) 
3.04 
***  
2.80 
***  
2.84 
RR 
(± s.d.) 
(msec.) 
419.5 
8.96 
374 
9. 97 
358.5 
10.55 
372.5 
11.12 
340.5 
10.s9 
368 
10. 85 
146 
Plasma concentration vs. time and response vs. time data following administration 
of 0.05 mg/kg digoxin i .v. (uniformly over 5 min) to a normal beagle dog. TIME 
= time post-infusion, RR = R-R interval. 
(***)  indicates serum concentrations were not monitored. 
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LVET, QS2 ,  P-R intE'rval and the R-R intE'rval vs. time and serum concen­
tration of digoxin were plotted . ThE' data appeared to be extremely noisy and no 
readily discernible relationship between the serum ]evels of digoxin and the response 
was apparent. The inherent noise in the data made simultaneous pharmacokinetic­
pharmacodynamk analysis impractical. However a linear direct relationship be­
tween LVET. QS2 and P-R interval and the HR was observed (fig. 9.1, 9.2 and 
9.9) .  
Results of the regression analysis are as fo] ]ows: 
LVET = - 1 .19HR + 312.66 corr. = 0.76 
QS2 = -1.49RR + 442.46 corr. =- 0.66 
PR = -0.13HR + 155.21 corr. = 0.26 
Although similar relationships have been observed betweE'n Q S2 , LVET, PR interval 
and the HR in humans by Weissler et al. , ( 1968 ) ,  similar relationships have not 
previously been reported in the l iterature for dogs. This observed relationship 
c.ould bE' m::efu l to investigators who intend to use the dog as a model for digoxin. It. 
is observed (fig. :l . 1 )  that Dog no.5 (Study no. l B) does not fol low :�he same linear 
relationship as ex.pressed by the data from other s1udies. Hence the data obtained 
from study no. lB was not incorporated in the regression analyses of LVET, QS2 , 
and PR interval with HR. Possible reasons for dog no. 5 not expressing the same 
linear relationship may be one or more of the following: 
1) Dog no. 5 was not. anesthetized, whereas all other studies were conducted with 
the dogs under pentobarbital anesthesia. 
2) Dog no. 5 had a low basal heart rate: and hence did not show a large change 
in heart rate as compared to the other dogs . 
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3) Dog no. 5 was a mongrel, whereas the dogs used in all other pharmacodynamic 
studies were beagles. 
Since there was a linear relationship between the measured pharmacodynamic 
responses viz. , LVET QS2 and PR-interval and heart rate, it was decided to identify 
pharma.codynamic models for heart rate so that these models may be incorporated 
in models for LVET, QS2 and other relevant pharmacodynamic responses in future 
studies. This was one of the primary reasons for conducting studies 4-10, where the 
serum concentrations of digoxin and HR were primarily measured. 
Pharmacodynamic modelling of heart rate 
The models investigated were: 
1) The linear linking model. 
2) The physiologic-pharmacokinetic model. 
3) The effect compartment model. 
The linear linking model: 
Relationships were sought between the serum concentrations ( concentrations 
in the central compartment) and response. No readily discernible relationships were 
evident. Peak bradycardic effects of digoxin were not observed until 60-120 mins. 
after the administration of the dose of digoxin and an anticlockwise hysteresis loop 
was observed on plotting the response and the serum concentrations. This implied 
that the biophase may be in one of the more slow]y equilibrating pharmacokinetic 
compartments. It was therefore decided to simulate digoxin concentrations in the 
pharmacokinetic shallow and deep compartments and to correlate these levels to 
the observed response. Since, it was established that digoxin obeys tri-exponential 
kinetics in the dog, the following three compartment versions of the following phar­
m�cokinetic models were investigated: 
a) The mammiillary model .  
b) The first pass model. 
c) The catenary model. 
Schematic representations of the above models are given in fig. 9 . ./. 
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The equations for the mammillary model were obtained from the literature 
(Gibaldi and Perrier, 1982) and are as follows: 
+ D(k21 - ,) (ka 1  - -y) e---rt (a - ,) (/3 - ,) 
. . .  (3.3) 
X -Dk1 2 (a - Ea) -at Dk1 2 (/3 - Ea) -f3t -Dk1 2 (, - Ea) ---rt 2 = (a _ f3) (o _ ,) e + (a _ /3) (,0 _ -y) e + (/3 _ ,) (a _ ,) e . .. (3.4) 
where, 
The equations for the first pass model were obtained from from the literature 
(Nagashima et al. ,1968) and are as follows: 
X v [  (E2 - a) (Ea -- (t) - att . (E2 - f3) (Ea - /3) -f3t 1 = (B  - a) ('-y - a) e � (a - fi) h - /3) e 
..... (E2 - ,) (Ea - -y) e---rt] . ( a - 'Y ) ((3 - , ) 
. . .  (3.6) 
D at  t=O 
Ir 
- k12 1 
k,':l -
2 k31 
3 
"'21 
l
k10 
3 compartment mam1 l l ary model . 
2 
' 
l 
D t t 0 l a 
= 
k21 r 
kjl 3 
k12 k13 
k20 3 compartment •ti rs.t pass "  open model . 
D at tc;Q 
2 
k12 ------1 k23 
k10 3 compar'bnent catenary model . 
FIG . 3 .4 Schematic representations of 3 compartment mode l s 
i"n_vesttgated . 
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X2 = k12D [ (Ea - a) e-c>tt + (Ea - /3) e-Pt + (Ea - '"Y) e-,..,t] (/3 - a) b - a) (a - /3) b - /J) (a - ')') (/3 - '"Y) 
. . . (3.7} 
X k D [ . (E2 - a) -at + (E2 - /3) e-Pt + (E2 - '"Y) -,..,t] a = 13 e e (/3 - a) b - a) (a - /3) b - /3) (a - ')') (/3 - "f) 
. . .  (3.8} 
where, 
Ea = ka1 
Equations for the 3-compartment catenary model could not be found in the 
Hterature and were derived. The derived equations are as follows: 
X Aa2 - Ba + C -at A/32 - B/3 + C _ Rt A"/2 - B"I + C _,.,t 1 = (a - "(} (a: - /3) e - (a - /3) (/3 - "t) e ,., + (a - ')') (/3 - --y) e ' . . .  (3.9} 
X _ k D [ ( a - Ea) -Ott + (/3 - Ea) -Pt + b - Ea) ] 2 - - 12 e e b - a) (a - /3) (/3 - --y) (a - P) (/3 - --y) (, - a)e-,..,t 
[ e-at e..-Pt . e-,..,t ] 
X3 = -k12k2aD _b __ a_)_( a---13-) + -(13-_-"I_)_( a---/3-) + -(/3 __  "1_)_(, __ a_) 
where, 
Ea = ka2 
. . .  (3 .10) 
. . . (3. 1 1 )  
A detailed derivation of the above �quations can be found in appendix  A.  
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a) The 9-compartment mammillary model 
The micro rate constants for the 3-compartment mammillary model were ob­
tained from the serum concentration time profile and using equations 3.3, 3.4 and 3.5 
The amounts of digoxin in the shaUow and deep compartments were simulated using 
the equations described before and parameters obtained from the tri-exponential fit 
of the data (fig. 9.5) .  
The simulations were confirmed by simulations using SPICE2. A detailed de­
scription of simulation methods using SPICE2 is given in a later part of the chapter. 
Results of linking the central, shallow and deep compartments for Study no.4 are 
given in figs. 9. 6, 9. 7 and 9.8 respectively. 
No apparent relationship is evident between the response and the simulated 
amounts of digoxm in the central and the deep compartment. However, there was a 
linear relationship (Corr. = 0.80) between the % change in heart rate and simulated 
concentrations of digoxin in the shallow compartment (fig. 9.9) .  
This implies that the biophase for the change in heart rate lies in the shal­
low pharmacokinetic compartment for the 3-compartment mammillary model for 
digoxin. 
b} The 9-compartment "first pass" model. 
The amounts of digoxin in the shallow and deep compartments were simulated 
usi�g the equations 3.6, 3.7 and 3 .8  (fig. 9.10) .  
The simulations were confirmed using SPICE2. Results of lin_king the central, 
shallow and deep compartments for Study no.4 are given in figs, 9.11, 9.12, and 
9.19 respectively. 
No apparent relationship is evident between the response and the simulated 
amounts of digoxin in the central and the p.eep compartments. However, a linear 
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relationship (Corr. = 0.80) is observed between the % change in heart rate and 
simulated concentrations of digoxin in the shallow compartment (fig. 9.1.J) . 
This again implies that the biophase for effecting the change in heart rate lies 
in the pharmacokinetic shallow compartment for the 3-compartment "first pass" 
model for digoxin. 
c) The 9-compartment catenary model. 
The amounts of digoxin in the shallow and deep compartments were simulated 
using equations 3 .9, 3.10 and 3.11 (fig. 9.15) .  
The simulations were confirmed using SPIC�2. Results of linking the central, 
shallow and deep compartments for Study no.4 are given in figs. 9.16, 9. 1 7, and 
9.18  respectively. 
No apparent relationship is ,evident between the response and the simulated 
amounts of digoxin in the central and the deep compartments. Again a linear re­
lationship was observed between the % change in heart rate and simulated concen­
trations of digoxin in the shallow compartment (Corr. = 0.80) . This again implies 
that the biophase for effecting the change in heart. rate lies in the pharmacokinetic 
shallow compartment for the 3-compartment catenary model for digoxin. 
Similar analyses were done on the data obtained using studies 7, 9 and 10. The 
results indicate that the biophase for the change in heaJ't rate does not .necessarily 
lie in the shallow pharmacokinetic compartment. This is evident from figs. 9.19, 
9.20, 9.21 where the response and the simulated amounts of digoxin in the shallow 
pharmacokinetic compartments for studies 7, 9 and 10 are plotted. Very little 
correlation is observed. 
It also appears that the response does not necessarily correlate with the simu­
lated levels in the shallow compartment for the same dog. A case in point is Dog 
no. I .  Study no. 4 and study no. 7 were conducted in this same dog. The % change 
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in heart rate correlated with the simulated levels of digoxin in the shallow compart­
ment in study no. 4 (fig. 3.9) . However, no such relationship was observed in study 
no.7 (fig. 3.22) . 
Similarly simulated concentrations of digoxin in the shallow and deep com­
partments for studies 9 and 10 did not correlate with the observed change in heart 
rate. The results also indicate that the linear linking model may not be an ade­
quate pharmacokinetic-pharmacodynamic model. A possible reason may be that 
the biophase for t�e bra�ycardic effect of digoxin may not be identical to any of the 
observed pharmacokinetic compartments. The amount of digoxin at the biophase 
may be insignificant- as far as mass balance considerations. Hence this amount of 
drug would not be expected to contribute to the observed pharmacokinetic profile 
of digoxin although it would contribute to the pharmacodynamic response being 
monitored. Investigation of other models is called for. 
The models proposea for investigation were: 
1) The linear model. 
2) The effect compartment model. 
3) The physiologic pharmacokinetic model with a linear linking model. 
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The Linear Model 
A number of studies have us,ed a linear pharmacodynamic model to simultane­
ously describe drug pharmacokinetics and pharmacodynamics. the model was pro­
posed by Kelman and Whiting (1980) to model digoxin pharmacodynamics. They 
observed that digoxin kinetics was best explained by a tri-exponential equation. 
Therefore the model used was 
where, 
R = a0 + b · XC + c · XS +  d · XD 
R = response 
XC = amount of digoxin in the central compartment 
XS = amount of digoxin in the shallow compartment 
XD = amount of digoxin in the deep compartment 
and, a0, b and d are constants. 
. . .  (3.12) 
The amounts XC, XS and XD are simulated amounts in the respective pharma­
cokinetic compartments. Kelman and Whiting (1980) contended that such a model 
might be appropriate since the biophase did not necessarily have to be situated in 
a single pharmacokinetic compartment. 
This model was initially investigated using the RSQUARE procedure (SAS 
User's Guide, 1982) to investigate the effect of various combinations of the terms in 
1 77 
eqn. 3.12,  on the resulting R-square values obtained. The results of the RSQUARE 
procedure are given in Tables 3 .17 and 3.18 
The results indicate that for all studies the best R-square value is given by the 
use of all three terms .in the equation (XC, XS, XD) . It was decided to investigate 
this model further. The models were investigated with and without an intercept 
term i.e. , for the model without an intercept ao (eqn. 3.12) was assigned a value 
of zero. Regression was conducted using the REG procedure (SAS User's Guide, 
1982) .  The results of the analyses are given in tables 3.19 and 3.20 
The results based on the residual sum of squares, the fit of the predicted and 
observed values and a plot of the residual vs. the observed response; indicate that 
the model fits the data well .  Better fits were obtained without an intercept term in 
the equation than with an intercept term. This is also evident in the large standard 
deviation for the estimated intercept. The RSQUARE procedure further indicates 
that the response may be adequately described with only the XS and XD terms in 
the equation. Addition of a XC term results in an increase in the R-square value 
but is no1 appreciable. Large variability was observed in the coefficients a0 ,  b and 
c. While the data indicate that a pharmacodynamic model for digoxin may be 
adequately described by linear model the following points need to be noted: 
1) The equation relating the amounts of digoxin in each of the pharmacokinetic 
compartments to the observed response implies the existence of receptors in 
each of these compartments. However a closer look at table 3.20 and the R­
square values in tables 3 .17 and 3.18 reveal that the coefficient b for the central 
compartment may be very cJose to zero and that its contribution to the overall 
response may be negligible. 
2) The large variability in ao , b c and d imply receptors with varying sensitivity 
for the same evoked response. It is observed that some of the coefficients 
are negative. This indicates that the receptors in the Sil,IDe pharmacokinetic 
NUMBER IN 
MODEL 
1 1 
I 
2 
2 2 
3 
NUMBER IN 
MODEL 
l 1 1 
2 
2 
2 
3 
TABLE 3.17 
STUDY NO. 4 
RSQUARE 
0.00495959 
0.01661 176 
0.53207427 
0.02691761  
0.60540457 
0.63143736 
0.6321 9704 
STUDY NO. 7 
RSQUARE 
0.0447746i 
0.1 2494592 
0.72401 900 
0.59086245 
0.95615120 
0.9738161 5 
0.97493637 
VARIABLES 
IN MODEL 
XC XD XS 
XC XD XS XD 
xc xs 
XC XS XD 
VARIABLES 
IN MODEL 
XC XD XS 
XC XD XS XD 
xc xs 
XC XS XD 
1 78 
RSQUARE fuialysis for the linear model (with intercept) proposed by Kelman and 
Whiting ( 1980) . 
XC, XS and XD are simulated amounts of digoxin in the central, shallow and deep 
compartments for a three compartment mamillary model. 
NUMBER IN 
MODEL 
1 1 1 
2 2 2 
3 
NUMBER IN 
MODEL 
1 1 1 
2 
2 
2 
3 
TABLE 3.18 
STUDY NO. 9 
RSQUARE 
0.00878101 0.28335729 0.37532803 
0.28509066 0.41868876 0.56372017  
0.59604948 
STUDY NO. 10 
RSQUARE 
0.07996451 0.08931063 0.24114265 
0.08973375 0.30735802 0.63093475 
0.65528679 
VARIABLES 
IN MODEL 
XC XD XS 
XC XD XS XD 
xc xs 
XC XS XD 
VARIABLES 
IN MODEL 
XC XD XS 
XC XD XS XD 
xc xs 
XC XS XD 
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RSQUARE analysis for the linear model (with intercept) proposed by Kelman and 
Whiting (1980) . 
XC, XS and XD are simulated amounts of digoxin in the central, shallow and deep 
compartments for a three compartment mamillary model. 
TABLE 3.19 
The Linear Model ( with intercept) 
STUDY 
NO.  4 
STUDY 
NO. 7 
STU DY 
N0. 9 
STUDY 
N0. 10 
• • • - .,. ••• o -..0 00 0·•• ••• • - ,.., • - • •• -•• • •• • • - •  • .. • •  •• --·---·-·- • - •  • • •�•, ••• •-,.. •-••• ,_, ___ • •• , _,.... • , ____ , ,.  - - • • •  - --·-----·- ----·.,•• •• -
... . , - £.,,-- · - ,.- ,..,., ________ _ 
1)08.E (mg/kg.) 0 .05 
£ rit.NCf' pt, ( <1,1 1 ) - J. 7 . 10 ( H .  I I )  
b -38.7'1 (25.78) 
C 21 7.67 (30.48) 
d - 14 .95 (59. 10) 
RESIDU A IJ (SSE) 2088.74 
TOTAL (Corr S�H;) 5678.96 
RSQl l AR.E 0 .63 
d .f. 34 
N 34 
p 4 
AIC 275.55 
0.025 
- J.93 . 10  (20.92) 
644 .48 (74 .641) 
684.50 (59.341) 
J 07i.70 ( 1 09.47) 
1 382.54 
7798.54 
0.82 
35 
35 
4 
268.34 
0.05 
-15.97 (7.84) 
39.46 (22.33) 
-387.21 (93.57) 
37.5.87 (68.60) 
1 889.73 
4678 .12  
0.60 
12 
'1 2  
4 
332.40 
0.05 
- J.1 7.64 ( 16.90) 
206.02 (32.42) 
-83.20 (49.49) 
263.97 (32.58) 
1106.70 
3210.48 
0.65 
43 
44 
4 
316.40 
,._ ... .... · -· ····--···· -· . . - . .  ----···---"··-·-·--- ·----------
Regression analysis of the l inear model proposed by Kelma.n and Whi1,ing ( 1980) . 
" numbers in brackets are standard deviations 
N == no. of observations used 
P =� no. of parameters in the model 
b, c and d are coefficients in the model ._. 
CX) 
0 
TABLE 3.20 
The Linear Model (without intercept.) 
.. · ··-- ---- -·--- · ·- · . - ·· ···- . ··- -·-····· · · · · · · -- ----- --·· · --- ·-- -·--------------
STUDY 
NO. 4 
·····-·· ·-···----------·------- ·--··· ·-----------
DOSE (mg/kg.) 
b 
r. 
d 
RESID UAL (SSE) 
TOTA L ( U ncorr. SSE) 
RSQU ARE 
d.f. 
N 
p 
A IC 
0.0.5 
- 10.56 ( 1. 1 .24) 
2 1 3.48 (30.50) 
55.72 (9.72) 
2187.75 
25738.68 
0.91 
35 
34 
3 
282.86 
.. ... . ..... . -----·--- -------· - -----------
STU DY 
N O .  7 
0.025 
- 1 7 .87 (:J8 .75) 
337 .46 (86.5:3) 
70.88 ( 1 7.67) 
5063.92 
22098.68 
0.76 
36 
35 
3 
32 l .6 1  
STUDY 
NO. 9 
0.05 
I . :m ( 'I 2 .62) 
-259.66 (72.20) 
240.36 ( 17 .34) 
2090.69 
26100.57 
0.9] 
43 
42 
3 
:342.39 _ _  ,. ... _ ._ ... ·-- . -· .. - -· . "'-· -- -· .... --·-
Regression an lysis of the linear model proposed by Kelman and W h iting ( 1 980) . 
• nu mbers in brackets are standard deviations 
N -== no. of observations used 
P =--· no. of parameters in  the model 
b. r. and d are coefficients in the model 
STUDY 
N0. 10 
0.05 
26.42 (28.83) 
-64.46 (72.58) 
37.65 (3.07) 
2446.84 
15435 . 1  
0.84 
44 
44  
3 
357 . 1 1  
.... 
CX) .... 
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compartment may have a positive contribution to the response in one dog and 
a negative contribution in another. This contradiction casts doubts on the 
possibility of multireceptor sites and the applicability of such models. 
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THE EFFECT COMPARTMENT MODEL 
The model was recently proposed by Sheiner et al., (1979) , and has been exten­
sively used. A schematic representation of this model may be seen in fig. 1 .2 A brief 
description of this model and a generalized derivation of the relevant equations fol­
lows has been presented in chapter 1 .  From equation (1 .19) the effect compartment 
model may be modelled using the following two equations: 
or, 
E c/ -- = ------C1 i> + CPss(so) t-
c/ 
E = Eo - Emaz · 6 0 C1 + JCcso) . . .  (3 . 13) 
where. JCso is the c.oncentration that effects a 50% inhibition of the maximal re­
sponse (decrease in heart rate) , and E is the response (heart rate) . Eqn . (3 .13) will 
be referred to as the "inhibitory model" and eqn . ( 1 . 19) as the "effect model" . Eo 
is usually the baseline value for the monitored response assuming that the base­
line value bas been reliably determined. Emaz cannot usually be physiologically 
determined . In this specific case the maximum decrease in heart rate cannot be 
accurately determined without result.ing non-reversible slowing of the heart. There­
fore, Ema:r may be assigned a theoretical physiologic maximum (which is a 100% 
decrease in heart rate) � the observed maximum response. or may be regressed as 
a variable with an upper constraint of the theoretic.al physiologic maximum. The 
response variable £ is the percent decrease in the heart rate relative to the b¥eline 
value and is given by 
E = % decrease in heart ratt: = H /le. ·- H Robs · 100 HRc. 
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where, 
H Ro - baseline heart rate 
and H Robs = the observed heart rate at any time. 
For our studies the p]asma concentration vs. time profile was described by 
and equation (1 . 18) is given by, 
C1 = D L Cie-0:it 
i=l 
3 
C - k D� Xi : -0:;t -k, . .  t � 1 eo · L...J V (k _ ·) le - e : 
i= I  
I e O  0:1, 
.. . (3. 14)  
. . .  (3. 15) 
General1y, it, is a.dvisab]e to fit equations 3. 14 and 1 . 19, or. 3. 14 and 3.13 simulta­
neous]y. However: when the plasma concentration vs. time profile is we11 described 
by eqn . (3.1 4 )  or a similar expression, equation ( 1 . 19) and (3. 14) may be regressed 
independent.ly ( Sheiner et al. , 1979). The plasma concentration vs. time profile for 
studies 4 .  7 :  9 and 1 0  were wel1 described by equation 3.13 and as evident from 
table 3.16 had correlation coefficients and R-square values greater than or equal to 
0.99 Therefore equations for the effect model and the inhibitory model were fitted 
without simultaneously regressing equation (3. 14) .  
Equation ( 1 . 19) and (3.1 3) were regressed using the nonJinear :regression pro­
gram NLIN (SAS User's Guide, 1982) . Ema.7. was assigned a value equal to the 
observed maximum percent decrease in heart. rate. regressed as a variable with the 
upper limit set at the theoretical physiologic maximum (100% decrease in heart 
rateL or assigned a value equal to the theoretical physiologic maxi�um (100% 
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decrease in heart rate) . The results are tabulated in tables 3.21, 3.22 and 3 .23 
respectively. 
The results indicate that the effect model adequately describes digoxin phar­
macodynamics in the dogs with respect to its bradycardic effect. A wide variability 
is seen in the parameters describing the the model viz . ,  Keo , o and Cp88(so) in 
table 3.21 The variability is indicative of the wide variability in the bradycardic 
effect of digoxin in beagle dogs. There does not seem to be a large differences in 
the lfe0 values for studies 7, 9 and 10 although there seems to be an appreciable 
difference in the values of the parameters obtained for studies 4 and 7 which were 
studies conducted in the same beagle dog at 0.05mg/kg. and 0.025 mg/kg. of 
digoxin respectively. Further studies will be necessary to determine whether these 
changes indicate saturation of the pharmacodynamic response measured. However. 
it is noted that the Cpss(5o) values for studies 4 and 7 are quite similar. It should 
also be noted that the 6 values for studies 6 and 7 are similar whereas these values 
are not. comparable to those obtained for study 4. Again, in studies 6 and 7 the 
dose was 0.025 mg /kg. whereas the dose was 0.05 mg/kg. in study 4 .  Studies 4 ,  6 
and 7 were studies conducted in the same beagle dog. 
The results of table 3.22 are those when Ema.r is regressed as a variable and has 
an upper limit of 1 00% decrease in heart rate. Except for studies 6 and 10 Ema.x 
attained a value of 100% after regression procedures. Again Keo values for studies 
7, 9 and 10 are not. comparable to those observed for study 4 and are independent 
of Ema.x · Howe\·er, in contrast. to the values in table. 3.21 ,  the Keo values for studies 
4 and o seem to be quit.e similar. This confuses the picture since studies 4 ,  6 and 
7 were conducted in the same dog. A fewer number of points were available for 
modelling the pha:rmacodynamics of study 6. This may detract. from �he reliability 
of the parameter vaiues for study 6. The l, values for study 4 are again quite 
dissimilar to those for studies 6. 7 .  9 and 10. 
TABLE 3.21 
The Effect Compartment Model 
-··-·· .. - • •  - --· WO - -· ·L-0 
STU DY STUDY STUDY 
NO. 4 N O .  6 NO.  7 - -·---·---... --·-·-·- ·---·--
DOSE (mg/kg.) 0.05 0 .025 0.025 
I<eo (min ._ 1 )  0.04 15  (0.028) 0.04 (0.022) 0.0088 (0.00066) 
Cpas(50) (ng/ml.)  8 .18 ( 1 .21) 9 .84 (0. 1 8) 3.77 (0.10) 
DELTA 0.92 (0. 1 7) 7. 1 5  (0.067) 5 . 16 (0.66) 
Emo.z (%) 50.20 46.68 45.46 
RESIDUAL (SSE) 2048.39 4 J .86 8107.53 
TOTAL (Corr. SSE) 4839.9 1 ,5968.4!) 7389.95 
RSQUARE 0.58 0.99 0.89 
d .f. 3 1  1 4  32 
N 34 J 7  35 
p 3 3 3 
AIC 265.24 69.48 228.27 
Results of regression analysis for the effect compartment model . 
.. numbers in brackets are standard deviations 
N = no. of observations used 
P = no. of parameters in the model 
Emaz = observed maximum response 
STUDY 
NO. 9 
· ·--·-- .. ·- - -
0.05 
0.0026 (0.00028) 
5.9 (0.27) 
5 .85 { 1 .27) 
45.55 
1967.32 
4 168.78 
0.53 
39 
42 
3 
324.54 
STUDY 
NO. 10 
0.05 
0.0027 (0.0003) 
5.05 (0.23) 
7 . 13  (2.00) 
27.96 
1 1 16. 1 4  
3419.90 
0 .67 
4 1  
44 
3 
314.77 
..... 
00 
O'I 
TABLE 3.22 
The Effect Compartment Model 
STUDY STUDY STUDY 
NO. 4 NO. 6 NO. 7 
·- ·-· 
DOSE (mg/kg.) 0.05 0.025 0.025 
Kr.o (min . .. 1 )  0.034 (0.023) 0.038 (0.0016) 0.0072 (0.00066) 
CPss(so) (ng/ml.) 56.00 (613.87) 10.20 (0. 19) 5.26 (0.25) 
DELTA 0.60 {0.42) 7 .16 {0.31)  3 .77 (0.38) 
Ema.:e (%) 100.00 (--·) 50.22 ( 1 .26) 100.00 (--) 
RESIDU AL (SSE) 1769.21 27.54 570.96 
TOTA L (Corr. SSE) 4839.91 5968.45 7389.95 
R.8QU A R.F.;  0.63 0.99 0.92 
d .f. 30 1 6  34 
N 34 1 7  35 
p 4 4 4 
AIC 262.26 64 .36 230. 16 _________ ., ,_ , _  - - ... 
Results of regression analysis for the effect compa.rtmE>n1, model . 
" numbers in brackets are standard deviations 
N 
= no. of observations used 
P == no. of parameters in the model 
Ema:e wa.c; regressed a.c; variable wi U-1 an upper l im i t; of 100% 
STUDY 
NO. 9 
0.05 
0.0026 (0.00036) 
7.94 ( 1 .56) 
4.033 { 1 . 17) 
100.00 (-) 
1838.57 
4 168.78 
0.56 
4 1  
4 2  
4 
323.70 
STUDY 
NO. 10 
0.05 
0.0024 (0.00018) 
5.65 { 1 .40) 
7 . 12 (3.95) 
47.77 (42.01) 
1040.31 
3419.90 
0.70 
43 
44 
4 
313.68 
I-' co 
""-J 
TABLE 3.23 
The Effect Compartment Model 
STUDY STUDY 
NO.  4 NO. 6 
DOSE (mg/kg.) 0.05 0.025 
Keo (min. _ t )  0.033 (0.014 )  0.041 (0.005) 
Cpas{50) (ng/ml.) 54.56 (0.000016) 15.95 { 1 .3) 
DELTA 0.61 (0. 11 )  2.42 (0.48) 
Emc,.x (%) 100.00 100.00 
RESIDUAL (SSE) 1941.86 260.71 
TOTAL (C.orr. SSE) 4839.9] 5968.45 
RSQ U ARE 0.60 0.96 
d .f. 33 16 
N 34 17 
p 3 3 
AIC 263.43 100.57 
Results of regression analysis for the effect compartment model. 
"' numbers in brackets are standard deviations 
N = no. of observations used 
P = no. of parameters in the model 
Emax was assigned a value of 100% 
STUDY 
NO. 7 
0.025 
0.007 (0.00004) 
5 .25 (0.25) 
3 .78 (0.42) 
100.00 
732.13 
7389.95 
0.90 
34 
35 
3 
236.86 
STUDY 
NO. 9 
0.05 
0.0026 (0.0002) 
7.93 (0.67) 
4.03 (0.86) 
100.00 
1907.84 
4168.78 
0.54 
4 1  
42 
3 
323.26 
STUDY 
NO. 10 
0.05 
0.0023 (0.00016) 
6.57 {0.49) 
6.34 (1.16) 
100.00 
1125.97 
3419.90 
0.67 
43 
44 
3 
315.16 
._. 
o::> 
o::> 
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The results of table 3.21 are quite similar to those of tables 3.22 and 3.23 
Emax was assigned a. value of 100%. Treatment of Emax as a variable and assigning 
fixed values does not seem to cause any noticeable deviations in the values of the 
estimated parameters. However, the best model of the various models investigated 
above will be further discussed. 
Results of modelling the inhibitory model described by eqn. (3.13) are given in 
table 3.24. 
The values for the parameters obtained are comparable to those in table 3.22 
The results indicate that significant differences may not exist when modelling is 
conducted using either of the equations (1.19 or 3.13) since mathematically they 
are but juxtaposed forms of each other. 
TABLE 3.24 
The JC50 Model 
STUDY 
NO. 4 
DOSE (mg/kg.) 0.05 
Keo (min, .- 1 )  0.03377 (0.0144) 
JCso (ng/ml.) 54 .65 (41 . 1 7) 
DELTA 0.61 (0.41) 
Emax (bpm) 104.426 (-) 
RESIDUAL (SSE) 1958.20 
TOTAL (Corr. SSE) 5277 .82 
RSQ U A R E  0.63 
d .f. 30 
34 
p 4 
STUDY 
NO.  6 ___ ,___ .. _ ___ 
. 0.025 
0.038 (0.0050) 
10.22 (0.57) 
7.16 (2.71) 
52.33 (5.32) 
219.12 
6494 . 1 3  
0.97 
7 
1 7  
4 
--·-·-·-· -· --
Results of regression analysis for the IC50 model .  
.. numbers in brackets are standard deviations 
N = no. of observations used 
P = no. of parameters in the model 
Ema:z; = var_iable with an upper l imit as thP. basal hP.a r1: rate. 
STUDY 
NO. 7 
0.025 
0.0073 (0.00033) 
5.26 (0.55) 
3.77 ( 1 .25) 
153.134 (-) 
969.51. 
1 7329.4.6 
0.94 
34 
35 
4 
STUDY STUDY 
NO. 9 NO. IO 
0.05 0.05 
0 .0025 (0.0002) 0.0023 (0.00016) 
7.86 (0.68) 6.65 (0.83) 
4.03 (5.66) 5.96 ( 1 .63) 
92.38 ( -) 167.412 (-) 
1575.53 2756.30 
3557.66 8351.21 
0.56 0.67 
41 40 
42 44 
4 4 
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COMPARISON OF VARIOUS MODELS 
The various models investigated were compared to determine the best model 
based on certain statistical criteria. The computational procedures which formed 
the basis for the comparison were the F-value (Boxenbaum et al.J 1974) and the 
Akaike information criterion jAIC (Akaike H., 1973,1976; Yamaoka et al., 1978)] . 
In general, a model A was considered to superior to model B if model A met one 
or more of the following criterion. 
1) Residual sum of squares for � is less than the residual sum of squares for B. 
2) Using the F-test, the weighted sum of squared deviations for model A is signif­
icantly lesser than that for model B. 
3) AIC for model A is less than AIC for model B. It is assumed that the models A 
and B provide adequate visual fit and that a plot of the residual sum of squares 
vs. the observed values does not display any systematic deviations. The results 
of the comparison of the various models investigated are given in table 3.25 
In the case of the linear models, the model without the intercept term was 
significantly better than the model with an intercept. The various models investi­
gated were compared to the effect model with Ema.x as a variable. Overall the effect 
model with Ema.x as a variable was the best model based on the AIC, F-value and 
the residual sum of squares. 
Very little difference was observed in the values of the parame�ers and the 
residual sum of squares obtained using either eqn. (1.19) or (3.13) . However based 
on the criteria mentioned above effect model seems to be superior to the inhibitory 
model and use of the effect model with Ema.x as a variable may be a more desirable 
approach compared to use of the inhibitory model. 
TABLE 3.25 
COMPARISON OF VARIOUS MODELS 
STUDY 
NO. 4 
STUDY 
NO. 6 
LINEAR 
with intercept 
AIC 275.55 
F value 5.96""" 
RESIDUAL (SS E) 2088 .74 
d.f. 30 ----· ·---···-... ·-·--·.--·-·· 
AIC --
F value -
RESIDUAL (SSE) -
d.f. -
LINEAR Ema.z = 
no intercept variable 
282.86 262.26 
3.90"" -
2187.75 1769.21 
31 30 
- 64.36 - -·-
-···-- 27 .54 
- 13 _ _ _____ _ ___ ,, . . ... . , , _  .. _____  ---
AIC 268.34 32 1 .61 230. 1 6  
STUDY F value 48.32 ... 1 33.77 " .  -·· 
NO. 7 RES IDUAL (SSE) 1382 .'.54 5063.92 570.96 
d.f. 32 31 31 ·------· ...... , .,, ___ - ·---- _ ,·--·-·-----···--· - . ----·---·--
AI.C 332.4 342.39 323.70 
STUDY F value 1 . 14 2.81 ··-
N O. 9 RESIDUAL (SSE) 1889.73 2090.69 1838.59 
d .f. 39 38 38 ____  ._ , 
AIC 316.40 357. 1 1  313.68 
STUDY F value 2.15 58.14 ' "  -
N0. 10 RESIDUAL (SSE) 1 106.70 2446.84 1040.31 
d.f. 4 1  40 40 
Results of comparison of various models. 
AIC 
= 
Akaike information criterion 
"'* indicates· statistical significance at P < 0.01 
Ema.z = 
1 00 
263.43 
2.93""' 
1941.86 
31 
100.57 
1 10.06",; 
260.71 
14  
236.86 
8.75""'  
732.13 
32 
323.26 
1 .43 
1907.84 
39 
315.16 
3.29"' "' 
1 1 25.97 
4 1  
Ema.z = ICso = 
max. observed variable 
265.24 265.71 
4.73"" -
2048.39 1958.20 
31 30 
69.48 
6.76"'* 
4 1 .86 
14  
240.27 232.68 
12.82"' ... 
807.00 969.51 
32 31 
324.54 301 .22 
2 .66 
1 967.32 1575.53 
39 38 
314.77 340.55 
2 .92"' " -
1 1 16.14 2756.3 
4 1  40 
193 
Physiologic Pharmacokinetic Models: 
Simulation Using SPICE2 
Introduct ion: 
Physiologic pharmacokinetic models have gained increasing acceptance since 
their application to drug disposition in t.he late 1960's by Bischoff and Brown ( 1966) . 
Investigators have recognized the fact that the compartment volumes, rate constants 
and other parameters obtained by cJassical pharmacokinetics, i.e, by empirical curve 
fitting, provide no information on the actual physiological and anatomical mecha­
nisms of the particular animal species being studied . In contrast, physiologic phar­
macokinetic models (Bischoff, 1967; Dedrick and Bischoff 1979; Chen and Gross, 
1979) allow animal data to be extrapolated to humans, in cases where "scale-up" 
techniques (Dedrick . 1978; Boxenbaum, 1982) are applicable. Parameters obtained 
by classical pharma.cokinetics in animals cannot usuaJly be related to s imilar pa­
rameters in humans. Also, physiologic pharmacokinetic models provide information 
on the dispostion of drug in a specific region of the body such as the heart, brain 
or tumors. For these reasons, physiologic pharrnacokinetic models are now being 
used to study the uptake and distribution of various drugs ranging from anesthetics 
(Mapleson, 1963; Saidman and Eger, 1973; lgari et al. . 1982; Bischoff and Dedrick, 
1968; Price et al.� 1960) to anti-cancer drugs (Ch(:'u and Gross, 1979; Himmelstein 
and Bischoff, 1973.; Chen and Coleman , 1978; Dedriick et. al. , 1973; Dedrick .et al., 
1972; Himmelstein and Gross, 1977·  Harris and Gross. 1975; Chan et al., 1978; 
Dedrick et al., 1973; Bischoff et al . . 1970: Bischoff et al . .  1971 ) .  Specific drugs that 
have been studied include thiopent.al (Saidman and Eger, 1973; lgari et al. , 1982; 
Bischoff and Dedrick, 1968; Price et al., 1 960) , lido,caine (Benowitz et al. , 1970) , 
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sulfabromothalein (Montandon et al., 1975), digoxin (Harrison and Gibaldi, 1977a, 
1977b), salicylat,es (Chen et al. , 1978) , Ar.a-C (Dedrick et al. ,  1972, 1973), cycloci­
tidine (Himmelstein and Gross, 1977a, 1977b) , adriamycin (Harris and Gross, 1975; 
Chan et al. , 1978), and methotrexate (Dedrick et al. , 1973; Bischoff et al., 1970, 
1971) . 
Although physiologic pharmacokinetic models have been in use over the past 
few years, their potential application to pharmacodynamics has not been exploited. 
Pharmacodynamic models ha:ve generally used conventional pharmacokinetic mod­
els with linear linking models (Kramer et al. , 1979; Kelman and Whiting 1980; ... .. ___ ...... .. . . , - -
Holford 1981;  Eichelbaum 1980) , the log linear model (Shephard 1979; Ishizaki 
1980) , the sigmoid model (Mitenko and Ogilvie 1973, Singh et al., 1980) and the 
more recent effect compartment model {Sheiner e� al., 1979; Hennis et al., 1985; 
Stanski et al. : 1 984 : Chiang and Barnett 1984). Therefore the primary aim was to 
develop and apply physiologic pharmacokinetic models using SPIGE2 (Mikulecky, 
1982, 1983; SPICE 1 981· Thakker et al. 1 1 982) and to investigate their possible 
application to pharmacodynamics. 
SPJCE2 is a powerful integrated circ:u i t. simulat.ion program. which was devel­
oped by electrical engineers at the Univerist.y of California. Berkeley for the purpose 
of designing and testing complicated circuit�. However, it has been recently realized 
that electrical elements and bioiogiea.1 .syst.ems are both governed by principles that 
emphasize force-flow relationships and consejvation of energy. It is an evolution of 
this understanding of common (thermodynamic) principles governing electrical and 
biological eiements that led to network thermodynamics. Network thermodynamics 
uses .elements that are distpiguished by their thermodynamic properties, namely 
their manner of manipulating energy. The resistor is an energy dissipator, the ca­
pacitor an energy storage element of one kind, and the inductor the representative 
of intertial energy storage. The morphology of a system can therefore be translated 
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into a network with little effort. The compartments become nodes, the dissipative 
barriers ( e.g. membranes) the branches between these compartmental nodes. Net­
work thermodynamics may therefore be thought of as a collection of parts which 
allows us to investigate the 'whole system' by representing the topology of interac­
tive systems by means of interconnected network elements which dissipate, store, 
supply or convert energy. It is this concept that allows us to use a circuit simulation 
program like SPICE2 to investigate the behavior of biological systems. 
SP1CE2 has been used extensively in simulating diverse and complex biological 
systems: but has been only recently introduced in the field of pharmacokineiics 
(Thakker et al . .. 1982) ; and here has been only applied to classical pharmacokinetics. 
Here SPICE2 has been adapted for simulating a physiologic pharmacokinetic model 
with a linking linear pharmacodynamic model for the cardioactive drug digoxin, 
administered to the rat (Harrison ·and Gibaldi, 1977a), dog and human (Harrison 
and Gibaldi, 1977b) . This model was developed so that simulated levels of digoxin 
in the heart may be obtained which could then be related to the pharmacologic 
responses in dogs. 
The biophase (i.e . �  the compartment in which the pharmacologic effect for 
digoxin occurs ) is in the heart and not readily accessible. Physiologic pharmaco­
kinetic models using cardiac physiologic parameters and pharmacologic responses 
as an indirect measurement of heart concentrat,ions wi ) ]  provide a new approach to 
understanding the relationship between digoxin plasma. concentrations and biopha­
sic concentrations. The developed models are �pplied to the results of our studies 
in dogs to illustrate the value of SPJ CE2 in modelling these data. 
Generally, physiologic pharmacokinetic models are described by differential 
equations. Conventional computer programs like the Continous system modelling 
program (CSMP, 1967) , General program for pharmacokinetic mode11ing (GPPM) 
(Dedrick et al., )�  SAAM (CONSAM 1983) are utilized in solving these differential 
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equations. It was therefore of interest to compare these programs with SPICE2 
which directly uses network topology rather .than differential equations to describe 
and simulate complex systems. 
Experimental: 
A program was designed using SPJCE2 to simulate the physiologic pharmaco­
kinetic model for digoxin in the rat, dog and man described by Harrison and Gibaldi 
(1977a, 1977b) . These models were simulated using SPICE2 and compared to those 
obtained using GPPM and CSMP. The <lat.a obtained from the initial pharmacokin­
etic studies (Tables 3. 1-3.3) and :from the. pharma.codynamic studies (Tables 3.11 
3.13, 3.15 and 3.16) were used to verify the accuracy and validity of the simulations. 
A general procedure developed for the simulation of physiologic pharmacokin­
etic models using SPICE2 is as follows: 
a) The Physiologic Pharmacokinetic Model: 
The physiologic pharmacokinetic model consists of blood ( or plasma) flows 
in and out of compartments. In general a flow-limited model is used (whenever 
applicable) for simplification purposes. Fig. 3.23 is a simple representation of a 
physiologic model . 
Using the "'I umped compartment approach" : anatomical regions of interest 
maybe lumped with other compartments of similar characteristics relative to drug 
disposition. Volumes for compartments. blood flows and other pertinent information 
are readily available in the literature. There have been several excellent reviews on 
creating physiologic pharmacokinetic models ( Chen and Gross, 1979; Himmelstein 
and Lutz, 1979; L-qtz, 1977: Gillett.e. 1982: Gerlowski and Jain, 1983) . 
BLOOD 
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b) Creating A Network: 
Creating a network for a given physiologic pharmacokinetic model, requires 
that the information needed to describe a physio)ogic pharmacokinetic mode) be 
incorporated in that network. It may be described by the following three steps: 
1) Constructing the blood flow network 
2) Constructing the mass balance network 
3) Link the blood flow and the mass balance networks 
1} BLOOD FLO W  NETWORK 
Fig. 3 .24 shows the network for blood flow corresponding to the physiologic 
model shown in Fig. 3.23 
In the physiologic pharmacokinetic model the total p)asma flow Qp is dis­
tributed into flows into the various compartments. The relationship between the 
flows into the various compartments is as follows: 
where, Qp : Qk . Qm. Q9 : Q8 , Qh, Qz , are the plasma flows through the p)asrna. 
kidney, muscle, gutwall: skin , heart and liver compartments respectively. The frac­
tion of the total flow (/;) through each compartment is therefore, 
f - Q, t - Q,, 
The network is then constructed based on the above relationships. Resistances are 
used to part ition the plasma-flow. The total plasma floy.: (cardiac output, Q,..) is 
--I la 
1 
-
f1S · 3 , 24 B lood f1 ow network for a ph,ys fo l ogic  phanna_coki netic model us i ng 
' ' SP1CE2 . · ·· .... 
\0 
\0 
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supplied by a constant current source termed !PLASMA. The relationship between 
plasma flows may be mimicked using a similar relationship between the resistances: 
1 1 1 
RGUTWALL 
+ 
RLIVER + RKIDNEY 
1 1 1 
+ RSKIN + RMUSCLE + RHEART = 1 
Hence, the resistances are assigned values as follows: 
RGUTW ALL = _!_ = Q,, Jg Qg RKIDNEY = 2_ = 
Qp etc .  
fk Qk 
{2} MASS BALANCE NETWORK 
Rate constants and tissue to plasma partition coefficients have to be incorpo­
rated into the mass balance network. The network which incorporates mass balance 
is given in Fig. 3.25 
The basic representation can. be understood by the example in fig. 3.26 
Flux through the compartment in fig. 3.26 is given by, 
KC = J  
where, K = rate constant ( equ.al. to clearance in 
pharmacokinetic terms) or permeability 
constant ( units of ml/ min.)  
C = concentration (mg /ml . ) .  and 
J = flux (mg /min.) 
The network for the above compartmental representation is also given in fig. 3.26 
In this case, 
C = voltage at node 1 
J = current flowing through the system 
K = value given to GRATE 
( GRATE is a voltage controlled current source) 
r-t 
e 
N .. 
� 
+11· •• , 
� 7.,Tl-'f"ITT 
.. 
fi"g . 3 . 25 Mll!iS bal ance netwerk for a pbys io1 o�ric pharmqcok.tnetic model us in.� 
SPICE2 . 
11 
1 
C I • J·  , I 
KC = .I COMPARTMENTAL REPRESENTATION .... k • Mn: CDNlr. (UNIIS Ol l&/IIN,) 
C • CDNCDffll'1laN (UMll 01 Ml/IL) 
J - 11.UX (UNnl 0, MG/MIN,) 
1 2 
SPICE2 
REPRESENTATION + C • VOLTME AJ NCIK I � 
" IL CUl1Dff WC 1NIOUGN NOO£ t · -----·��� 
Fig. 3 . 26 Compari son between- compartmental and SPlCE2 representations . 
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For an explanation of the network given in fig. 3.25, one can consider the mass 
balance for drug in the heart compartment in -fig. 3.25, where, 
Amount in 
Rh 
Hence, in fig. 3.26 we assign a 
value = 1 . for GHEART and a 
1 
value = - for GHEARTB (GHEART back) 
Rh 
where, Gp is the concentration in the plasma at any time and Rh is the tissue to 
plasma concentration ratio for the heart. 
(3) LINKING THE BLOOD FLQ'W AND MASS BALANCE NETWORKS: 
To combine the blood flow a11d mass balance networks the SPICE2 program 
provides (a) F elements and (b) Polynomial G elements. 
The G elements, as mentioned before, are vo)tage controlled current sources 
and as the name implies, are voltage controlJed elements. But, in fig. 3.24 the 
plasma flows are represented by current flows. Therefore, to use G elements for 
mass transfer, current flowing through the nodes in fig. 3.24 have to be converted 
to vol�ages. To accomplish this, the network shown in fig. 3.27 is used. 
The network in fig. 3.27 is composed of F elements which are cur.rent controlled 
current sources, and are defined as follows: 
F * * * * * * * N+ N- V NAM value 
11 
7-.,, ,� 
37 
--
38 ... 
-
� 
------...... 
•• -
l -
� 
E 
'i· 
Fi g .  3 . 27 SP ICE2 network l i nki ng the· bl ood fl ow and mass ba l ance networks . 
• 
I\) 
0 
.;:a 
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where, F*******  represents the name assigned to the element, N+ and N- are the 
positive and negative nodes which describe the location of the F element. VNAM = 
name of the voltage source through which the controlling current flows and value = 
current gain. 
Since V = J . R, the F elements are assigned a value = 1, and multiplied by 
a Resistance = 1 in order to convert the current flow to a voltage.. This technique 
has been used to convert the currents flowing in fig. 3.24 to voltages in fig. 3.27 at 
nodes 35, 36, 37, 38, 39, 40, 41, 42 and 43. For example, in the circuit given fig. 
3.27; FHEART is defined as, 
FHEART O 36 V HEART 1 
This auxiliary circuit converts the current flowing through the dummy ammeter 
VHEART, to a voltage at node 36; by multiplying it by a resistance of value 1. 
In fig. 3.23. the net flux into or out of any compartment is a product of: 
a) plasma flow through the compartment (Q) 
b) Concentration in the compartment ( C) 
Specifically, the rate of change of drug in the heart. is given by: 
v ( dch ) = Q i c _ ( ch ) i h dt h L p Rh J 
where, Vh is the volume of the heart, Ch and C1. are the concentrations of drug 
in the heart and plasma respectively, Q h is the plasma flow through the heart and 
Rh is the tis�ue to plasma partition coefficient. Hence, to obtain the prp�uct of Q 
and C, polynomial G elements are used. A polynomial G element is described as 
follows: 
G * * * * * * * POLY (n) 
' .  
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In fig. 3.25, GHEART is described as, 
GHEART 19 20 POLY (2) 36 0 19 0 O O o O 1 
Here, 19 20 describes the location of the element. 36 0 and 19 0 are the flow and 
concentration controlling nodes . The polynomial is given by: 
if, x = plasma flow and y = concentration, flux = xy 
Therefore, GHEARTB is defined as, 
1 
GHEARTB = 20 19 POLY(2) 36 0 19 O O O O O 
Rh 
Here, 
1 hence, a4 = Rh 
A computer listing of the program is given in Table 3 .26. 
Results : 
SPICE2 SIMULATIONS A ND COMPARISONS TO CSMP A.VD GPPM 
The physiologic pharmacokinetic model for digoxin in t.he rat (Harrison and 
Gibaldi ,  1977a) , dog and human (Harrison and Gibaldi .  1977b) ,  was simulated 
using SPICE2 and using the programs, CSMP and GPPM, in order to validate 
and identify comparative advantages and disadvantages of the programs. Values 
for flows, compartment volumes, and tissue to plasma partition coefficients were 
obtained from Harrison and Gibaldi ( 1977a, 1977b) . 
TABtE 3 . 26 
PHYSIOLOGIC PBARKACOEIJIETIC MODEL POR DIG0%1N IN DOGS 
IPLASNA 0 2 DC 63 
lll01 1 0 111 
llll& 1& 0 1U5 
VPLASllA 2 S DC 0 
RGUTWAL Z 4 S . &  
IU.IYBR S 5 10 . &  
UnDIBY 8 e & . as 
RSEIN 9 7 S . 25 
JUroSCLE 8 e & . as 
RDART 8 9 21 
YGUTVAL 4 15 DC 0 
YGUTVALE 15 14 DC 0 
VLIYBRl 6 14 DC 0 
VJ:IDRBY 6 1 DC 0 
YRIN '7 l · DC 0 
YJmSCLB 8 1 DC 0 
VBBART 9 l DC 0 
VLIVBR2 14 1 DC 0 
. IC V( l )•0 V(2)•63 V(3)•63 V(4)•0 V(5 )•0 V(6)•0 V(7)•0 
+ V(8)•0 V(9)•0 V( l4)•0 V(l5 )•0 V( l9)•1000 V(23)•1R V(25 )•1R 
+ V(26)•lR V(27)•1B-S V(24)•lB-5 V(28 )•lB-5 V(29)•lU V(20)•1R 
+ V(2l )•lN V(22)•1N 
CPI.ASHA 19 0 O . S  IC•l000 
CDART ao 0 0 . 05 IC•lJI 
GBBART 19 20 POLY (2)  16 0 19 0 0 0 0 0 l 
GBEARTB 20 19 POLY (2)  16 0 20 0 D O O O 0 . 025 
U6 ao o 1a2s 
CMUSCLE 21 0 & IC•lR 
GJIUSCLE 19 21 POLY (2)  87 0 19 0 0 0 0 0 l 
GIIUSCLBB 21 19 POLY ( 2 )  87 0 21 0 0 0 0 0 0 . 1 11 
R37 21 0 1B25 
CRIJI 22 0 a . s  IC•lR 
G$UJI 19 22 POLY (2) 88 0 19 0 0 0 0 0 1 
GRIIIB 22 19 POLY (2)  38 0 22 0 0 0 0 0 0 . 111  
R38 22 0 1B25 
GUDDY 19 23 POLY (2)  89 0 19 0 0 0 0 0 l 
aID1'EY 23 0 0 . 05 IC•lR 
GUDJraYll 23 19 POLY (2)  39 0 23 0 0 0 0 0 0 . 005 
. PRINT TRAN V( 19) V(20) 
R35 19 0 1B25 
R39 23 0 1B25 
GURDIE 23 24 23 0 0 . 012 
CURDIE 24 0 1 IC•lE-.5 
R40 24 0 lB25 
GLIVER 19 25 POLY (2)  40 0 19 0 0 0 0 0 1 
CLIVER 25 0 0 . 25 IC•lN 
GLIVBRB 25 19 POLY (2)  41 0 25 0 0 0 0 0 0 . 066'7 
GIIETAB 25 28 25 0 O . OS54 
CKETAB 28 0 1 IC•lE-4 
R44 28 0 lE25 
R41 25 0 1E25 
GGUTVAL 19 26 POLY (2)  42 0 19· 0 � 0 0 0 l­
GGUTVALB 26 25 fOLY ( 2 )  43 0 26 0 0 0 0 0 0 .  0333 
R42 26 0 lB25 
CGUTVAL 26 0 0 . 24 IC•lR 
CGUTCON 27 0 0 . 42 IC•,lE-5 
GGUTCON 26 27 26 0 0 . 106 
GGUTCOllB 27 26 27 0 0 . 0924 
GFECES 27 29 27 0 0 . 04 
CFECBS 29 0 1 IC•l'O 
R45 29 0 1E25 
GBILE 25 27 25 0 0 . 0333 
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TABLE 3 . 26 contd . 
Jl43 27 D 1B25 
• TRAIi O .  16667 80 . 18667 VIC 
PPLASIIA O 85 VPLASIIA l 
PBBART O 86 VBBART l 
PIIUSCLE O 8'7 WOSCLB 1 
PBIR O 88 VBlR 1 
PUimEY O 89 VUDIIBY 1 
PLIYDl O 40 VLIYBRl 1 
PLIVBR2 'l 41 VLIVD2 1 
PGUTWAL O 42 VGtmfAL 1 
PGtmfALB O 43 VGtmfALB 1 
R8 S5 0 1 
Jl9 86 0 1 
JtlO 37 0 1 
Jlll SB O 1 
R12 S9 0 l 
RlS 40 0 l 
ll14 41 0 l 
Jll5 42 0 l 
Jll6 l O lB25 
Rl7 2 0 1B25 
RlB S O lB25 
Rl9 4 0 1B25 
R20 5 0 1B25 
R21 6 0 lB25 
R22 7 0 1B25 
R23 8 0 1B25 
R24 9 0 1B25 
R29 14 0 lB25 
Jl46 85 0 1B25 
ll47 S6 0 1B25 
ll48 87 0 1B25 
R49 88 0 1E25 
R50 89 0 1B25 
Jt51 40 0 1B25 
ll52 41 0 1B25 
Jl53 42 0 1B25 
ll54 43 0 lE25 
R55 43 0 l 
. OPTIORS ITL1•500 ABS'l'OL•lP VR'l'OL•iR RBL'l'OL• lU RODE LIST ROPAGE 
.OP 
.DD 
Typ ica l  program l i·st i ng for SPI CE2 . The program l i sti ng i s  
for a phys iol og i c  phannacoki neti c model  for d i gox i n  i n  dogs 
(G i ba l d i  a nd Harri son ,  �977 } .  
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Fig. 3.28 gives the SPICE2 simulated concentrations of digoxin in the plasma 
of a 10 kg. dog given a 0.05 mg/kg. dose of digoxin i.v. 
The three sets of data points ( denoted by O's, 1 's and 2's) are the actual serum 
levels that were obtained experimentally in three dogs administered 0.05 mg/kg. i .v. 
There is good agreement between the actual observed values and those predicted 
by SPICE2 using the digoxin model. 
Statistical comparisons were made on the simulations obtained using SPICE2 
and those obtained using GPPM and CSMP. The simulated values obtained from all 
three programs were very much similar to each other as evident from the correlation 
tests and regression procedures (table 3.27) . 
Regression of SPICE2 simulated values against simulated values obtained us­
ing CSMP and G PPM resulted in slopes of one and intercepts very close to zero 
indic.ating t.he similarity of the values obtained . 
.4.pplicat 10n to pharmacodynamics 
It wa5 intended to simulate digoxin levels in the heart using the physiologic 
model and to relate it to the bradyc.ardic' ef
f
ect observed in studies 4, 7, 9 and 
10. Simulations of digoxin plasma levels using the model of Harrison and Gibaldi 
( 1977b) , did not agree with the plasma levels of d igoxin observed in studies 4, 6, 9 
and 10. However. the same model was useful in predicting plasma levels of digoxin 
in the initial pharmacokinetie studies (fig. :3 .28 ) .  A possible explanation is that the 
plasma to tissue partition coefficients used in the physiologic pharmacokinetic model 
by Harrison and Gibaldi ( 1 977b) are obtained at equilibrium. Hence the model does 
not accurately predict the levels of digoxin in the distributive phase i.e. the first 6 
hours (which comprise most of the data from studies 4 .  7. 9 and 1 0  ) .  The model 
was therefore modified to simulate the levels observed in the above studies. This 
involved altering the plasma to tissue partition coefficients. The el imination rate 
constants were assigned values obtained from pharmacokinetic analysis of the data. 
-
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SPICE2 vs . GPPM 
l t PLASMA CONC , (.SPI CE2 ) 
vs . 
PLASMA CQNC ,  (�PPMl 
21. H.EART CONC . LSP I CE2l 
vs t 
HEART CONC ,. U1PPM). 
SPl.-CE2 V$ � CSMP 
1 ). PL.ASMA CQNC t (SP.!CE2 )_ 
vs , 
PL.ASMA CONC ! LCSMP ) .  
21.. H.tA�T CQNC , (. SPICE2 ). 
V$· . 
HEART CONC , ( CSMP ). 
SPEARMAN , KENDALL 
AND PEARSON 
CORR. COEFF . 
1 
1 
l 
l 
REGRESSION MODEL 
PLASMA CONG . · (SPICE2 l = 
PLASMA CONG . (GPPM) - 0 . 0025 
HEART CONC .  ( SPICE2 } = 
HEART CONC . (.GPPM } - 9 . 55xl0-5 
PLASMA CONC . (.SPJ'CE2 }_ ::; 
PLASMA CQNC . (CSMP l. + 4 .lxlo�5 
HEART CONC . tSPICE2l. = HEART CONC , CSMP l. + 9 . 3xl0�5 
R2 
1 
1 
1 
TABLE .3 . 27  Ta:bl e  comparing concentraUons i n  the pl asma arid fo the heart a s  s imul ated · 
b.y SPICE2 to those obta in�d us i ng CSMP and GPPM . Concentrati"ons were stmul ated 
fQr a 10. kg . dog a'dmi nistered a .as mg/ kg of d igoxi:n i . v .  
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The model developed was found to predict the observed concentrations extremely 
well. The simulations are given in figs. 3.29, 3.30 and 3.31 
The levels in the heart were then simulated. The results of the simulation may 
be seen in figs. 3.32 and 3.33 
It is observed that the bradycardic effect does not correlate well with the sim­
ulated levels in the heart. In fig. 3.32 and 3.33 the peak levels of digoxin in the 
heart occur much earlier than the peak bradycardic effect. This implies that the 
biophase for the bradycardic effect for digoxin may be a subcompartment of the 
heart whose diffusion characteristics are different from those of the highly perfused 
regions. However efforts at modelling the biophase as a subcompartment of the 
heart were not successful. This may indicate that the biophase for the bradycardic. 
effect. of digoxin may lie in a compartment other than the heart . This is possible 
since the heart rate is strongly influenced by the sympathetic and parasympathetic 
controls on the. heart . The biophase then could bE' thE' nodose gangliqn or the carotid 
sinus (Chai et al., 1967; Higgins et al., 1973; Abiko 1963; Eliakim et al., 1961). The 
tissue to plasma partition coefficients used to fit the plasma concentration time 
profile obtained in the pharmacodynamic studies (studies 4, 7, 9 and 10) are arbi­
trary values. Therefore, the simulated concentrations in the heart obtained from 
this model may not be predictive of the true concentrations observed in the heart. 
This could be a possible explanation for the lack of correlation between simulated 
conceptrations of digoxin in the heart and the observed bradycardic response. 
Discussion 
Pharmacokineticists have long recognized the fact that the compartments in 
conventional models, cannot usually be translated directly into the physiologic or 
anatomic regions that they represent. Hence� the concentrations of drug in specific 
organs of the body. where the toxic or therapeutic responses may be elicited cannot 
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be obtained from conventional models. A few examples where such information is 
needed are: 
1) concentrations in the heart (cardioactive drugs) e.g., digoxin. 
2) concentrations in the brain for monitoring CNS effects, e.g., side effects, of 
digoxin, and therapeutic effects of antipsychotic drugs. 
3) concentrations in the CNS, e.g. , (anesthetics) lidocaine, thiopental. 
4) concentrations in tumors of anti-cancer drugs, e.g., methotrexate, adriamycin. 
Since regions such as brain, tumor or heart are not accessible in clinical practice, 
models that will simulate the levels of drugs in these compartments are neeeded. 
Such models can also be used to design dosage regimens to achieve desired drug 
levels in a target organ. The interest in physiologic pharmacokinetic models has 
also been partly fueled by the renewed interest in pharmacodynamics. This is 
because in order to completely define a drug effect we must know not only its 
kinetics ! but also the relationship between levels in the various tissues and the 
observed therapeutic and adverse responses. Comprehensive, descriptive models 
and techn iques are thus needed to simulate the levels of the drug at the biophase 
which may then be related to the observed pharmacodynamic response(s) .  SPICE2 
would appear to fulfill these requirements. It is · a simple, yet powerful, simulation 
program that can simulate complex systems by using network thermodynamics to 
describe the physiologic pharmacokinetic models. 
SPJCE2 provides several advantages over conventional simulation techniques, 
including: 
1) It requires no knowledge of computer languages such as FORTRAN. SPICE2 
is a tool that one can use without having to master complex computer languages. 
2) SPJCE2 programs were found t.o be more robust than the CSMP and GPPM 
programs. The GPPM program bas the drawback of a fixed step size for compu­
tational and print-out routines. Tliis led to abnormal termination of the program 
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when using smaU step sizes. Tightening the error limits could also led to abnormal 
termination of the program. 
3) Multiple dosing is very easily simulated using PULSE or PIECEWISE LIN­
EAR functions. This can be accomplished by connecting an independent current 
source IDOSE to the plasma compartment (node 19 in fig. 3.25) . The PULSE 
function is then defined as follows: 
!DOSE N ... N- PULSE (Vi V2 TD TR TF PW PER) 
where, 
Vi = initial val'ue 
V2 = pulsed value 
TD = delay time 
TR = rise time 
TF = fall time 
pJ,l,' = pu.lse width 
PER = period 
The period (PER) above can be used as the dosing interval. The pulse width 
(PW) is assigned small or large values depending upon whether an intravenous 
bolus dose, or a slow i.v . infusion is required. Oral dosing can be similarly simu­
lated by connecting the source IDOSE to a G element, which in turn is connected 
to the plasma compartment. The value assigned to the G element would be the 
rate constant for t.he process of absorption of drug in to the plasma compartment. 
Thus by introducing only two additional cards describing IDOSE and the PULSE 
specifications,  the sophistication of simulating multiple dosing can be added to an 
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existing model. The original program requires no reinitialization, since the dose is 
directly introduced into the desired compartment in the fashion desired. 
Conventional programs (including GPPM and CSMP) require the original pro­
gram to be drastical1y changed to convert. an existing model for oral dosing, to 
a model for rnu]tiple dosing: or, vice-versa. Also, conventional programs require 
reinitialization steps after every dose administered 
4) In most cases : extra compartments or additional sophistication can be in­
troduced into the main SPICE2 program by introducing additional cards . These 
cards can be introduced anywhere in the existing program. Conventional programs 
do not offer this advantage, since the main program or subroutines would have to 
be re-written. 
5) One of the salient advantages tha.t SPICE2 offers is the ease with existing 
programs can be modified. Ex., deleting one card describing GBILE in fig. 3.25 
gives a model of a bile-ligated rat (dog or human : depending upon the model in 
use).  Similarly. deleting the card describing GURINE converts the model to that 
of a. ureter-ligated rat. 
6) The SPICE2 program can also simulate sophisticated physiologic pharmaco­
kinetic models which additionally specify the residence times of the drug in the 
various compartments. SPICE2 can also simulate with considerable ease, physio­
logic phenomena like gastric emptying (Thakker et al., 1982), urine flow, and drug 
responses such as increasing cardiac output with time. 
This can be a very important feature with cardioactive drugs (e.g., digoxin) 
which increase cardiac output as a function of time, thus altering drug kinetics. For 
the example given in fig. 3.25, the cardiac output can be changed over time by as­
signing the independent current source, !PLASMA, a time-dependent value(s) or by 
using the independent source functions: PULSE. PIECEWISE LINEAR. Another 
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example of physiologic response that can be varied is the increase in splanchnic flow 
in response to various stimuli (e.g., food) . 
Conclusion: 
It has been demonstrated that SPJCE2 can be used to simulate physiologic 
pharmacokinetic models and that the physiologic pharmacokinetic model may be 
extended to model drug pharmacodynamics. SPICE2 can be used as a powerful 
simulation tool by clinicians, physiologists and pharmacokineticists, due to the rel­
ative ease with which it can simulate complex systems. SPICE2 possesses distinct 
advantages over conventional simulation programs such as CSMP and GPPM. It. 
can be used to simulate physiologic pharmacokinetic models, to obtain simulated 
concentrations of drugs in the various physiological compartments in order to relate 
them to their obseTVed therapeutic and non-therapeutic responses. Using SPICE2 
and physiologic. pharmacokinetic models, we thus have the capability to obtain sim­
ulated drug concentrations in the various organs in the body. This information 
can also be used to design dosage regimens, to give desired concentrations in the 
target organ, or to avoid undesired side effects due to accumulation of drug or its 
metabolite(s) in organs other than the target organ. 
CHAPTER 4 
DISCUSSION 
The primary objective of the research was to develop and evaluate analytical, 
pharmacokinetic and pharmacodynamic methods for the study of digoxin . 
Plasma digoxin samples obtained from studies conducted in normal beagle dogs 
were assayed using the HPLC-RIA and R IA procedures. It was observed that there 
existed little difference between the values obtained using the HPLC-RIA and RIA 
methods. This implies that upon digoxin administration, significant amounts of 
metabolites are not formed by the normal beagle dog. Since plasma samples of 
digoxin were obtained frequently in the initial distributive phase as wel l  as over a 
period of 72 hours (post digoxin administration) .  h seem� apparent that. significant 
amounts of metabolites are not formed or do not accumulate in the normal dog. 
This correlates well with the information available on humans . Gibson and Nelson 
( 1979� 1980) reported that the values obtained were essent.ially ident-ical in patients 
with glomeru)ar filtration rates greater than 40 ml min. They suggested that the 
differences in the values may be significant in patients with renal failure presumabl-y 
due to accumulation of cross-reading metabolites. The specific HPLC-RIA assay 
developed could be of clinical value in determining digoxin levels in patients with 
poor renal function . The assay would also be of value in studies with digoxin in 
dogs with induced renal failure or altered renal function. Based on these studies it is 
possible to conclude that for studies in dogs with normal renal function. the greater 
specificit.y achieved with the use of specific. HPLC-RIA assay is not, necessary and 
the conventional RIA would generally be sufficient. 
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Having developed a specific method for assaying digoxin, the next objective 
was to develop and evaluate pharmacokinetic and pharmacodynamic methods for 
studies in dogs. Conceptually, the relationship between pharmacokinetics and phar­
macodynamics may be depicted as in figure 4.1 
It is necessary to simultaneously monitor both the plasma levels of drug and the 
response over time, to characterize the pharmacokinetic-pharmacodynamic model. 
There have been very few studies that have investigated digoxin pharmacokinetics 
in dogs. Hence. the initial studies conducted were primarily designed to elucidate 
pharmacokinetics of digoxin in beagle dogs. Results of the compartmental analy­
sis conducted (tables 3.5 and 3.6) indicate that digoxin disposition in dogs is best 
described by a tri-exponential equation. The terminal half-life for the initial phar­
macokinetic studies was 57 .5 hrs. and 46.2 hrs. for dogs 2 and 3. However a half-life 
of 216.56 hrs. was estimated for dog 1. This enormously large half-life for dog no. 1 
is probably an artifact arising from fitting the data to a tri-exponential equation 
and the weighting function used. Another probable reason is that the changes in 
concentration observed during the terminal elimination phase border on the lower 
limits of the sensitivity of the assay. The la.rge half-life for digoxin observed for 
dog no. 1 on using a tri-exponential equation could possibly be an. artifact since a 
half-life of 46.2 hrs. was estimated using a bi-exponential equation to describe the 
data. This is supported by observed half-lives of 49.5 hrs. for both dogs 2 a.nd 3 on 
using a bi-exponential equai.ion to describe the data. However, statistical analysis 
of the plasma concentration vs. time data from initial pharmacokinetic studies and 
the pharmacodynamic studies indicate a tri-exponential equation to be superior to 
a bi-exponential equation. 
Pharmacodynamic st,udies using digoxin in dogs revealed linear relationships 
between LVET, ,QS2 and PR-intervals vs. HR. Similar relationships have been es­
tablished for humans by Weissler et al., (1966, 1968). These re1ationships have 
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not been established before in dogs. Further there have been no studies in which 
LVET has been non-invasively determined in dogs. The exteriorization of the 
carotid artery in the dog provides a method of non-invasively measuring LVET 
(post surgery) in the dog. T his represents an important contribution to the use of 
the dog as a model for investigating digoxin pharmacodynamics . It should be noted 
that although linear relationships exist between STI and HR, the slopes and the 
intercepts for the relationship obtained in dogs is not identical to those observed 
in humans. It is observed in figs. 3.1 ,  3 .2  and 3.3 that the dog no. 5 (study no. 
lB) , does not obey the same linear relationship. As mentioned before dog no. 5 
was different from the other dogs in that dog no. 5 was a mqngrel whereas the 
dogs used in the remaining studies were beagles. Dog no. 5 also had a much lower 
basal HR compared to the other dogs. Further dog no. 5 was not under anesthe­
sia, whereas the studies in beagles were conducted under anesthesia. T he serum 
potassium levels and the thyroid function for all the dogs were normal. Any one or 
more of the above mentioned factors could be contributory to the different linear 
relationship observed in the case of dog no. 5. This is indicative of the differences 
in the observed pharmacodynamic relationship that may arise from differences in 
experimental conditions or selection of experimental animals. 
Similarities in the relationship between HR and STl in dogs and in humans 
indicate the �dequacy of the dog as a model for investigative pharmacodynamic 
studies. Further 2 or 3 compartment models have also been used to describe digoxin 
disposition in humans ( Sumner et al., 1976, Shenfield et al., 1977, Koup et al., 
1975). T he half-life for digoxin in humans and in dogs is similar. Also, the plasma 
concentration vs. time profile following the administration of a single dose of digoxin 
may be described by a tri-exponential equation in both dogs and humans indicating 
the dog to be an adeq-q.ate model for investigational pharmacokinetic studies using 
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digoxin. These studies therefore indicate that the dog is an adequate model for 
investigative pharmacokinetic-pharmacodynamic studies with digoxin. 
Pharmacodynamic modelling of the STI was investigated. The STI viz. , P­
R interval, LVET, QS2 and PEP, as a function of time after administration of a 
intravenous dose of digoxin, is given in figures 4.2-4.9 The data did not lend itself 
well to pharmacodynamic modelling. Also, as mentioned before, the STI were 
related to the the HR. Further: the bradycardic response to digoxin was readily 
monitored and lent itself to pharmacodynamic modelling. For the the above reasons 
the bradycardic response to digoxin was primarily investigated for the purposes of 
pharmacodynamic modelling. 
Quest and Gillis (1972) , suggest that the rapid initial fall in HR after digoxin 
is probably due to sensitization of the carotid sinus a.nd aortic a.rc11 ba.roreceptors. 
A direct effect of digitalis on the sinus node could not be demonstrated (Ten Eick 
and Hoffman ! 1969) . Pace et al. , (1974) ,  also suggest that the most important 
mechanism involved in the effect of digoxin on the sinus and AV-node may be reflex 
inhibition of the nervous system. 
Abiko et al., (1963) , suggest the vagus nerves which contain both afferent and 
efferent fibres and the sympathetic nervous system as pathways through which the 
bradycardic response to digoxin may be media.ted. These two systems are inde­
pendent of each other in producing cardiac slowing. Impulses sent to the central 
nervous system through the sinus nerves are suggested to exert an inhibitory ef­
fect on the sympathetic center. This effect may be relayed to the heart through 
the cervical cord and the stellate or nodose ganglia. Yet another mechanism that 
has been suggested is that cardiac glycosides stimulate chemoreceptors in the body. 
It was suggested that the impulses originate in the chemoreceptors in the carotid 
body, pass through the cervical cord an4 the ste11ate ganglia to the heart to exert an 
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inhibitory effect on the heart rate. It is probably due to these two co-existing path­
ways that, administration of either atropine or propanolol alone, does not abolish 
the bradycardic response to digoxin in animals (Higgins et al., 1973) . 
Having conducted pharmacodynamic st,udies in dogs, the next objective was 
the modell iJ?-� of digoxin induced bradycardia as a pha.rmacodynamic response. It 
has been noted that simultaneous fitting of pharmacokinetic and pharmacodynamic 
data is perhaps more desirable that individually fitting the data (Sheiner et al. 
1979) . However, he noted that little harm �s done in fitting the pharmacodynamic 
data. alone when the pharmacokinetic data is well defined by the fitted equation . 
Kramer et al. , ( 1979) . however, suggest that in attempting to establish a relation­
ship between drug levels and response it is important. that the relationship not be 
"forced" by the simultaneous fitting of both drug level-time and response-time data. 
As discussed earlier: the pharmacokinetic data in all the studies conducted were 
very well describied by a tri-exponential equation, with correlation coefficients and 
R-square values of greater than 0.90 The pharmacodynamic models investigated 
were therefore fitted to the response-t,ime data alone, instead of a simultaneous 
fitting of respons,e-time and concentration-time data. 
Linear Model: 
The l inear model used was essentially that of Kelman and Whiting (1980 ) .  
The model did not. adequately describe the <lat.a in all the studies. The model 
suffers from several drawbacks. The model c�nnot be used to extrapolate or to 
predict pha.rmacodynamics when d ifferent doses are used . The model is related to 
simulated levels in the central, shallow and deep compartments. This implies the 
presence of multiple receptors of varying sensit.iv it}·· A lso, the negative coefficients 
obtained upon regression (tables 3 . 19 and 3.20) imply the existence of receptors 
with opposing functions. This has detracted from the acceptance of this model by 
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previous investigators. The implication of multiple receptors may be unacceptable 
in the case of many drugs since it implies a non-specific effect site or multiple ef­
fect sites. However for the bradycardic effect of digoxin the existence of multiple 
receptors may be reconciled by the observation that the HR is controlled by both 
sympathetic and parasympathetic controls which have opposing functions. The 
feedback mechanisms that control the HR may therefore account for the negative 
coeffici�nts observed. Comparison of tables 3 . 19 and 3 .20 reveal �hat better cor­
relations are obtained using a mode] without an intercept term as compared to 
using an intercept term. The inclusion of an intercept term is also physiologically 
unappealing since it implies the existence of an effect (a change in heart rate) when 
no drug has been administered. For study no. 7 table 3 .20 shows values of -17  .87, 
337 .46 and 70.88 for 'b'. 'c, and 'd,; the coefficients relating the observed effect to 
the simulated �mounts in the central shallow and deep compartments respectively. 
The values are associated with relatively large standard deviations. Although fairly 
good R-square values and correlation coefficients are obtained using the model, a 
plot of the predicted and the observed response against time reveals the inadequacy 
of the model (Fig. 4 . 10  and 4 . 1 1 ) .  
I t  i s  apparent from the figures that the model does not adequately explain 
the pharmacodynamics of the bradycardic effect of digoxin. Although not accepted 
by some invesi igat,ors: the existence of multiple recepi,ors sites is reasonable since 
the pharmacokinet.ic compartments may include various subcompartments at the 
physiologic effector site v iz . ,  heart. Further, negative coefficients are physiologically 
mean!Iigful since t hey may be indicative of the co-existence of physiological feedback 
. . 
mechanisms at the effector site. The observed negative or positive coefficients would 
then be dictated by t.he dominance of a particular type of receptors over the other. 
The model is .simple and shows promise, but bas not yet been shown to be appJicabJe 
to a specific drug. 
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The Linking Model. 
Another model investigated was the linking model. The simulated levels in 
each of the pharmacokinetic compartments was linked to the observed response. 
(% decrease in bradycardic effect) through a linear relationship. The simulated 
amounts of drug in the various pharmacokinetic compartments was related to the 
response. This relationship may be expressed as follows: 
where E = measured response i.e. , % decrease in HR 
S = sensitivity constant 
Xi = simulated amount of drug in itb compartment. 
. . .  (4. 1 )  
The measured response was plotted against the simulated amounts of drug in 
the various pharmacokinetic compartments to determine whether such a relation­
ship was visually discernible. The pharmacokinetic models investigated were the 
three compartment mammillary, catenary and first pass models. For study no. 4 
the biophase was identified to be in the pharmacokinetic shallow compartment for 
all three models. However for the remaining studies the biophase could not be 
identified with any of the pharmacokinetic compartments. The implications of this 
finding are noteworthy. It indicates that: 
1) The biophase may be identifiable with the pharmacokinetic compartments only 
when the amount of drug in the biophase i.e. at the receptor site is large enough to 
contribute to the mass balance of the drug and therefore contributes appreciably 
to the observed pharmacokinetics of the drug. 
2) In consideration of the above, when the biophase is not readily identifiable with 
any of the pharmacokinetic compartments, the conventional compartmental ap­
proach of describing drug kinetics cannot be extended to describe the pharmacody­
namics of a drug. 
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For study no. 4 the biophase for all three models ( three compartment mam­
millary, three compartment cate�ai:y an.cl the three compartment first pass) was 
identified with the pharmacokinetic shallow compartment, indicating that the three 
models are unidentifiable based purely on the pharmacokinetics of the drug in the 
central compartment and based on its pharmacodynamics. Supportive reasoning 
for this observation is supplied below: 
For a three compartment first pass model , the amount of drug in the pharmacoki­
netic shallow compartment (X2) is given by eqn . (3.  7) . viz. , 
X2 = k 1 2D [ (Es - a) e-oct + . (E3 - (3) e-f3t + (Es - ,) e--rt ] (.B - a) (, - a) (a - 8) b - (3) (a - ,) ((3 - ,) 
The amount of drug in the pharmacokinetic shallow compartment for the 3 
compartment mammillary and catenary models is given by equations 3 .4 and 3 .10 
respectively. Equations 3 .4 ,  3.7 and 3 . 10 appear to be identical. However, these 
equations are not identical since, although the numerical values for a, fi: and 1· 
are identical the numerical values obtained for Es is disimilar in each of the models 
considered. For the 3 compartment mammillary model and the 3 compartment first 
pass model Es = ks 1 and for the 3 compartment catenary model Es = ks2 - Also 
a and (3 are much larger than 'Y, therefore the amount in the shallow compartment 
during the distributive phase, is largely dictated by the first two terms in equations 
3.4, 3 .7  and 3 .10 And, since a and {3 are much greater than Es , similar profiles 
for the amount of digoxin in the shallow compartment as function of time, are 
obtained using equations 3.4, 3.  7 and 3 .10 And since, the biophase is identifiable 
with the shallow pharmacokinetic compartment, the 3 models investigated are non­
identifiable. Based on the results arrived at: the inadequacy of a pharmacokinetic 
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model with a linear linking model m describing digoxin induced braydcardia is 
evident. 
Physiologic-pharmacokinetk model with a linear linking model. 
The physiologic-pharmacokinet.ic model with a linear linking model was investi­
gated. The model is quite complex and incorporates a large number of parameters 
viz. , blood flows to the various compartments, tissue to plasma partition coeffi­
cients for the various compartments, volumes of the compartments etc. These may 
be used as constants if accurately determined. The physiologic-pharmacokinetic 
model proposed by Harrison and Gibaldi (1977) , did not accurately predict digoxin 
concentration-time profile in the first 6 hours, although the model was quite ad­
equate in predicting the concentration-time profile in the post-distributive phase. 
The physiologic-pharmacokinetic mod.el was therefore modified by substituting var­
ious values for the tissue to plasma partition coefficients until a good visual fit was 
obtained between the observed and the model predicted concentration-time profiles 
(fig. 3.29-3.31) . Since, the tissue to plasma partition coefficients used in (modifying 
the model) were not, experimentally determined, they may not reflect the actual 
tissue to plasma partition coefficients that exist among the various compartments. 
This physiologic-pharmacokinetic model was used to simulate the levels of digoxin 
in the heart. It was attempted to relate the levels of digoxin in the heart to the 
response using a linear linking model. The model did not adequately predict the 
bradycardic response observed. 
The tissue to plasma partition coefficients used could possibly be a contrib­
utory factor for the observed inadequacy of the model. However, the physiologic 
pharmacokinetic model shows promise as a powerful investigative tool. It has the 
capability to predict the concentrations at the physiologic site of action. Further 
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since it incorporates the blood flows it can account for changes in the pharma­
cokinetics and pharmacodynamics of a drug due to local or systemic changes in 
blood flow. This could be a very important factor particularly with a drug like 
digoxin since it increases cardiac output in patients with congestive heart failure. 
The pharmacodynamics of digoxin could therefore be constantly changing with. an 
improvement in cardiac function. 
The physiologic-pharmacokinetic model was simulated using SPICE2. SPICE2 
is a computer program that, uses network thermodynamics to describe physiological 
systems. A detailed description of SPICE2 and its capabilities ·have been described 
in the previous chapter. 
The Effect Compartment Model 
Another model evaluated was . the 'effect compartment' model. The model 
proved quite satisfactory in describing the pharmacodynamic data obtained in all 
the studies. This was evidenced in the low residual sum of squares, the R-square 
values, correlation coefficients and from plots of the predicted and observed response 
against time (Fig. 4.12 and 4.13).  
However, a large variability is observed in the parameters describing the model. 
Large differences in the E eo are not observed for studies 7: 9 and 10 in which the dogs 
were dosed at 0.05 mg/kg. However apreciable differences are seen in the Keo values 
for study 4 and 7 which were studi1es conducted in the same dog. The dose of digoxin 
administered was 0.025 and 0.05 mg/kg. for studies 4 and 7 respectively. The Keo 
for study no. 7 (0.0088 min- 1 ) is much smaller than the value obtained in study no. 
4 (0.042 min- 1 ) .  The longer half-life for the decline of response with time, for the 
lower dose in for study no. 7, seems to suggest. that saturation of the bradycardic 
effect in dogs does not occur even at a dose of 0.05 mg/kg. of digoxin. The value of 
CPss (so) ranged from 3.77 ng/ml to 9.84 ng/mJ. This is the predicted steady state 
4"°3 
X -l 
D � 
� asj 
E � 
A :l 
s j 
: 291 
N "' 
� 
H :: 
R 1� 
� . 
� 
EFFECT COMPARTMENT MODEL 
STUDY ND. 9 
• 
• 
• • • • • • 
• • • 
• • 
• • • • • • 
• 
• 
.U,.,.,. l"""=T" =•• "T''"" '""1""'='"T""""'1'=•• n•r=nn:•p-n=n1 nn=,,.....�n""l= 
0 se 1EJIII 1S!I 2"8 25111 ase 35111 400 45e see ss0 
TIME <MINS. > 
OBSERVED • • • •  PREDICTED • • • .t. • 
Fig. 4 . 12 Bradycard i c  response to d i gox i n  pred i cted by t�e effect compartment model . 
The response i s  the observed response on admi n i stra tion  of 0 . 05 mg/kg . d igox i n  i . v .  ( i nfused un i formly over 5 mi ns . )  to a norma l beag l e  dog . 
N 
.$:>, w 
1 
. 7  
EFFECT COMPARTMENT MODEL 
STUDY NO. 18 
• 
• 
• 
• 
• 
25-1 
D j 
E J 
C � 
R 28-! 
E � 
A 
s � • 
E 15:1 
• 
• 
I j 
N 
H 
1
"1 • 
R � 
• 
• • 
iJ  . . . 
�
-r·r.,-•r , , , , , I , , , , , 1...-r-T"TTTr-,.-r,-,,r..--r·,...,..,-.-.......... .,-y-,:.-....... r, , , , , , , 
• 
8 ea J28 188 248 388 
TIME <MINS. > 
OBSERVED ca 111 111 m 
3e8 '428 488 
PREDICTED • • • • A 
548 ea, 
Fig. 4 . 13 Bradycard ic  response to d i goxi n as predicted by the effect compartment model . 
The bradycardi c response i s  the response observed on the admi ni stration of 
0 . 05 mg/ kg . di goxi n i . v .  ( i nfused un iformly over 5 mi ns . ) to a no·rmal 
anestheti zed beagl e dog . 
N 
� 
� 
245 
plasma concentration of digoxin that will effect 50% of the maxima] response. One 
of the drawbacks of using a sigmoid relationship to describe a pharmacodynamic 
response is the need to determine Emax, the maxiima] response. This may be used 
as a constant if it can be accurately determined. However some in vivo systems 
do not permit an accurate determination of Emax since the maximal response may 
be associated with concomitant non-reversible changes or death and hence wou]d 
be of very little or no clinical vallue. The effect compartment model was therefore 
modeled wit.h Emax assigned a value of 100 (i.e. a 100% decrease in HR) : as a 
variable or assigned a va]ue equal to the observed maximum response. A mode] also 
investigated was one in which the response modelled was not the per cent decrease in 
HR, but HR itself (JC50 model) . All of the models adequately described the data. 
DELTA (S) values ranged from 0.60 to 7 . 12  These values have been previously 
proposed as an indication of the number of drug molecules interacting with the 
receptor molecule. However it has also been noted that such an interpretation is 
not often applicable since the S values obtained are often non-integers . T hese values 
do however indicate the steepness of the response-concentration relationship. This 
may be visualized in fig . 4 . 14, where the effect of changing S values is demonstrated 
(CP:s:s{&O) is held constant at 7.94 ng/ml. ) .  
Comparison of various models 
Comparison of the various models based on their adequacy of describing the 
data, SSE, F-tests and AIC revealed the the effect compartment model with Emax 
as a variable to be the best mode]. The model adequately described the data 
obtained from aU of the pharmacodynamic studies conducted (studies 4-10) . After 
the model has been identified, and the parameters describing the model have been 
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determined (CPss (50) and 8) , the model may be used to predict the dose-response 
curve for steady state concentrations of drug using eqn. (4.2) . 
. . .  (4.2) 
where Cp88 is the concentration in the blood or plasma compartment at steady 
state, and E(%) is the response observed as a percent of the maximum response. 
The model can also be used to predict the respone-time profile for any known 
concentration-time profile. The effect compartment model is model-independent in 
its approach since it does not presume a pharmacokinetic model but utilizes an 
exponential equation that best describes the concentration-time profile. 
Variability in the monitored response 
Results of studying and modelling the bradycardic effect of digoxin reveal a 
large variability in pharmacodynamic response. Further, as mentioned before the 
variability in the response prevented modelling of STI as the pharmacodynamic 
response. The inherent variability and the oscillatory nature of the STI and HR 
require these responses to be monitored freqently ( or continously, if  possible) to 
completely characterize the response-time profile. The results of studies 4 to 10 
indicate that the observed bradyca.rdic effect may also be related to the basal heart 
rate prior to administration of digoxin and also to the levels of sympathetic and 
parasympathetic simulation that exist. This may also be responsible for the oscil­
latory nature of the data. 
Kramer et al., ( 1979) , also reported that the variability inherent in the re­
sponse measurement, both intrasubject. and intersubject. l imited their quantitative 
treatment of 1),,,QS2 1 data: in their pharmacodynamic studies with digoxin in 12 
normal volunteers. They found that although a rel�tionship could be established 
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for averaged data from 12 subjects, the same relationship could not be established 
for individual subjects. The results of their study suggested that further efforts 
designed to develop more reproducible measurements for digoxin response would be 
desirable. 
Applications of the effect compartment model 
The pharmacodynamic models investigated reveal that the pharmacokinetic 
model with linking pharmacodynamic models and the linear model may not be 
adequate in describing the pharmacodynamics of a drug. The effect compartment 
model on the other hand is predictive of pharmacodynamic effects at steady state 
and hence is of clinical value in this respect. Also, it adequately describes data even 
in situations where the drug in the biophase may not be present in amounts large 
enough to contribute to the observed mass balance of the system. 
1) Duration of effect: 
The model will enable estimation of the cumulative effect, since the overall drug 
effect may be given by 
- J Cpt. 
E = Emaz 
C .J.. C E 
• dt , 
Pss(50) · P 
. . .  (4 .3) 
where E is the cumulative effect over a certain time period. The model will also 
enable better understanding of the relationship of drug levels to response during 
the different phases of drug disposition in the body e.g., distributjon, elimination. 
When concentrations are much larger than the Cpt1s(SO) the effect will be close to 
the maximal effect and will show little change for large changes in concentration. 
For concentrations between 20% - 80% of the Cp88(so) the effect will change in 
proportion to the change in concentration, although the proportionality constant 
to this change is related to the b value for the mod�l. 
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2} Influence of dosing regimen 
The overall drug effect is given by eqn . (4.3) . Gp is a constant at steady state 
fo1lowing continous infusion, but varies over the dosing interval if the dosing is 
intermittent. Equation (4.3) enables mathematical estimation of the differences in 
clinical benefit that may result due to changes in the overall effect arising from 
differences in dosing. This could be important e.g. :  if the peak levels of drug are 
associated with toxicity and the trough levels with therapeutic benefit. 
9) Investigative pharmacodynamic studies 
The effect model for the bradycardic response to digoxin may be incorporated in 
pharmacodynamic studies measuring cardiac response so that these responses may 
be corrected for contributions made by concomitantly occuring changes in heart 
rate. Similar models may be derived in clinical situations. These models would 
then afford the capability of accurately predicting heart rate and cardiac function 
in clinical situations. This could be important when patients ar,e administered 
more than one drug that contributes to or affects cardiac function.. The b values 
and Cp88 (so) values derived for a patients would then help individualize therapy 
and drug effect monitoring. 
4) As  a predictor of drug levels 
The usefulness of the effect mode] in predicting the response for a known drug con­
centration is the body has been discussed earlier. Conversely, provided the time and 
route of administration of drug are known, the effect- model may be used to predict 
the concentration of drug in the body any time (t) for a given measured response at 
time t .  These models could therefore reduce the frequency of venupuncture associ­
ated with drawing blood samples for drug level monitoring. Such models could also 
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offer an immediate reliable estimate of drug levels in cases of accidental poisoning 
or over-ingestion of drug until a more accurate 'laboratory value' is obtained. 
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SUMMARY 
1.  An HPLC-RIA assay specific for digoxin in the presence of its major metabolites 
viz., digoxig;enin mono- digitoxoside, digoxigenin bis- digitoxoside and digoxi­
genin, was developed. 
2. Methodology for non-invasive measurement of LVET and other STI in dogs was 
developed. However, the STI measured did not lend itself to pharmacodynamic 
mode1ling. 
3. Relationships between the STI and HR in the presence of digoxin were estab­
lished in dogs. 
4. The bradycardiac response to digoxin was investigated in beagle dogs: and 
pharmacodynamic modelling conducted. 
5. The pharmacodynamic models investigated and evaluated were the pharma­
cokinetic model with a direct linear link, the linear model, the physiologic­
pharmacokinetic model with direct linear link and the effect compartment 
model. 
6. The phsyiologic pharmacokinetic model was investigated using a computer pro­
gram SPICE2, which uses a thermodynamic network to simulate biological sys­
tems. The model simulated using SPICE2 was compared to the same model 
simulated using two other computer programs viz. , CSMP and GPPM. 
7. Criterion for selecting the best model are discussed including evaluation of 
'fits · ,  F-values, AJC's and the weighted residua] sum of squares. 
8 .  The effect compartment model was demonstrated to be the best model. 
9. The implications and applications of pharmacodynamic models in general and 
specificalJy of the pharmacodynamic model for the bradycardiac response to 
digoxin are discussed. 
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CHAPTER 5 
APPENDIX 
APPENDIX A - MATERIALS 
Analytical: 
Al] solvents used for the extraction or chromatography were HPLC grade and 
were obtained from Fisher Scientific Co. (Pittsburgh, PA, USA) . Digoxin was ob­
tained from Sigma Chemical Co. (St. Louis, MO, USA). Digoxigenin, digoxigenin 
mono-digitoxoside and digoxigenin bis-digitoxoside were purchased from Boehringer 
Mannheim Biochemicals (Indianapolis, IN, USA) . Dihydrodigoxin was a gift from 
H .  Hull (Burroughs Wellcome, Research Triangle, N.C. , USA) . RIA was performed 
using the Digoxin RIA kit (Diagnostic Products Corp. LA, CA, USA). The HPLC 
system used was Waters M-6000 A solvent deliv,ery system (Waters Associates, 
Milford, Mass.).  The column was Lichosorb SI-100 (Hewlett Packard). A C 1 8  
µ,Bondapak reverse phase column (Waters Associates, Milford, Mass.) was also 
used during assay development. The UV detector used was a Gilson variable wave­
length spectrophotometer. (model: HM Holochrome UV monitor, Gilson Medical 
Electronics, Middleton, WI.) The injector used was Rheodyne syringe loading sam­
pling injector (model 7125, Rheodyne Inc. , Berkeley, CA.).  The refractive index 
(RI) detector used during assay development was a Differential Refractometer R401 
(Waters Associates, Milford, Mass.) and the liquid chromatography electrochemical 
(LCEC) detector used was a LC-4B/17 with a glassy carbon electrode (Bioanalytical 
Systems, West Lafayette, Indiana). FlouriI;netric measurements were made using 
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an Am.inco-Bowman spectroflourometer (American Instrument Co., Silver Springs, 
MD.) . 
Dog studies: 
Digmtln administered to the dogs was Lanmtln (0.25 mg/ml. ,  Burroughs Wellcome 
Co. ,  Research Triangle, N.C.) . Heparin locks were Butterfly (21 ¾ ,  12 inch tubing 
infusion set, Abbott Hospitals, N. Chicago, N. IL.) .  Normal saline used for intra­
venous administration flushing the heparin locks and for diluting heparin .  Hep­
arin (Heparin Sodium Injection, USP 10,000 units/ml, Lypho-Med Inc. ,  Chicago, 
IL.) diluted with normal saline to give a concentration of 100 U/ml .) was used 
to flush the heparin locks to keep them patent. Blood samples were drawn with 
disposable sterile syringes (Becton-Dickinson, Rutherford, N.J.)  into 10 ml. red­
top sterile Vacutainers CR) (Becton-Dickinson) .  After centrifugation the serum was 
transfe�red using disposable glass pipettes (Fisher Scientific Co. Pittsburgh, PA) 
into polystyrene tubes (FaJcon, Fisher Scientific Co.) and frozen. Electrocardiog­
raphy was done using a VS4 Electrocardiograph ( Cambridge Instruments, N.  Y.) . 
The microphone pick-up unit for recording the heart. sounds was the Cambridge 
Instruments microphone transducer head (Part no. 03040500) and the pressure 
transducer used to record the carotid pressure tracing was the Cambridge Instru­
ments pressure transducer head (Part no. 03040000) connected to a funnel�shaped 
pickup unit (diameter 1 .9 cm, volume 0.94 cc) attached to a tubing (internal dia. 
0.4 cm, volume 0. 79 cc) . For invasive measurement of the ventricular pressure 
tracing (Study 1A) a pigtail catheter (5 fr.) was connected to a strain gauge pres­
sure transducer through a dome (Disposable dome no. 1295 A,  Hewlett Packard, 
Palo Alto, CA) . The carotid pressure tracing was also non-invasive]y obtained after 
exteriorization of the carotid artery. Tbe ·exteriorized artery was retained in posi­
tion using 2-prolene, blue mono:filament, polypropy Jene retaining sutures (Ethicon, 
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Somerville, N .J. ) .  The suture used for closure of the incision was 00 black silk. T he 
dogs were anesthetized using pentobarbital (60 mg/ml . ,  Barber Veterinary Supply 
Co. Inc. Richmond, VA) .  The endotracheal tube used was a sterile tracheal tube 
(American Hospital Supply, McGaw Park, IL, USA) . The respirator used was an 
animal respirator (Model 6 16, Harvard Apparatus Co. Inc, Millis ,  Mass., USA). 
Computer analysis : 
A ll computer analysis was done on the combined computer facilites of Virginia 
Commonwealth University East and West campuses. Pharmacokinetic analysis us­
ing the nonlinear regression program NONLIN (NONLIN 1972) was done on the 
IBM 3081-D (IBM Corporation) . Statistical analyses were done using the statisti­
cal package SAS (SAS 1982, SAS Institute, Cary, NC) . Graphics was accomplished 
using the SAS graphics package and an HP7221B plotter (Hewlett Packard, Palo 
A lto, CA.) .  All statistical analyses, editing and graphics was done using the men­
tioned packages on a VAX/VMS 11/780 (Digital Equipment Corporation, Maynard 
Mass., operating system version 4.1). 
APPENDIX B 
ASSAY DEVELOPMENT 
Objective: 
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To develop a specific . sensitive assay for digoxin in the presence of its major metabo­
l ites viz. , digoxigenin mono- digitoxoside, digoxigenin bis-digitoxoside, digoxigenin 
and dihydro-digoxin. 
Introduction: 
Recent HP LC Assays 
Initial studies measured digoxin concentrations by administration of 3H-digoxin 
to patients (Bean et. al. 1963; Doherty et al. 1961 ;  Doherty et al . 1969; Hernandez 
et al. 1963) . Most of the subsequent studies have used RIA for measuring d igoxin 
concentrations (Biddle et al. 1978; Coltart et al. 1974; Gorodischer et al. 1976: 
Gullner et al. 1974 ; Jusko et al. 1974: Karjalainem et al. 1974; Krasula et al. 
1974; Park et al. 1982) . 
It has been demonstrated that the digoxin metabolites: digoxigenin, d igoxi­
genin mono-digitoxoside, digoxigenin bis-digitoxoside; cross-react extensively using 
RIA (Stoll et al. 1972) . Kramer et al. ( 1976) , showed that dihydrodigoxin also 
cross-reacts. 
Recent methods have separated digoxin from its metabolites by HPLC. H the 
digoxin fraction at the end of the HPLC column is collected, then, by either applying 
RIA or measuring radioactivity (when radiolabeled digoxin is used) , specific assay 
methods for digoxin have been made available (Eriksson et al. ]981 ;  Loo et al. 
1977, 1981; Morais et al. 1981 ;  Nelson et al. 1 979) . 
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It was therefore decided to follow a similar procedure i.e., to separate digoxin 
from its metabolites using HPLC and to quantitate the digoxin fraction after chro­
matography, by conventional RIA. 
Structure: 
Digoxin is a 'cardiac glycoside which represents the combination of an aglycone, 
or genin, with 3 digitoxose sugar molecules. The basic structure of the genin is 
a cyclopentanoperhydrophenanthrene nucleus to which is attached an unsaturated 
lactone ring at C 1 7. The sugar moieties are attached at C 3. (Fig. 1.1) . 
Molecular weight: 781 .0 
Solubility : 
Almost insoluble in water, ethanol : ether and chloroform; soluble 1 in 22 of 80% 
ethanol and 1 in 4 of pyridine. 
UV Absorption spectrum: 
Digoxin in sulfuric acid, maxima at 230 mµ (El%� 1 cm. 260). 
320 mµ (E 1 %, 1 cm. 225) . 
390 mµ (El%, 1 cm. 305). 
490 mµ (E 1%, 1 cm. 2100) . 
Dihydrodigoxin absorbs under UV light. very poorly. A 125 µgiml. solution 
in ethanol absorbed only to the extent of 0.01 AUFS. It therefore seemed unlikely 
that quantities in the low nanogram range could be detected using a UV detector. 
This is in agreement with Eriksson and Tekenbergs (1981), who indicated that 
dihydrodigoxin (DH) absorbs approximately 1000 times less than digoxin. Therefore 
it may be neccessary to inject mg. quantities of dihydro-digoxin to determine its 
retention time on the column. 
EXPERIMENT 1 
Objective: 
To separate digoxin from its metabolites using HPLC. 
Introduction: 
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The intended procedure involved separation of digoxin and metabolites using HPLC 
and collection of digoxin fraction to be assayed by RIA. Since the fractions were to 
be evaporated for RIA it was decided to use a norm.al phase HPLC procedure, so 
that organic solv,ents constituting; the collected eluant could be easily evaporated. 
The assay selected for modification after review of the literature was that by Loo 
et al., ( 1977). 
Procedure: 
Column: Lichosorb Sl-60 (5µm.) 
length = 25 cm. 
internal diameter = 4.0 mm. 
Mobile phase: Hexane : Methylene chloride : Ethanol 
Amax = 230 nm. 
Flow rates and t11e concentrations of hexane, methy Jene chloride and ethanol were 
varied to achieve optimal separation. 
Results : 
The following chromatographic conditions were found optimal for the separation of 
· digoxin and its metabolites. 
Flow rate = 2.5 ml/min. 
Mobile phase: Hexane : Methylene Chloride : Ethanol (50:40:10) 
Retention times were: 
Digoxin 
Digoxigenin bis-digitoxoside 
Digoxigenin mono-digitoxoside 
14.2 min. 
12.0 min. 
9.2 min. 
Digoxigenin 6.8 min. 
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A peak for dihydrodigoxin was not observed even after injection of 400 µg. on 
to the column. This is probably due_ to the low UV absorption of dihydrodigoxin. 
Conclusion: 
Dihydrodigoxin cannot be detected using a UV detector. Detection using a UV 
detector in conjuction with HPLC procedures may require mg. quantities to be 
injected onto the column. The peak for dihydrodigoxin detected in such cases may 
not reflect the true retention time for digoxin due to "column loadingr. . It was 
therefore decided to determine whether an electr,o-chemical detector may be used 
to detect digoxin. It was also decid�d to investigat.e the refractive index detector 
for detection of dihydrodigoxin s .ince the refractive index detector is a non-specific 
detector. 
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EXPERIMENT 2 
Objective: 
To determine whether dihydrodigoxin can be detected in HPLC eluant using an 
electrochemical detector. 
Introduction : 
Reverse phase HPLC systems are generally used in conjuction with an electrochem­
ical detector (ECD) , since the ECD requires a polar medium in which the calomel 
electrodes are immersed and to facilitate electrical conduction . Therefore the HPLC 
procedure used in Experiment 1 . was not suitable for the present needs. 
Review of the literature revealed a reverse phase HPLC procedure for chro­
matographing dihydrodigoxin (Eriksson and Tekenbergs, 1981) . The chromato­
graphic procedure used was a modification of their procedure. 
Procedure: 
Column : Spherisorb RP-8 (reverse phase) 
Mobile Phase : MeOH : Phosphate buffer (0. 1  M) pH=6.3 (60 : 40) 
Flow rate = 1 ml :'min. 
Digoxin had a retention time of 6.0 mins. 100 µ,g. of digoxin was injected on to 
the column and it was attempted to detect digoxin with the ECD at 0.95v. The 
injection was repeated with the ECD at -0.95v. The procedure was r.epeated using 
500 µg. of dihydrodigoxin . 
Results: 
No peaks for digoxin or for dihydrodigoxin were detected using an ECD, although 
peaks for digoxin were detected using an UV detector. 
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Conclusion: 
Since digoxin and dihydrodigoxin could not be detected using an ECD it was decided 
to investigate the detection of dihydrodigoxin using a refractive index detector. 
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EXPERIMENT 3 
Objective: 
To determine whether the refractive index detector may be used for the detection 
of dihydrodigoxin. 
Introduction: 
Morais et al. (1981) indicated that digoxin could be separated from dihydrodigoxin 
using the following chromatographic procedure : 
Column : Cl8, Reverse phase, µBondapak (3.9 mm. i.d. x 30 cm.) 
Mobile phase : Acetonitrile : water (29:71 v /v) 
Flow rate : 3 ml. jmin. 
It was therefore decided to use the above system for separation and detection of 
digoxin and dihydrodigoxin. 
Procedure: 
A chromatographic system similar to that described by Morais et al. (1981) , 
was used and the refractive index detector attached in series to an UV detector, 
was used to detect dihydrodigoxin in the post column eluate. Various amounts of 
dihydrodigoxin or digoxin alone were injected on to the column. 
Results : 
100 µg. of digoxin and dihydrodigoxin both demonstrated peaks using using the 
refractive index detector. Both had identical retention times. It was also observed 
that injection of digoxin gave rise to one large peak and one other much smaller 
peak. This may indicate possible hydrolysis of digoxin on the column since the 
digoxin was found to be chromatographically pure. 
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Conclusion: 
The reverse phase HPLC procedure proposed by Morais et al. ( 1981 ) ,  did not 
meet the chromat,ographic needs because of the following reasons: 
1 .  Dihydrodigoxin may be detected using a refractive index detector only when 
large amounts ( 100 µg. or more) are injected on an HPLC column. 
2. Identical retention times were observed for digoxin and dihydrodigoxin i .e .  sep­
aration could not be achieved. 
3. Possible hydrolysis of digoxin: Although not conclusively proven; results indi­
cated possible hydrolysis of digoxin in the presence of an aqueous mobile phase 
associated with reverse phase HPLC procedures. 
It was therefore decided to attempt separation of dihydrodigoxin and digoxin using 
a silica-gel column and a R.I. detector. 
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EXPERIMENT 4 
Objective: 
To attempt separation of dihydrodigoxin and digoxin using a silica- gel column 
coated with silver nitrate. 
Introduction: 
Review of the literature indicated that positional and geometrical isomers of some 
alkenes and unsaturated fatty acid esters have been separated by HPLC on silver 
nitrat,e coated silica-gel columns (Mikes et al. 1973, Heath et al. 1975: 1977; 
Lam and Grushka 1977: Aigner et al. 1976, Ozcimder and Hammers 1980) . It 
was therefore decided to attempt separation of digoxin and dihydrodigoxin using 
a similar column. Jt was felt that possible attraction of Ag-r to the 7i electrons in 
the unsaturated lactone ring of the digoxin molecule would lead to separation, since 
the lactone ring in the dihydrodigoxin molecule is sat.urated. It was also decided to 
use the refractive index detector for detection purposes in light of previous success 
with the refractive index detector (Experiment 3) in detecting dihydrodigoxin . 
Procedure : 
Column : Lichosorb Sl-60 coated with silver nitrate 
Mobile phase : Hexane : Methylene chloride : Ethanol 
(various ratios were attempted) 
Flow rate : flow rat.es ranging from 1-3 ml . /min. were used 
The procedure for the preparation of the column was similar to that of 
Yamauchi et al. ( 1980) . 3 gms. of Licbosorb Sl-60 (5 µ) and 0.3 gm. of s ilver 
nitrate were mixed together in 50 ml. of acetonitrile. This was evaporated to 
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dryness under a vacuum on a rotary evaporator at 40 °c. A slurry was made in 1-
hexanol (freshly distilled) saturated with silver nitrate and the column was packed 
at 6000 psi using 1-hexanol as the flushing solvent. 
The output end of the column served as the input of eluant mobile phase into 
the UV detector for the detection of digox.in; and the outlet end of this detector 
served as the inlet into the refractive index detector for the detection of dihydrodi­
goxin and digoxin { Fig. 67) . 
Results : 
On passage of the mobile phase a large amount of the silver nitrate was washed 
off the column. The column failed to separate digoxin and dihydrodigoxin. This 
indicates that a very non-polar mobile phase needs to be used to prevent silver 
nitrate from being washed off of the column. It was felt that use of a very non-ploar 
mobile phase would result in excessive tailing and prohibitively large retention times 
for the digoxin and dihydFodigoxin peaks. 
Conclusion: 
The silver nit.rate coated silica-gel column was found to be impractical for separation 
of dihydrodigoxin and digoxin. It was therefore decided to pursue an ordinary silica.­
gel column to study the separation of digoxin and dihydrodigox.in. 
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EXPERIMENT 5 
Objective: 
To au.empt separation of digoxin and dihydrodigoxin using a silica-gel column and 
a normal phase HPLC procedure. 
Int.rod uction: 
Previous experiments (1  to 4) , had determined that the RI detector could be used 
to det,ect dihydrodigoxin . However certain reservations exist to the use of the RI 
detector viz . ,  
1 )  µg. quantities of both dihydrodigoxin and dilgoxin have to be injected on to 
the HPLC column so that they may be detected by the RI detector. It is felt that 
the retention times evidenced by these injections may not neccessarily reflect the 
retention times upon injection of ng. quantities (which are the levels expected in 
pharmacokinet ic-pharmacodynamic studies) . 
2) The RI detector has an extremely noisy baseline and is suceptible to minor 
changes in the mobile phase, temperature and flow rate. 
It was therefore decided that other means of detection were to be investigated . 
Review of the literature showed that digoxin could be detected fluorimetrically 
(Wells et. al. 1961 ; Jensen 19S2) .The fluorimetric procedure for digoxin was a 
non-specific procedure for cardiac glycosides, and involved oxidation of the steroid 
nucleus. It was therefore deduced that the same procedure may be utilized for the 
detection of dihy drodigoxin. 
Procedure: 
Column : Lichosorb Sl-60 4 mm. i .d. Length 25 cm. 
294 
Mobile phase : Hexane Methylene chloride : Ethanol (various ratios were at­
tempted) 
Flow rate : 3 ml/min. (other flow rates from 1 - 3 ml/min. were also used) 
Detection: 
Digoxin was detected using a UV detector. Digoxin (DIG) and dihydrodigoxin 
(DH) , were also quantitated using the :fluorimetric procedure as follows: 
The eluant was collected at regular intervals. These fractions were evaporated to 
dryness and assayed for digoxin using the fluorometric method of Wells et al . ,  (1961) .  
To the dry residue was added 2 ml . of methanol containing 2 mg. ascorbic acid, 
3 ml.  concentrated hydrochloric acid and 0.2 mJ. of 0.003 M aqueous hydrogen 
peroxide. The t-ubes were immediately vortexed to mix the contents and are then 
allowed to stand at room temperature. After 20 - 40 mins. the samples and a 
reagent blank were then read in a Aminco- Bowman spectro:flourometer ( .t\.merican 
Instrument Company, Silver Springs, MD.) . The amounts were then obtained from 
a standard curve obtained using standard solutions of digoxin and dibydrodigoxin of 
0, 0.25: 1 .0 and 3.0 µg/ml.  The standard curves for both digoxin and dihydrodigoxin 
were linear. An excitation wave]ength was 360 nm. and an emission wavelength 
of 490 nm were used for digoxin . and an excitation wavelength of 360 nm. and an 
emission wavelength of 420 nm. was used for dihydrodigoxin . 
Results : 
The nature and the retention time of the digoxin peak were determined. Under 
i dentical conditions dihydrodigoxin was injected on the column was injected on the 
column and fractions 6 to 2 mins. before the onset of the digoxin peak (A) , 2 
to 0 mins. before the onset of the digoxin peak (B) , the fraction corresponding 
to the digoxin peak (C) and the fraction ·corresponding to a duration of 2 mins. 
TABLE 5.1 
Fractions (%) of the amount of dihydrodigoxin injected on column. 
INJ . 
1 
2 
3 
A 
47.0 
35.8 55.7 
B 
2 1 .3 23. 1 26.8 
C 
28.6 37.3 1 1 .3 
D 
3 . 1  3.8 6.2 
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after the digoxin peak (D) were collected, evaporated to dryness and assayed for 
dihydrodigoxin . The results are given in Table 5 . 1  
The results indicate that an average of 25 .  7% of the dihydrodigoxin appears un­
der the digoxin peak. The mobile phase was Hexane : Methylene chloride : Ethanol 
(50 : 42 :8) . The retention time for digoxin was 34 .2 rains. - 37.2 mins. This was 
considered prohibitively too large a retention time for regular batch analysis of sam­
ples. During development of the chromatographic procedure it was observed that 
the degree of separation between digoxin and its metabolites was largely influenced 
by the ethanol concentration in the mobile phase; a reduction in the ethanol con­
centration leading to greater separation. However reduction of the ethanol concen­
tration to 5% of the mobile phase resulted in retention times greater than 1 hr. for 
d igoxin along with an unacceptable level of tailing of the digoxin peak. It therefore 
seemed unlikel;"r that a. separation of digoxin and dihydrodigoxin could be arrived 
at by HPLC procedures. 
Conclusion: 
It was concluded that due to the minor differences in structure betw,een digoxin· and 
dihydrodigoxin ( a double bond in the lactone ring ) separation using conventional 
HPLC systems was unlikely. Hence it was decided to investigate radioimmunoassay 
procedures for digoxin that did not. cross-react with dihydrodigoxin. 
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Evaluation of lmmunoasays 
Specific for Digoxin in the Presence of Dihydrodigoxin. 
Introduction: 
Kramer et al., (1976) , reported that commercial radioimmunoassay kits cross-react 
with dihydrodigoxin. Specifications on commercially available kits either revealed 
no information regarding its cross-reactivity to dihydrodigoxin or r,evealed that the 
kits did cross-react to an appreciable extent with dihydrodigoxin. Hence a few 
commercially available kits were selected for evaluation of their cross-reactivity to 
dihydrodigoxin. 
EXPERIMENT 6 
Objective: 
To evaluate the TDx procedure for assaying, for specificity to digoxin in the presence 
of dihydrodigoxin. 
Introduction: 
Review of the specifications on the TDx (Abott Laboratories, Diagnostics Division, 
Irving , Texas USA) procedure revealed no information about its cross-reactivity 
to dihydrodigoxin. It was therefore decided to investigate this assay due to its 
advantage of automation. 
Procedure: 
9 serum samples were spiked with digoxin, qihydrodigoxin or both were assayed in a 
blinded manner (by a technician) using the automated TDx system at the toxicology 
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laboratory of the McGuire Veterans Administration Hospital, Richmond, VA. The 
results are given in Table 5.2 
Results: 
Appreciable cross-reactivity with dihydrodigoxin is noticed in the prescence and 
absence of digoxin. 
Conclusion: 
The TDx sustern for assaying digo?'in is not specific for digoxin in the presence of 
dihy drodigoxin. 
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TABLE 5.2 
SAMPLE NO. ACTUAL CONC. (ng/ml .) ASSAYED CONC. (ng/ml.) 
DlGOXIN DIBYDRODIG. DIGOXIN EQUNALENT 
1 1 .0 0.0 0.9 
2 1 .0 1 .0 1 . 1 
3 1 .0 2.0 
4 1 .0 4 .0 1 .6 
5 0.0 0.0 0.0 
6 0.0 1 .0 0.3 
7 0.0 2.0 0.4 
8 0.0 4.0 0.7 
9 1 .0 0.0 LO 
Cross-reactivity of the antibody (used in the TDx system for assaying digoxin) to 
dihy�rodigoxin is noticed in the presence and absence of digoxin . 
EXPERIMENT 7 
Objective: 
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To evaluate the digoxin RIA kit by Diagnostic Products Corporation, Los AJ?.geles, 
CA; for specificity for digoxin in the presence of dihydrodigoxin. 
Introduction: 
Specifications on the digoxin RIA kit (Diagnostic Products Corporation, LA: CA ) 
indicated a cross-reactivity for dihydrodigoxin of only 1.4% corresponding to 50% 
binding of the antiserum. Specifications also indicated that a digoxin equivalent 
of only 0.1 ngi ml. would be observed on assaying a serum sample of 5 ng/ml. 
of dihydrodigoxin (implying 2% cross-reactivity).  Experiments were conducted to 
validate this Jack of cross-reactivity. 
Procedure: 
Samples of dihydrodigoxin were assayed in duplicate using RIA. The results are 
listed in Table 5.3 
ANALYTE 
Dihydrodigoxin 
TABLE 5.3 
CONC. (ng/ml.)  OBSERVED 
DIGOXIN EQUIVALENT (ng/ml.) 
0.98 
3.92 
5.88 
0.10 
0.14 
0.175 
For the calibration curve for digoxin Corr. = 0.998 
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T he results indicate that dihydrodigoxin cross-reacts to a minimal extent with 
the RIA antiserum. 
Conclusion: 
It was found that the RIA kit by Diagnostic Products Corporation (DPC), cross­
reacts with dihydrodigoxin to a minimal extent. Further studies need to be con­
ducted to validate this lack of cross-reactivity to dihydrodigoxin. 
EXPERIMENT 8 
Objective: 
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To further evaluate the specificity of the DPC RIA kit for digoxin in the presence 
of dihydrodigoxin. 
Introduction: 
This experiment is similar to Experiment 7 
Procedure: 
Similar to Experiment 7 In this study plasma samples containing known amounts of 
both digoxin and dihydrodigoxin were assayed in duplicate for their digoxin content. 
Results: 
The results are 1isted in Table 5.4 
For the calibration curve for digoxin Corr. = 0.998 
The results indicate a trend towards cross-reactivity when higl� concentrations 
of dihydrodigoxin (approx. 8.0 ng/ml.) are present concomitantly with low concen­
trations of digoxin (0.5 ng/ml. ) . The observed trend towards cross reactivity could 
also be variability inherent in the assay. A larger number of samples need to be 
assayed to determine if the cross-reactivity is a significant phenomenon. 
Conclusion 
As seen in experiment 7 a certain trend to cross-reactivity is observed at higher 
concentrations of dihydrodigoxin concomitant with low concentrations of digoxin. 
It is proposed to evaluate this trend thorougly so that we may assess whether 
significant cross-reactivity exists. It was also decided to verify the purity of digoxin 
and dihydrodigoxin by TLC. 
ANALYTE 
DIG + 
DH 
DIG + 
DH 
DIG + 
DH 
DIG + 
DH 
CONC. 
(ng/m1.) 
0.50 
0.00 
0.50 
0.98 
0.50 
3.92 
0.50 
7.84 
TABLE 5.4 
DIGOXIN EQUIVALENT OBSERVED 
(ng/ml.) 
0.49 
0.60 
0.60 
0.67 
0.72 
For the calibration curve for digoxin Corr. = 0.998 
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Digoxin equivalent observed on assaying serum containing known amounts of digoxin 
and dihydrodigoxin using RIA (Diagnostic Products Corp. ,  LA, CA, USA) 
DIG = digoxin 
DH = dihydrodigoxin 
EXPERIMENT 9 
Objective: 
To verify purity of digoxin and dihydrodigoxin by TLC. 
Introduction: 
Since a trend towards cross-reactivity of dihydrodigoxin to the R]A kit w� ob-
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served in the previous experiments (7 and 8) , it was decided to verify that the 
dihydrodigoxin was pure. 
Procedure: 
The TLC procedure selected was that of Carvalhas and Figueira {1973) . The purity 
of digoxin and dihydrodigoxin was verified using TLC on silica-gel plates (F254, E. 
Merck) . The plates were heat activated at 100 degrees for 1 hour. They were then 
spotted with 10 µg. of digoxin and dihydrodigoxin. The solvent system used was 
Chloroform : Methanol : Acetic add (9 : 0.9 : 0 .1 ) .  After chromatography the plate 
was treated with a solution of chloramine T and trichloroacetic acid in ethanol and 
viewed under long wave UV light for visualisation of digoxin and dihydrodigoxin. 
Results : 
Digoxin and dihydrodigoxin had Rf values of 0.348 and 0.383 respectively. Single 
symmetric spots were observed for both compounds. 
Conclusion: 
Dihydrodigoxin and digoxin are both chromatographically pure. Specifications ob­
tained from Sigma Chemical Company (for digoxin) , and Burroughs Wel lcome Com­
pany (for dihydrodigoxin) also indicated that 1,he compounds were 99.9% pure. 
Since digoxin and dihydrodigoxin are both pure. the cross-reactivity of dihydro­
digoxin to the antiserum is not due to the presence of impurities present in the 
compounds, but is due to interaction of dihydrodigoxin with the RIA antiserum. 
Further studies were conducted to verify this cross-reactivity. 
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EXPERIMENT 10 
Objective: 
To determine whether dihydrodigoxin in serum samples cross-reacts significantly 
with the RIA antiserum of the digoxin RIA kit by DPC. Also to determine whether 
addition of dihydrodigoxin to the antiserum minimizes this interaction. 
Introduction: 
It was observed in previous experiments that dihydrodigoxin possibly cross-reacts 
with the digoxin antiserum. Consultation with the R & D personnel at Diagnostic 
Products Corporation (manufacturers of the digoxin RIA kit) yielded a suggestion 
to minimize the error for digoxin in the prescence of dihydrodigoxin. This involved 
adding a small amount of dihydrodigoxin to the antiserum prior to its use in the 
assay. The objective therefore, was to determine the extent of the dihydrodigoxin -
antiserum interaction and to determine whether addition of dihydrodigoxin to the 
antiserum minimizes this interaction. 
Procedure: 
Studies were conducted with various amounts of dihydrodigoxin in the prescence 
of digoxin to study the effect of dihydrodigoxin cross-reactivity to the RIA anti­
serum. Studies were also conducted with various a.mounts of spiked dihydrodigoxin 
in the antiserum (prior to the assay) to assess the effect of minimizing the cross­
reactivity of dihydrodigoxin to the antiserum using kits from 3 different lots. Blank 
serum was spiked with varying amounts of digoxin, dihydrodigoxin or both. These 
samples containing known amounts of digoxin, dihydrodigoxin or both digoxin and 
dihydrodigoxin were assayed by RIA using antiserum spiked with 0, 4 .0, 6.0, 8.0, 
12.0, 16.0 or 32.0 ng/ml. of dihydrodigoxin. The error upon assaying the samples 
was computed as a percentage of the deviation from the known or actual digoxin 
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concentration. Statistical tests were then carried out on the data to determine 
whether 1) the contribution of diliydrodigo?(in (DH) to the error is significant. 2) 
the interaction between dihydrodigoxin and digoxin (DH *DIG) contributes signifi­
cantly to the error of the assay 3) whether dihydrodigoxin in the antiserum (DHA) 
contributes significantly towards minimizing the error 4) whether the contribution 
of the DH*DHA interaction is significant, i .e., whether the addition of dihydrodi­
goxin to the antiserum results in a reduction of the error contributed to the assay, 
by dihydrodigoxin in the serum samples. 
Results :  
The data from all of the samples assayed are give111 in tables 5.5-5.10 
DIGOXIN CONC. 
ACTUAL (ng/ml.) 
0.5 
0.5 
1 .01 
1 .01 
1 .01 
2.01 
2.01 
2.01 
4 .02 
4.02 
4 .02 
8.05 
8.05 
8.05 
TABLE 5.5 
DIGOXIN CONC. 
OBSERVED (ng/ml.) 
0.47 
0.30 
0.93 
0.94 
1 . 14 
1 .97 
2 . 16 
2.14 
4 .26 
4 .06 
4 .34 
8.22 
8.38 
7.71 
ERROR 
(%) 
-6.0 
-40.0 
-7.9 
-6.0 
14 .0 
-2.0 
8.0 
6.5 
6.0 
1.5 
8.0 
2.1 
4.1 
-3.6 
306 
Serum containing known amounts of digoxin assayed by RIA (Diagnostic Products, 
LA, CA, USA) . 
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TABLE 5 .6 
DIG DH DIG . EQUIVALENT % ERROR 
ng/ml. ng/ml. ng/ml. 
0.0 0.0 0.12 12.0 
0.50 0.0 0.42 -16.0 
0.50 0.0 0.70 40.0 
0.50 0.0 0.66 32.0 
0.52 0.0 0.36 -30.8 
1 .04 0.0 0.98 -5.8 
2.07 0.0 1 .99 -3.8 
4 .00 0.0 4 .25 6.2 
4 .00 0.0 3.84 -4 .0 
4 .00 0.0 4 .20 5.0 
4. 14 0.0 3.76 -9.2 
8.28 0.0 6.56 -20.8 
0.0 0.49 0.20 20.0 
0.0 0.98 0.32 32.0 
0.0 1 .97 0.22 22.0 
0.0 3.84 0.32 32.0 
0.0 7.88 0.38 38.0 
0.52 0.49 0.51 -1 .9 
0.52 0.98 0.55 5.8 
0.52 1 .94 0.59 13.4 
0.52 7.88 0.72 38.4 
1 .04 0.49 1 . 14 9.6 
1 .04 0.98 1 .06 1 .9 
1 .04 1 .97 1 . 12 7.6 
1 .04 3.84 1 . 17  12.5 
1 .04 7.88 1 .30 25.0 
2.07 0.49 2.14 3.4 
2.07 0.98 2.20 6.2 
2.07 1 .97 1 .99 -3.9 
2.07 3 .84 2.09 0.97 
2.07 7.88 2.35 13.5 
4 .14 0.49 3.80 -8.2 
4. 14 0.98 3.86 -6.8 
4 .14  1 .97 4 .32 4 .3 
4 .14 3 .84 4 .45 7.5 
4 .14 7.88 4 .33 6A 
DIG 
ng/ml. 
8.28 
8.28 
8.28 
8.28 
8.28 
DH 
ng/ml. 
0.49 
0.98 
1.97 
3.84 
7.88 
TABLE 5.6 (contd.) 
DIG .  EQUIVALENT 
ng/ml. 
7.88 
7.22 
7.44 
7.64 
7.86 
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% ERROR 
-4.8 
-12.8 
-10.1 
-7.7 
-5.1 
Digo:,dn equivalent observed on assaying serum containing known amounts of digoxin 
(DIG) and dihydrodigoxin (DH) using RIA (Diagnostic Products Corp., LA� CA, 
USA). 
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TABLE 5.7 Lot NO. 141 
DIG DHs DHa, ERROR MEAN (SD) 
ng/ml ng/ml ng/ml % % 
0.5 0 8 -10 -4 (8.48) 
0.5 0 8 2 
0.5 0.5 8 -16 -13 (4.24) 
0.5 0.5 8 -10 
0.5 2.0 8 -8 -2 (8.48) 
0.5 2.0 8 4 
0.5 8.0 8 14 12 (2.82) 
0.5 8.0 8 10 
1.0 0 8 -1 1  -5.5 (7.8) 
1.0 0 8 0 
1.0 0.5 8 -6 -6 (0) 
1.0 0.5 8 -6 
1.0 2.0 8 -9 5.5 (20.5) 
1.0 2.0 8 20 
1.0 8.0 8 16 14.5 (2.12) 
1.0 8.0 8 13 
2.0 0 8 0 0 (0) 
2.0 0 8 0 
2.0 0.5 8 0 4.5 (6.4) 
2.0 0.5 8 9 
2.0 2.0 8 1 -5.75 (9.5) 
2.0 2.0 8 -12.5 
2.0 8.0 8 9 15.S (9.19) 
2.0 8.0 8 22 
Error observed in assaying serum containing known amounts of digoocin and dihydro-
digoxin using RIA (Diagnostic Products Corp. ,  LA, CA, USA) . The antiserum used 
in the RIA was spiked to result in a final concentration of 8 ng/ml. of dihy�odi-
goxin . DIG = digoxin 
DH 8 = digoxin in serum 
DH a = digoxin in antiserum 
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TABLE 5.8 
NO. 141 
DIG DHs DHa ERROR MEAN ± (s.d.) 
ng/ml ng/ml ng/ml % % 
0.5 0 0 -7.0 -3.5 (4 .9) 
0.5 0 0 0 
0.5 0.5 0 26 36.0 (14 .1) 
0.5 0.5 0 46 
0.5 2.0 0 74 67 (9.9) 
0.5 2.0 0 60 
0.5 8.0 0 88 88 (0) 
0.5 8.0 0 88 
1.0 0 0 -9 -11 (2.8) 
1.0 0 0 -13 
1.0 0.5 0 20 18 (2.8) . 
1.0 0.5 0 16 
1.0 2.0 0 17 19.5 (3.5) 
1 .0 2.0 0 22 
1.0 8.0 0 52 52.5 (0.7) 
1.0 8.0 0 53 
2.0 0 0 1 1.5 13.75 (3.2) 
2.'0 0 0 16  
2.0 0.5 0 7 15. 75 (12.4) 
2.0 0.5 0 24 .5 
2.0 2.0 0 12 19.25 (10.2) 
2.0 2.0 0 26.5 
2.0 8.0 0 39.5 40.25 (1 .1) 
2.0 8.0 0 41 
Error associated with assaying serum containing known amounts of digoxin and 
dihydrodigoxin using RIA (Diagnostic Products Corp. ,  LA, CA, USA) . 
DIG = digoxin , DHs = dihydrodigoxin in serum DHa = dihydrodigoxin in anti-serum. 
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TABLE 5.9 
LOT NO. 142 
DIG DHs DHa. ERROR MEAN ± s.d. 
ng/ml ng/ml ng/ml % % 
0.5 0 0 4 .4 3.5 ± 1.3 
0.5 0 0 2.6 
0.5 0 1 15.8 13.3 ± 3.5 
0.5 0 1 10.8 
0.5 0 4 -6.4 -6.7 ± 0.4 
0.5 0 4 -7.0 
0.5 0 8 -3.6 2.4 ± 8.5 
0.5 0 8 8.4 
0.5 0 16 -20.0 -21.0 ± 1.4 
0.5 0 16 -22.2 
0.5 8 0 60.0 62.7 � 3.8 
0.5 8 0 65.4 
0.5 8 1 46.0 52.0 ± 8.5 
0.5 8 1 58.0 
0.5 8 4 40.0 32.8 ± 10.2 
0.5 8 4 25.6 
0.5 8 8 62.0 57.0 ± 7 . 1  
0.5 8 8 52.0 
0.5 8 16 12.8 14.2 ± 3.8 
0.5 8 16 15.6 
Error associated with assaying digoxin in serum containing known amounts of 
digox.in and dihydrodgioxin using RIA (Diagn<;>stic Products Corp. ,  LA, CA, USA) . 
The antiserum used in the RIA was spiked. with dibydrodigoxin in varying (known) 
amounts. DIG = digox.in 
DHs = dihydrodigoxin in serum 
DH a. = dihydrodigoxin in antiserum 
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TABLE 5.10 
Lot NO. 146 
DIG DHs DHa ERROR MEAN (SD) 
ng/ml ng/ml ng/ml % % 
0.5 0 0 4 .8 
0.5 0 0 5.2 3.0 (3.5) 
0.5 0 0 - 1 .0 
0.5 0 4 4.2 
0.5 0 4 22 8.5 ( 1 1 .9) 
0.5 0 4 -0.6 
0.5 0 6 6.4 
0.5 0 ,6 7.4 8.6 {3 .0} 
0.5 0 ,6 12.0 
0.5 0 8 27.4 
0.5 0 8 22 24 .3 (2.8) 
0.5 0 8 23.6 
0.5 0 10 14.2 
0.5 0 10  12.0 14 .9 {3.2) 
0.5 0 10 18.4 
0.5 2 0 1 7.2 
0.5 2 0 25.0 23.4 (5.6) 
0.5 2 0 28.0 
0.5 2 4 1 1 .2 
0.5 2 4 8.6 12.3 {4.4 ) 
0.5 2 4 1 7.2 
0.5 2 6 22.6 
0.5 2 6 1 1 .4 16.6 (5.6) 
0.5 2 6 15.8 
0.5 2 8 25.4 
0.5 2 8 1 7.6 18.2 {6.9) 
0.5 2 8 1 1 .6 
contd . . . .  
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TABLE 5 .10 (contd.)  
DIG DHs DHa. ERROR MEAN (SD) 
ng/ml ng/ml ng/ml % % 
2.0 0 0 -4 -3 (1.4) 
2.0 0 0 -2.0 
2.0 0 4 -7.0 4 ( 15.5) 
2.0 0 4 15 1 .25 ( 1 .8) 
2.0 0 8 2.5 1.25 (1.8) 
2.0 0 8 0 
2.0 0 12 5 -2 (9.9) 
2.0 0 12 -9 
2.0 0 16 -7 -0.75 (8.8) 
2.0 0 16 5.5 
2.0 8 0 8 1 9  ( 1 5.6) 
2.0 8 0 30 
2.0 8 4 22 24.5 (3.5) 
2.0 8 4 27 
2.0 8 8 16 14 (2.82) 
2.0 8 8 12  
2.0 8 12  18.5 14.75 (5.3) 
2.0 8 12 11 
2.0 8 16  18 18 (0) 
2.0 8 16 18 
Error associated with assaying digoxin in serum containing known amounts of 
digoxin and dihydrodigoxin using RIA (Diagnostic Products Corp., LA, CA, USA) . 
The antiserum used in the RIA was spiked with varying (known) a.mounts of 
dihydrodigoxin. 
DIG = digoxin 
DH 8 = dihydrodigoxin in serum 
DH 0_ = dihydrodigoxin in antiserum 
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TABLE 5.11 
Lot no. 146 
DIG DHs DHa ERROR ERROR % (ng/ml.) (ng.ml . )  (ng/ml .) % MEAN ± s.d. 
0.5 0.0 0.0 -3.6 
0.5 0.0 0.0 8 .7 2.0 
0.5 0.0 0.0 -2.2 ± 
0.5 0.0 0.0 5 . 1  5.9 
0.5 0.0 4 .0 1 .8 
0.5 0.0 4 .0 1 1 .3 2.4 
0.5 0.0 4.0 -3.4 ± 
0.5 0.0 4 .0 0.0 6.3 
0.5 0.0 6.0 14 .0 9.5 
0.5 0.0 6.0 6.4 + 
0.5 0.0 6.0 8.2 4 .0 
0.5 0.0 8.0 6.7 
0.5 0.0 8.0 -4 .9 2.8 
0.5 0.0 8.0 -4 .0 ± 
0.5 0.0 8.0 1 3.6 8.9 
0.5 0.0 10.0 ] 5.3 
0.5 0.0 1 0.0 6.2 ] 0.9 
0.5 0.0 10.0 22.2 
0.5 0.0 10.0 0.0 9.8 
0.5 0.0 12.0 9. 1 12.0 
0.5 0.0 12.0 ] 7.1  ± 
0.5 0.0 12:0 0.9 8.9 
0.5 0.0 16.0 1 1 . 1  
0.5 0.0 16.0 8.4 8.8 
0.5 0.0 16.0 13. 1  ± 
0.5 0.0 16.0 2.7 4 .5 
0.5 0.0 32.0 9. 1 
0.5 0.0 32.0 9. 1 6.8 
0.5 0.0 32.0 9.1 ± 
0.5 0.0 32.0 0.0 4 .6 
contd . . . .  
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TABLE 5 .11 (contd.)  
DIG DHs DHa. ERROR ERROR % (ng/ml.)  (ng.ml .) (ng/ml. )  % MEAN ± s.d.  
0.5 8.0 0.0 30.7 
0.5 8.0 0.0 32.5 
0.5 8.0 0.0 29.9 24.8 
0.5 8.0 0.0 25.4 ± 
0.5 8.0 0.0 17 . 1  7.9 
0.5 8.0 0.0 13.1 
0.5 8.0 4.0 20.4 
0.5 8.0 4.0 16.5 
0.5 8.0 4.0 4.5 14.4 
0.5 8.0 4.0 13.8 ± 
0.5 8.0 4.0 10.0 6.6 
0.5 8.0 4.0 22.0 
0.5 8.0 6.0 5.4 
0.5 8.0 6.0 10.7 
0.5 8.0 6.0 5.2 6.26 
0.5 8.0 6.0 10.0 
0.5 8.0 6.0 0.0 2.5 
0.5 8.0 6.0 36.0 
0.5 8.0 8.0 21.3 
0.5 8.0 8.0 19.6 
0.5 8.0 8.0 19.5 13.3 
0.5 8.0 8.0 2.0 ± 
0.5 8.0 8.0 17 .4 9.6 
0.5 8.0 8.0 0.0 
0.5 8.0 10.0 0.0 
0.5 8.0 10.0 14.0 
0.5 8.0 10.0 9.J 7.1 
0.5 8.0 1 0.0 2.0 
0.5 8.0 10.0 10.4 5.3 
0.5 8.0 10.0 7.l  
0.5 8.0 12.0 16.4 
0.5 8.0 12.0 12.4 
0.5 8.0 12.0 12.9 13.8 
0.5 8.0 12.0 141.4 ± 
0.5 8.Q 12.0 4 .4 5.8 
0.5 8.0 12.0 22.0 
contd . . . .  
DIG DHs 
(ng/ml.) (ng.ml.) 
0.5 8.0 0.5 8.0 0.5 8.0 0.5 8.0 
0.5 8.0 0.5 8.0 
0.5 8.0 0.5 8.0 0.5 8.0 
0.5 8.0 0.5 8.0 0.5 8.0 
TABLE 5.11 (contd.) 
DHa ERROR 
(ng/ml.) % 
16.0 16.4 16.0 12.4 16.0 12.9 16.0 14.4 
16.0 4 .4 16.0 22.0 
32.0 0.0 32.0 -5.4 32.0 0.0 
32.0 -5.6 32.0 2 . . 5 32.0 12.2 
ERROR % 
MEAN ± s.d. 
8.0 ± 
10.0 
0.62 ± 
6.5 
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Error associated with assaying digoxin in serum containing known amounts of 
digoxin and dihydrodigoxin using RIA (Diagnostic Products Corp. ,  LA, CA, USA) . 
The antiserum used in the RIA was spiked with varying (known) amounts of 
dihydrodigoxin . 
D 1 G = digoxin 
DH 8 = dihydrodigoxin in serum 
DH a = dihydrodigoxin in antiserum 
The results of the statistical analysis are given in tables 5.12 and 5.13. 
When all the data. are included in the analysis the results indicate that contri­
bution of DH is significant. This therefore implies that there exists a definite cross­
reactivity of DH to the digoxin antiserum. The results also show that the DH*DIG 
interaction is significant . This indicates that the presence of dihydrodigoxin con­
tributes significantly to the error in the measurement of digoxin concentrations. 
However, re-analysis of the data after deletion of data containing dihydrodi­
goxin (DH) concentrations of 8 ng/ml. ( in serum) , indicate different results. In this 
case. the contribution of DH to the error is significant, indicating again that the 
DH cross-reacts with the digoxin antiserum. However, the DIG*DH interaction is 
DEPENDENT VARIABLE : 
SOURCE 
MODEL 
ERROR 
CORRECTED TOTAL 
R-SQUARE 
0 . 563674 
SOURCE 
ANTISER 
DIG 
DH 
DIG"DB 
DB" ANTISER 
SOURCE 
ANTISER 
DIG 
DB 
DIG"DB 
DB*ANTISER 
Table 5 . 1 2 
GENERAL LINEAR MODELS PROCEDURE 
CLASS LEVEL INFORMAT'.IQN 
CLASS LEVELS 
DIG 3 
DB 4 
VALUES 
1 2 0 . 6  
0 2 8 0 . 6, 
ANTISER 9 0 1 4 6 8 10 1 2  16 32 
NUMBER OF QiBSERVATIONS IN DA,TA SET • 1 97 
GENERAL LINEAR MODELS PROCEDURE 
ERROR 
DF SUM OF SQUARES MEAN SQUARE 
32 34377 . 53704704 1 074 . 29803272 
16-4 26610 . 82985651 162 . 26115766 
1 96 60988 . 36690355 
c . v. ROOT HSE ERROR MEAN 
96 . 8290 1 2 . 73817717 1 3 . 15532995 
DF TYPE I SS F VALUE PR , F 
8 9441 . 49354839 7 . 27 0 . 0001 
2 1 062 . 73806051 3 . 27 0 . 0403 
3 1 1 140 . 52710597 22 . 89 0 . 0001 
6 2310 . 20159729 2 . 37 0 . 0317 
13  10422 . 57673487 4 . 94 0 . 0001 
DF TYPE III 66 F VALUE PR > F 
8 1 145 1 . 41 963014 8 . 82 0 . 0001 
2 947 . 94222063 2 . 92 0 . 0667 
3 3246 . 45847404 6 . 67 0 . 0003 
6 1095 . 64447076 1 . 13 0 . 3498 
13  1 0422 . 57673487 4 . 94 0 . 0001 
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p VALUE 
6 . 62 
PR > F 
0 . 0001 
The table indicates that Dihydrodigoxin (DH) and the DIG*DH interaction 
contribute signi.ficantly to the error when digoxin is assayed using RIA 
in the presence of dihydrodigoxin. 
DEPENDENT VARIABLE : 
SOURCE 
HODEL 
ERROR 
CORRECTED TOTAL 
R-SQUARE 
0 . 631841 
SOURCE 
ANTISER 
DIG 
DB 
DIG·DB 
DB "'ANTISER 
SOURCE 
ANTISER 
DIG 
DB 
DIG"DB 
DH•ANTISER 
Table 5 . 13 
GENERAL LINEAR MODELS PROCEDURE 
CLASS LEVEL INFORMATION 
CLASS LEVELS 
DIG 3 
DB 3 
VALUES 
l 2 0 . 6  
0 2 0 . 6  
ANTISER 9 0 l 4 6 8 10 12 16 32 
NUMBER OF OBSERVATIONS I-N DATA SET • 1 17 
GENERAL LINEAR MODELS PROCEDURE 
ERROR 
DF SUH OF SQUARES HEAN SQUARE 
21 12691 . 66492396 604 . 36023447 
96 11171 . 90806750 1 1 7 . 69903229 
1 16 23863 . 47299145 
c . v .  ROOT HSE ERROR HEAN 
131 . 0321 10 . 84430875 8 . 27606838 
DF TYPE I SS F VALUE PR > F 
8 3582 . 98809364 3 . 81 0 . 0006 
2 752 . 78747942 3 . 20 0 . 0452 
2 3818 . 69167393 16 . 24 0 . 0001 
4 515 . 19446650 1 . 1 0 0 . 3635 
5 4021 . 90321046 6 . 84 0 . 0001 
DP TYPE III SS p VALUE PR > P 
8 4970 . 80828837 5 . 28 0 . 0001 
2 1043 . 37017061 4 . 44 0 . 0144 
2 564 . 23084966 2 . 40 0 . 0963 
4 704 . 30497093 1 . 50 0 . 2:092 
5 4021 . 90321046 6 . 84 0 . 0001 
3.18 
F VALUE 
5 . 14 
PR > P 
0 . 0001 
Table indicates that DIG*DH interaction is not significant when digoxin is 
assayed using RIA in the presence ,of dihydrodigoxin (DH) . 
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not significant. This indicates that although, DH cross-reacts with the antiserum, 
DH ( at concentrations less than 8 ng/ml.) in the presence of DIG does not add 
significantly to the error associated with assaying digoxin alone. In both analy­
ses the DH*DHA interaction was significant, indicating that dihydrodigoxin in the 
antiserum minimizes the cross-rectivity of DH to the digoxin antiserum. 
The results therefore indicate that dihydrodigoxin does cross-react with digoxin 
to a maximum of 20% when dihydrodigoxin concentrations are 4 times greater than 
the digoxin concentrations. However, this would not be expected to contribute 
to error in clinical samples since dihydrodigoxin has a much shorter half-life than 
digoxin.The results also indicate that the RIA kit by DPC may be used for the 
assaying of samples collected off the HPLC column in our assay, which may contain 
DH along with the digoxin being collected, provided the DH levels are expected to 
be less than 8 ngiml. 
Conclusion: 
1)  Provided dihydrodigoxin concentrations are less than 8 ng/ml. ,  DH in the pres­
ence of digoxin does not significantly increase the error normally associated with 
the assaying of digoxin alone. 2) The addition of DH to the antiserum significantly 
reduces the cross-reactivity of the DH to the digoxin antiserum. 
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EXPERIMENT 8.0 
Objective: 
To confirm that the presence of DH does not contribute significantly to the error 
associated with assaying digoxin levels in serum samples obtained from pharma­
cokinetic studies in beagle dogs. 
Introduction: 
Results of the previous experiment (experiment 7.3) , indicated that DH in the · 
presence of digoxin did not contribute significantly to the error associated with 
assaying digoxin provided DH concentrations were less than 8 ng/ml. 
To confirm this result, the samples from a representative pharmacokinetic study 
were assayed in the presence and absence of added dihydrodigoxin. 
Procedure: 
Samples from study no. 1 (refer to the experimental section) were used for the 
assays. The samples were divided into two parts A and B. The samples in Part 
B were spiked with dihydrodigoxin such that the samples had a final concentra­
tion of dihydrodigoxin of 4 ng/ml. Also, the antiserum in the RIA kit was divided 
into two halves. One half of the antiserum was spiked with dihydrodigoxin to re­
sult in a dihydrodigoxin concentration of 8 ng/ml. Samples from both part A and 
B were assayed by RIA using the unaltered antiserum and the antiserum spiked 
with dihydrodigoxin . Univariate analyses were conducted to determine whether the 
samples of part A ( labeled "ONEr and "TWO" in table 5 .14) and part B (labeled 
"THREE"and "FOUR" in table 5.14) were statistically different and whether ad­
dition of DH to the serum or to the antiserum produced any statistical differences 
in the observed concentrations. 
Results: 
The results are listed in table 5 .14 .  
TIME 
(hrs) 
0.33 
1 .33 
1 .83 
3.08 
4 .92 
7.0 
23.33 
30.83 
48.00 
54.75 
72.42 
78.5 
PART A 
ONE 
( DIG ) 
33.28 
7 .65 
5.36 
3.76 
3.30 
3.1 
1.7 
2.0 
1.2 
0.91 
0.71 
0.41 
TABLE 5.14 
0 
PART B 
TWO 
(DIG + DH) 
31.7 
8.1 
6.0 
4 . 1  
3.11 
2.85 
1.5 
2.2 
1 .4 
0.89 
0.68 
0.54 
PART A 
THREE 
( DIG ) 
30.00 
7 .88 
6. 1 2  
3.64 
3.8 
3 .0 
1 .6 
2.0 
1 .4 
0.93 
0.70 
0.56 
8 
PART B 
FOUR 
( Dig + DH) 
32.6 
7.5 
5.8 
4 .2 
3.6 
3 .. 3 
1 .8  
2.1 
1 .3 
1 .0 
0.70 
0.57 
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DIG = digoxin 
DH = dihydrodigoxin 
DH a = dihydrodigoxin in the antiserum 
The statistical analyses were conducted as follows: H the addition of DH to the 
serum does not produce any statistical differences in the measured concentrations 
of digoxin, then, the variable "E" (E = ONE - TWO) should have a mean of zero 
provided it has a. normal distribution. The t-statistic for the hypothesis that the 
mean of E = 0, was calculated. Also, if ONE is not statistically significant from 
TWO then the ariable "I" (I = ONE/TWO - 1 )  should also ha.ve a mean of zero 
provided it has a normal distribution. A test of normality was also conducted on 
the generated variables. The generated variables were: 
E = ONE - TWO 
F = ONE - FOUR 
G = TWO - FOUR 
H = ONE - THREE 
1 = (ONE/TWO - 1) 
J = (ONE/FOUR - 1) 
K = (TWO/FOUR - 1 )  
L = (ONE/THREE - 1 )  
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The resu]ts of the statistica] analyses are given in tab]e 5.15 
Variables E, F, H and J do not have a normal distribution. Hence variables 
I ,  K ,  L and G were used in the analyses. The t-statistic and the rank values both 
indicate that the variables I, K,  L and G all have a mean of zero and are normally 
distributed. This indicates that the addition of DH to the serum or the antiserum 
does not produce any difference in the measured concentration of digoxin. 
Conclusion: 
The results indiicate that addition of DH to the serum or the antiserum does not 
produce any sign ificant differences in the measured concentrations of digoxin. This 
is in agreement with the findings of Malini et al. : ( 1982) who after evaluating several 
radioimmunoassays kits f�und that the RIA kit by the Diagonostic Products Corp. 
was specific for digoxin in the presence of dihydrodigoxin. It was therefore expected 
that serum samp]es of digoxin in our studies that may contain dihydrodigoxin (in 
concentrations of < 4 ng/ml.) wou]d not contribute to a "false positiver. in the 
measured digoxin concentration. 
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Table 5 . 1 5 
UNIVARIATE 
VARIABLB•E 
MOMENTS 
N 12 SUM WGTS 12  
HEAN 0 . 0341667 SUM 0 . 41 
STD DEV 0 . 585964 VARIANCE 0 . 343354 
SKEWNESS 1 . 75541 KURTOSIS 4 . 09385 
USS 3 . 7909 css 3 . 77689 
CV 1715 . 02 STD HEAN 0 . 169153 
T : MEAN•O 0 . 201986 PROB • ! T l  0 .-843614 
SGN RANK -4 PROB • I S i  0 . 783652 
NOH A- 0 12 
W : NORMAL 0 . 851843 PROB< W  0 . 043 
QUANTILES(DEF•4) EXTREMES 
lOOCJ, MAX 1 . 58 9� 1 . 58 LOWEST HIGHEST 
75'l Q3 0 . 235 95 ... 1 . 58 - 0 . 64 0 . 03 
5 0'l MED -0 . 055 90 ... 1 . 256 -0 . 45 0 . 19 
2 5'l Ql -0 . 385 10 ... -0 . 583 -0 . 4  0 . 25 
OCJ, KIN -0 . 64 5 ... -0 . 64 -0 . 34 0 . 5  
l'l -0 . 64 -0 . 2  1 . 58 
RANGE 2 . 22 
Q3-Ql 0 . 62 
MODE -0 . 64 
VARIABLE•F 
MOMENTS 
N 12 SUM WGTS 12 
HEAN -0 . 0908333 SUM - 1 . 09 
STD DEV 0 . 296478 VARIANCE 0 . 0878992 
SKEWNESS 1 . 57853 KURTOSIS 3 . 88655 
USS 1 . 0659 css 0 . 966892 
CV -326 . 4  STD HEAN 0 . 0855858 
T : HEAN•O -1 . 0613 PROB > I T  0 . 3H294 
SGN RANK -20 PROB • 1 S :  0 . 125361 
NOH A - 0 12 
W : NORMAL 0 . 847276 PROB • W  0 . 039 
QUANTILBS(DEF•4) EXTREMES 
lOO'l MAX 0 . 68 99 ... 0 . 68 LOWEST HIGHEST 
75'l Q3 -0 . 015 95'l. 0 . 68 -0 . 44 -0 . l  
50'lb MED -0 . l  90'lb 0 . 521  -0 . 44 -0 . 09 
25'lb Ql -0 . 275 10% -0 . 44 -0 . 3  0 . 01 
0% KIN -0. 44 5CJ, -0 . 44 -0 . 2  0 . 1 5 
1 ... -0 . 44 -0 . 16 0 . 68 
RANGE 1 . 12 
Q3-Ql 0 . 26 
MODE -0 . l  
VARIABLE•G 
lOOll MAX 
75 ... Q3 
501l MED 
25 ... Ql 
Oil MIN 
RANGE 
Q3-Ql 
MODE 
, VARIABLE•H 
l OO'K, MAX 
75 ... Q3 
501l MED 
25% Ql 
Oil HIN 
RANGE 
Q3-Ql 
MODE 
Table 5 . 1 5 (contd . )  
UNIVARIATE 
MOMENTS 
N 12  SUM WGTS 
MEAN -0 . 125 SUM 
STD DEV 0 . 420876 VARIANCE 
SKEWNESS -0 . 219514 JtORTOSIS  
USS 2 . 136 css 
CV -336 . 7  STD HEAN 
T : HEAN•O -1 . 0288 PROB > I T '  
SGN RANK -12 PROB > 1 S 1  
NUM � .  0 12 
W : NORMAL 0 . 977498 PROB • W  
QUANTILES(DEF•4 ) 
0 . 6  99% 0 . 6  
0 . 175 95'K, 0 . 6  
-0 . 065 901l 0 . 51 
-0 . 48 10,, -0 . 81 
-0 . 9  5% -0 . 9  
lll -0 . 9  
1 . 5  
0 . 655 
-0 . 9  
MOMENTS 
N 12  SUM WG'l'S 
HEAN 0 . 145833 SUM 
STD DEV 1 . 02163 VARIANCE 
SKEWNESS 3 . 03273 JtORTOSIS 
USS 1 1 . 7363 css 
CV 700 . 549 STD MEAN 
T : HEAN•O 0 . 494484 PROB , ! T i  
SGN RANK -9 PROB > I S i  
NUM � .  0 1 1  
" :1'0RMA1, O . S'l'Ol2l PROB· W 
QOANTILES( DEF•4) 
3 . 28 9� 3 . 28 
0 . 1 95% 3 . 28 
-0 . 01 90'K, 2 . 332 
-0 . 2225 10 ... -0 . 682 
-0 . 76 5'K, -0 . 76 
1 ... -0 . 76 
4 . 04 
0 . 3225 
0 . 1 
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12 
-1 . 5 
0 . 177136 
-0 . 1996 
1 . 9485 
0 . 121496 
0 . 325648 
0 . 366617 
0 . 937 
EXTREMES 
LOWEST HIGHEST 
-0 . 9  -0 . 02 
-0 . 6  0 . 1 
-0 . 49 0 . 2  
-0 . 45 0 . 3  
-0 . 1 1 0 . 6  
12 
1 . 75 
1 . 04374 
1 0 . 0527 
1 1 . 4811 
0 . 29492 
0 . 630691 
0 . 44958 
, . Ol 
EXTREMES 
LOWEST HIGHEST 
-0 . 76 0 . 01 
-0 . 5  o .  l 
-0 . 23 0 . 1 
-0 . 2  0 . 12 
-0 . 15 3 . 28 
Table 5 . 1 5  (contd . )  
VARIABLB•I 
N 
MEAN 
STD DEV 
SKEWNESS 
USS 
CV 
T : MEAN•O 
SGN RANK 
NUM A- 0 
W : NORMAL 
QUANTILBS(DEF•4) 
100% MAX 0 . 333333 
75% Q3 0 . 0582805 
50% MED -0 . 01165418 
25% Ql -0 . 13381 
99'. 
95% 
90'*' 
10'*' 
0% MIN -0 . 240741 
RANGE 
Q3-Ql 
MODE 
0 . $'74074 
0 . 1 9209 
-0 . 240741 
VARIABLB•J 
N 
MEAN 
5% 
1-.. 
STD DEV 
SKEWNESS 
USS 
CV 
T : MEAN•O 
SGN RANJC 
NUM A - 0 
"lf :;NORMAL 
QUANTILES(DEF•4) 
1 00'*' MAX 0 . 0208589 
75% Q3 - . 001 19048 
50'*' MED -0 . 0682341 
25% Ql -0 . 0683333 
0'*' MIN -0 . 280702 
RANGE 
Q3-Ql 
MODE 
0 . 301561 
0 . 0871429 
-0 . 280702 
· UNIVARIATE 
MOMENTS 
12  
-0 . 0183871 
0 . 1 53565 
0 . 807651 
0 . 26346 
-835 . 18 
-0 . 414775 
- 9  
1 2  
0 . 939133 
0 . 333333 
0 . 333333 
0 . 259649 
-0 . 22566·1 
-0 . 240741 
-0 . 240741 
SUM WGTS 
SUM 
VARIANCE 
JCURTOSIS 
css 
STD MEAN 
PROB , • T l  
PROB > 1 S 1  
PROB , W  
MOMENTS 
12 
-0 . 0683515 
0 . 0800502 
- l . 6296 
0 . 12655 1 
-117 . 12 
-2 . 9579 
-33 
12 
0 . 81 1449 
0 . 0208589 
0 . 0208589 
0 . 0206012 
-0 . 22792 
-0 . 280702 
-0 . 280702 
SUM WGTS 
SUM 
VARIANCE 
JCURTOSIS 
css 
STD MEAN 
PROB • I T !  
PROB > 1 S 1  
PRO» , V  
1 2  
-0 . 220645 
0 . 0235821 
1 . 39321 
0 . 259403 
0 . 0443303 
0 . 686281 
0 . 504903 
0 . 474 
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EXTREMES 
LOWEST 
-0 . 24:0741 
-0 . 190476 
-0 . 142857 
-0 . 1 06667 
-0 . 0829268 
12 
-0 . 820218 
0 . 00640803 
4 . 43397 
0 . 0704883 
0 . 0231085 
0 . 0130252 
0 . 0107874 
0 . 013 
HIGHEST 
0 .  0441176 
0 . 0498423 
0 . 0610932 
0 .  0877193 
0 . 333333 
EXTREMES 
LOWEST 
-0 . 280702 
-0 . 104762 
-0 . 09 
-0 . 0833333 
-0 . 0769231 
HIGHEST 
-0 . 0555556 
-0 . 047619 
0 . 0142857 
0 . 02 
0 . 0208589 
Table 5 . 1 5 (contd . }  
VARIABLB•lt 
N 
MEAN 
STD DEV 
SKEWNESS 
USS 
CV 
T : MEAN•O 
SGN RANK 
NUM � .  0 
W : NORMAL 
QUANTILBS(DEF•4) 
100% MAX 0 . 166667 
75% Q3 0 . 086313 
50% MED -0 . 0280894 
25% Ql -0 . 129583 
0% MIN -0 . 285714 
RANGE 
Q3-Ql 
MODE 
0 . 452381 
0 . 196896 
-0 . 286714 
VARIABLB•L 
1'l 
KEAN 
99% 
95% 
90% 
1 0% 
5$ 
l'i 
STD DEV 
SKEWNESS 
USS 
CV 
T : HEAN•O 
SGN RANK 
NUM � .  0 
W : NORMAL 
QUANTILBS(DEF•4) 
100$ MAX 0 . 109333 
75% Q3 0 . 0332418 
50% MED -0 . 0107527 
25% Ql -0 . 12973 
0% HIN -0 . 267857 
RANGE 
Q3-Ql 
MODE 
0 . 37719 
0 . 162972 
-0 . 267857 
99% 
95$ 
90% 
10% 
5% 
1% 
UNIVARIATE 
MOMENTS 
12  
-0 . 0368947 
0 . 120876 
-0 . 363685 
0 . 177053 
- 327 . 62 
-1 . 0573 
-11  
12  
0 . 971878 
0 . 166667 
0 . 166667 
0 . 140667 
-0 . 240909 
-0 . 285714 
-0 . 285714 
SUM WGTS 
SUM 
VARIANCE 
ltURTOSIS 
css 
STD MEAN 
PROB , I T I  
PROB > ! S t  
PROB • W  
MOMENTS 
12  
-0 . 0387292 
0 . 107224 
-0 . 826844 
0 . 144467 
-276 . 86 
- 1 . 2612 
-10 
1 1  
0 . 930717 
0 . 109333 
0 . 109333 
0 . 0962833 
-0 . 230357 
-0-. 267857 
-0 . 267857 
SIDI WGTS 
SUM 
VARIANCE 
KURTOSIS 
css. 
STD MEAN 
PROB > I T I  
PROB , I S i  
PROB,W  
12  
-0 . 442736 
0 . 0146108 
0 . 509203 
0 . 160719 
0 . 0348936 
0 . 313021 
0 . 410117 
0 . 885 
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BXTREMES 
LOWEST 
-0 . 285714 
-0 . 136364 
-0 . 136111  
-0 . 1 1 
-0. 0526316 
12 
-0 . 48475 
0 . 01 1497 
0 . 318688 
0 . 126467 
0 . 0309529 
0 . 236808 
0 . 398305 
0 . 418 
HIGHEST 
-0 . 0238095 
0 . 0344828 
0 . 0769231 
0 . 08 
0 . 166667 
EXTREMES 
LOWEST 
-0 . 267857 
-0 . 142867 
-0 . 131579 
-0 . 124183 
-0 . 0291878 
HIGHEST 
0 . 0142857 
0 . 032967 
0 . 0333333 
0 . 0625 
0 . 109333 
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APPENDIX C 
Although equations to obtain the micro- rate constants for a three compartment 
mammillary and "first pass" ·model may be found in the literature, equations to 
obtain the micro- rate constants for a three compartment catenary model could not 
be found in the literature. The equations were therefore derived. 
The following equations are derived for· a three compartment catenary model. 
In the following derivation 
E1 = (k1 2 + k1 0) 
E2 = (k2a + k2 i )  
For an i .v .  bolus dose (D) administered in to.the sampling compartment (compart­
ment 1) ,  
dX i 
k ,� k '" k ·v dt = - 1 2 -A l - 1 0 -A l + 2 1 A 2  
Taking laplace transforms of eqn. (5.1) 
therefore, 
- ·k21 X2 -;- D 
X1 = -----­(s + k1 2 + k10) 
. . .  (5.1) 
. . .  (5.2) 
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For compartment 2, 
. . .  (5 .3) 
Taking laplace transform of eqn.(5.3) 
... (5.4) 
Therefore 
... (5.5) 
From egn.(5.2) and (5.5) , 
. . .  (5 .6) 
... (5.7) 
Taking laplace transforms, 
Therefore, 
Substituting for Xa in eqn . (5.7) and on rearrangement, 
X2 = sk1 2 D + k1 2 EaD 
(s + E1 ) (s + E2 ) (s + Ea) - k12k21 (s + Ea) - Eak2a(s + Ei ) 
This is of the form 
As2 + Bs + C 
(s + a) (s + P) (s + ,) 
where 
A = 0 
Taking inverse laplace transforms, 
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. . . (5.8) 
-:- b - o:) ( -k 1 2 DB + k1 2 Ea D) e-f3t 
+ (a, -· /3) ( - k 1 2D'"'! + k 1 2Ea D) e-,yt] 
Therefore. 
X k D : 
(a: - Ea) -at
+ 
(/1 - Ea) -f3t + (, -
Ea) -,yt] 2 - - 12  e e e 
· h - o:) (o: - P) (p ·- '"'!) (a - P) (P - --r) (, - o:) 
From eqn. (5.7) and (5.8) 
X'l 
(s + Ea ) = k12 D + Ea (s + E1 )>G 
"
k23 (s + �1 ) (s + E2) - k1 2k21 -
. . .  (5.9) 
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Therefore, 
After expansion of the denomina.tor and rearrangement the above equation may be 
represented as 
Taking inverse )aplace transforms� 
-1 
Xs = 
(/3 _ '"Y) b  _ a) (a _ /3) 
[ CB - '"'t) (k 1 2k2aD) e-oct + h - a) (k12k23 D) e-f3t 
+ (a - f3) (k 12k2aD)e- "tt] 
The equation may be rearranged to give 
where, 
e-crt e-fJt e--rt 
Xa = -k12k2a D [  . + ---- -:- -----] (, - a) (a - /3) (/3 - ,) (a  - {3) (/3 - '"Y) b  - a) 
From eqn.(5.2) 
... (5.10) 
Rearrangement of eqn. (5.5} gives, 
From eqn. (5.8) and (5. 1 1 ) ,  
Therefore, 
Substituting for X2 from eqn.(5.13) in to eqn. (5. 10) gives, 
Xi = 
k21 k12 (s  + E3)Xi . + D 
(s + E1 ) [ (s + E2) (s + E3) - k23k32J (s + E1) 
Rearrangement of the above equation gives. 
Xi = 
D [(s + E2) (s + Eg) - _k23k32) 
(s + E1 ) (s + E2) (s + Ea ) - k2sk32 (s .- EJ ) - k12k211 (s + Es) 
On expansion and rearrangement the above equation is of the form: 
where, 
As2 ...1. Bs + C 
(s + a) (s + f3) (s + ,) 
A = D  
B = D(E2 + E3) 
C = D(E2Es - k23E3) 
and 
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... (5 .11} 
. . .  (5.12) 
. . .  (5 .13) 
. . .  (5 .14) 
Therefore, after taking inverse )aplace transforms 
X1 
= 
(.8 _ ,) (, -=_
1
a) (a _ .8) [
(,8 - ,) (Aa:
2 
- Ba + C)e-od 
+ (, - a) (A.82 - B.8 + C)e-f3t 
+ (a - .B) (A,2 - B"/ + C) e--rt] 
(Aa2 - Bex + C) -at (A.82 - B.8 + C) -flt X1 = ------e - -- --- e · (ex - ,) (a - .8) (a - .8) (.8 - ,) 
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. . .  (5.15) 
+ (A,2 - B, + C) e--rt 
(ex - ,) (.8 - ,) 
The concentration in compartment 1 is then given by, 
C 
1 
[ 
(Aa2 - Ba + C) -at. (A.8
2 
- B.8 + C) -f3t (A-·,
2 - B, + C) ·--] 1 = - ----------e - -----'- e + ----- ---=-e ,. V1 (a .:_ ,) (a - .8) (a - .8) (.8 - ,) (a - ,) (.8 - ,) 
... (5.16) 
where Vi is the volume of distribution of compartment 1 .  
Determination of the micro- rate constants 
If the concentration time profile is described by a tri-exponential expressed as, 
... (5.17) 
then X Y and Z and a, .8, , may be obtained by linear regression on the 
concentration time data. 
Compar.ison of egn. (5.16) and (5 .1 7) yields, 
.. . (5.18) 
From eqn.(5.18) , 
y = -1  r (A,82 - B{J + C) 1 V1 l (o: - /3) {,8 - "I) J 
z = _!_ r (A,·2 - B"I + C) ] V1 L ( 0: - "/ ) (,8 - "/) 
C = XVi (a - "!) (o: - /3) - Ao:2 + Ba 
From egn. (5. 19), 
From eqn. (5.20), 
From egn. (5.21) and (5.22) , 
-B = XVi (a - "I) + YVi (/3 - "I) - A(o: + ,8) 
At time = 0, X1 = D Therefore from eqn_. (5. 15) and (5. 16) , 
V - _D __ 
i - X + Y . Z  
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. .. (5.19) 
... (5.20) 
... (5.21) 
. . .  (5.22) 
. .. (5.23) 
.. . (5.24) 
Now a numerical va]ue for B may be obtained in eqn.(5.24) , by substituting the 
• •  
0 
known values. Having determined B� a numerical value for C may he obtained from 
eqn. (5.21) .  
As noted before, 
C = D(E2Ea - k2aEs) 
= DEa (E2 - k2a) . .. (5.25) 
Also, 
From eqn. (5.25) and (5.26), 
Therefore, 
Since, 
a + /3 + "Y = E1 + E2 + Ea 
and 
B = D(Ez + Ea) 
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... (5.26) 
... (5.27) 
... (5.28) 
E1 may.therefore be determined. By definition E1 = kw +  k 12  Therefore, from 
eqn. (5.27) and (5.28), 
... (5.29) 
and a numerical value may be determined. 
As noted before, 
C = DEa (E2 - k2a) 
= DEak21 
therefore, 
Also, 
Therefore, 
k _ DE1 (E2 7 Ea) -t C - D(a{J + fl"f + ,a) 2 1 - k 1 2 D 
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. . .  (5.30) 
k2 1  is the only unknown constant in the above equation and may be determined by 
substituting the values for the Qther constants . . 
Since, 
and, 
Therefore, 
C Es = Dk21  
B B C Therefore: E2 = - - £,, = - - --D .., D Dk21  
B C = - - --D Dk21 
B C 
k23 = - - -- - k2 1 D Dk2 1 
From eqn. (5.30) and (5.31 ) k23 may now be determined. 
. . .  (5.31) 
Having determined k23 (eqn. 5.31 ) ,  ka2 may now be determined, since, 
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